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Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that causes major 
morbidity and mortality around the world [1]. It is the currently the third leading cause of 
death worldwide and the fifth leading cause of morbidity [2, 3]. COPD is a preventable 
disease that is usually characterized by a progressive decrease in lung function associated 
with chronic lung inflammation as a consequence of exposure to inhaled noxious gases and 
particles, such as cigarette smoke. Patients with COPD suffer from chronic and progressive 
dyspnea on exercise and in advanced stages also dyspnea at rest, cough and sputum 
production. Currently, bronchodilators can relieve symptoms of dyspnea in many patients, 
but there is a continuing debate about the efficacy of anti-inflammatory medication. This 
thesis describes the results of studies on the clinical and pathological changes in the airways 
in COPD during use and after withdrawal of anti-inflammatory intervention.
Classification of COPD
COPD is classified in severity stages by the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) [1]. From 2007, the severity COPD was based on the degree of airflow 
limitation obtained by spirometry (GOLD stage 1 to 4, Figure 1). A ratio of the forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC) ≤ 0.70 after 
bronchodilator use and the level of FEV1 are the main parameters used for the GOLD 
classification. Since 2011, the assessment of COPD is based on the combination of post-
bronchodilator spirometric values, the annual number of exacerbations and the impact 
of the disease of the patient’s health status, as measured by the mMRC (Modified Medical 
Research Council) and CAT (COPD Assessment Tool) [1], as presented in Figure 1. In the 
GLUCOLD study presented in this thesis, we also used measurements of health status not 
included in the assessment tool, such as the CCQ (Clinical COPD Questionnaire) and the 
St George Respiratory Questionaire (SGRQ). The combined COPD assessment tool was 
developed to predict future exacerbations and mortality. Some COPD patients do not fit 
perfect in one category and severity  of the disease should be determined by the method 
with the highest score, thereby shifting the COPD severity distribution towards more severe 
categories [4]. In addition, both COPD GOLD classifications cannot adequately predict 
total mortality for an individual COPD patient [4]. This suggest that there is still room for 




Figure 1:  COPD assessment of severity. Adapted from Vestbo, et al. [1].
Comorbidities
Comorbidity can be defined as two or more diseases which exist simultaneously in an 
individual, but have a different pathogenetic mechanisms; there is however no agreement 
on this definition [5]. Multimorbidity implicates that two or more diseases are simultaneously 
present which do not have a mutual connection [5]. When these definitions are applied to 
patients with all stages of COPD, they have one or more comorbidities (or multimorbidities) 
which have a major impact on quality of life and survival [6]. Smoking is not only a risk 
factor for COPD, but also for numerous other diseases, such as cardiovascular disorders 
[7], including ischemic heart disease, coronary artery disease and cardiac failure. Other 
comorbidities of COPD are metabolic syndrome, osteoporosis [8], skeletal muscle weakness, 
gastroesophageal reflux, obstructive sleep apnea, normocytic anemia and depression. 
However, for the majority of these diseases it is unclear whether these are a comorbidity or 
multimorbidity of COPD. Severe COPD patients have a 3-4 times increased risk to develop 
lung cancer compared to smokers with a normal lung function, fitting it to the definition of 
a comorbidity [9]. A recent study showed that after correction for smoking, no elevated risk 
was found between COPD and ischemic and hemorrhagic stroke, implicating that COPD and 
stroke are multimorbidities [10]. 
Exacerbations
Exacerbations of respiratory symptoms are common in patients with COPD and can be 










































1: FEV1 ≥80% of predicted
Mild
2: 50% ≤ FEV1 <80% 
    of predicted
Moderate
4: FEV1 ≤ 30% of predicted
Very severe
3: 30% ≤ FEV1 <50% 







During an exacerbation, COPD patients suffer from increased dyspnea, which in stable state 
already shows a day-to-day variation, coughing and sputum production. These features 
are accompanied by increased airway inflammation, severe hyperinflation of the (already 
hyperinflated) thorax and decreased expiratory flow [11]. Exacerbations are associated with 
a steeper decline in FEV1 and an increased mortality, especially in those who are admitted 
to the hospital [12]. In-hospital mortality of hypercapnic patients is approximately 3-8%, and 
all-cause mortality during 3 years after hospital admission is 31-49% [13-15]. This shows 
that long-term mortality after admission for an exacerbation is higher than that following 
admission for myocardial infarction (30 day mortality 15%, 1-3 year mortality 9-24%) [16-
18]. Therefore, it is highly relevant to early detect and treat exacerbations of COPD. Timely 
treatment is associated with faster recovery of symptoms, reduced number of future 
hospital admittances and improved quality of life [19]. Assessment and treatment of acute 
exacerbations of COPD is beyond the scope of this thesis.
Epidemiology
The prevalence of COPD varies across countries and even within different populations [1], 
but is directly related to the cumulative exposure to cigarette smoke. For decades, COPD has 
been an underrecognized and underdiagnosed disease, especially in low income countries 
[20, 21]. However, even in industrialized countries, COPD is often underdiagnosed. This is 
evident from several large epidemiologic population-based and general practice-based 
studies, in which participants were screened for COPD. Among those who had COPD, 70% did 
not have a previous physician-recorded diagnosis of COPD that was confirmed by spirometry 
[22-24]. Approximately 4-10% of the general adult population worldwide will develop 
COPD [25]. However, among long-term smokers the prevalence of COPD can be as high as 
47% [26]. The World Health Organization (WHO) estimates that worldwide 64 million people 
suffer from COPD, thereby it is the third leading cause of death worldwide [3]. Currently, 
COPD is already the third cause of death in the United States [2]. Moreover, hospitalizations 
contribute to the costs of and the burden to COPD patients. In the Netherlands over 350.000 
people suffer from COPD and each year almost 50.000 new patients are added [27] and in 
2014 almost 6000 patients had COPD as a primary cause of death [28], indicating that even 
in our country COPD is the fifth cause of death. Therefore, COPD is a major health problem 




Risk factors for COPD
Why do some smokers develop COPD, while others do not? COPD results from a tangled 
interplay between genetic susceptibility and exposure to environmental stimuli, of which 
cigarette smoking is the major risk factor [29]. Already in 1977, Fletcher and Peto showed 
that FEV1 decline over time is much higher in susceptible smokers compared to non-
smokers (Figure 2) [30]. Smoking cessation in a group of susceptible smokers can revert 
the FEV1 decline to ‘normal physiologic’ deterioration [30, 31]. Although smoking is the 
most important risk factor in over 1 billion people globally, it is certainly not the only one. 
Inhalation of secondhand smoke, smoke from biomass fuel, occupational exposure to 
vapor, gases, dust and fumes and outdoor pollution have been particularly associated with 
the development of airflow limitation and chronic respiratory symptoms especially in low 
income countries in 3 billion people worldwide but also in the Netherlands [32, 33]. This 
suggests that exposure to biomass smoke is even a bigger risk factor for COPD in these 
countries than cigarette smoking, as 25-45% of the patients with COPD has never smoked. 
In addition, birth weight, maternal smoking, childhood asthma, atopy and (childhood) 
respiratory infections as well as previous tuberculosis are all associated with a reduced 
lung function [34, 35]. α1-Antitrypsin deficiency is a well-known genetic (and familial) 
cause and is present in 1-2% of patients with COPD [36]. Genome-wide association studies 
have shown several single nucleotide polymorphisms (SNPs) that are associated with an 
increased susceptibility for COPD, like ‘hedgehog interacting protein’ (HHIP) and ‘family with 
sequence similarity 13, member A’ (FAM13A, both on chromosome 4), ‘advanced glycosylation 
end product-specific receptor’ (AGER, on chromosome 6), ‘bicaudal homolog 1’ (BICD1, on 
chromosome 12), ‘α-nicotinic acetylcholine receptor 3 and 5’ (CHRNA3 and CHRNA5) and ‘iron-
responsive element binding protein 2’ (IREB2, on chromosome 15) and ‘transforming growth 
factor-β1’ (TGF-β1, on chromosome 19) [37-42]. Although the role of genetic polymorphisms 
in most of these genes in disease pathogenesis is incompletely understood, the gene 
products may clearly be linked to COPD pathogenesis.
Heterogeneity of COPD
Traditionally COPD was clinically phenotyped as chronic bronchitis and emphysema, 
reflecting the ‘blue bloater’ and the ‘pink puffer’, respectively. However, COPD is a far more 
complex and heterogeneous disease than this division and can be classified on the basis of 
clinical, physiologic, molecular, cellular, pathologic and radiographic variables with effects 
modified by varied host susceptibility [43]. Clinical parameters that differentiate one COPD 
patient from the other are age, smoking, number of packyears, degree of dyspnea, exercise 
14
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Figure 2:  Effect of smoking cessation on lung function decline by Fletcher and Peto [30].
capacity, frequent exacerbations, poor quality of life, low body mass index (BMI) and 
symptoms of depression or anxiety [44, 45]. Physiological phenotypes in COPD are based 
on airflow limitation, rate of FEV1 decline (rapid versus slow decliners), responsiveness to 
bronchodilators, airway hyperresponsiveness, low diffusion capacity (DLco), hyperinflation 
and pulmonary hypertension [46]. More extensive emphysema, increased airway wall 
thickness and an increased ratio of pulmonary artery and aortic diameter are associated 
with an increased rate of exacerbations [47, 48]. One study group found a relation between 
some parameters in COPD patients: one group with severe airflow limitation and many 
respiratory complaints; the second group had less severe airflow limitation; and the third 
group had mild airflow limitation, but had comorbidities such as obesity, cardiovascular 
diseases, diabetes and systemic inflammation [49]. These outcomes were related with more 
frequent hospitalizations due to COPD in the first group and a higher all-cause mortality, 
whereas the third group had more admissions due to cardiovascular diseases. To make the 
heterogeneity of COPD even more complex, some patients with COPD demonstrate typical 
features of asthma, including reversible airway obstruction, bronchial hyperresponsiveness, 
sputum eosinophilia, high IgE levels and atopy [50, 51]. This has recently been covered by the 
term asthma-COPD overlap syndrome (ACOS), although the exact definition of ACOS is still 
a matter of debate and this likely does not reflect a syndrome, but rather the heterogeneity 
of COPD that is also influenced by aging [52, 53]. These considerations indicate that the 
diagnosis ‘COPD’ alone is incomplete to cover the wide variety of phenotypic differences 
between patients, and that the adequate phenotyping as is being developed in asthma 
[54] is also needed for COPD and preferably should be done for chronic airways diseases 
collectively [55].
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chest wall with aging.19,20 Respiratory muscle function also 
changes with age. Studies of diaphragm strength have shown 
a 13% to 25% drop in the maximal inspiratory force generated 
with aging.21,22 In general, skeletal muscle function, which 
predicts maximal inspiratory and expiratory pressure (MIP 
and MEP), also decreases with age.23,24 Taken together, these 
changes may limit the maximal inspiratory and expiratory 
effort that contribute to FEV
1
. Perhaps most important in 
explaining the age-related decline are changes in the lung 
parenchyma. Pathological studies have shown that beyond 
age 50 years, elastic fibers at the level of the respiratory 
bronchiole and alveolus degenerate, or rupture and appear 
coiled – although the total number of alveolar connections 
remains unchanged (in contrast to emphysema induced 
by cigarette smoking).25,26 The abnormal and presumably 
weakened connections lead to uniform airspace dilatation, 
a condition that Verbeken and colleagues called “senile 
emphysema.” The functional result of these parenchymal 
lung changes are a decrease in the elastic recoil pressure of 
the lung and a weakening of the supporting structures of the 
small airways, which more easily close, even during tidal 
breathing.27–29 All of these changes contribute to the gradual 
decline in FEV
1
 with increasing age.
The changes in lung parenchyma (decreased elastic 
recoil), chest wall (increased stiffness), and the respiratory 
muscles (decreased force generation) explain the observed 
changes in lung volume with aging. Total lung capacity 
remains relatively preserved since the increased distensibility 
of the lung is offset by the stiffer chest wall. Residual volume 
(RV) and functional residual capacity (FRC) both increase, 
but expiratory reserve volume (ERV) decreases.30,31
Changes in lung function with  
smoking and COPD
Smoking impacts all phases of lung development and 
growth, and can limit the maximal lung function attained,32,33 
shorten the duration of the plateau phase prior to the decline 
with aging,34 and accelerate the decline in lung function.13 
Although the precise numbers may vary slightly in other 
studies,35,36 the findings of Fletcher and Peto encapsulate the 
known consequences of smoking on lung function decline 
(see Figure 2).13 First, smokers show an accelerated rate of 
decline in FEV
1
 compared to those who have never smoked; 
an average loss of approximately 50 mL per year. Of note, 
while this rate may be approximately double the normal 
rate of decline, this small absolute change per year could be 
difficult to detect in short trials. Second, on average there is 
a dose-dependent loss in lung function: in general, greater 
amounts of smoking lead to greater declines in FEV
1
. Third, 
there is variable susceptibility to the effects of smoking. 
That is, for a given amount of smoking, there is a variable 
rate of decline in lung function among different subjects, 
 presumably reflecting genetic37 or other environmental 
 factors, although the rate of decline appears to be similar 
between men and women.35,38 Studies of lung function 
decline must be interpreted in terms of this “Horse Racing 
Effect” – the observation that in a race, the faster horse will 
be out in front in the middle of the race. In the context of 
 smoking and lung function decline, subjects with evident 
lung function loss and clinical COPD are likely those with 
the fastest loss of lung function. Conversely, most smokers 
will not develop clinically significant COPD.39 Finally, the 
rate of lung function decline will slow, and may return to 
normal with smoking cessation. Whether the diagnosis of 
COPD by itself (ie, after smoking cessation) causes more 
rapid decline in lung function is unknown, and is difficult 
to decipher from the effects of smoking unless there is 
adequate follow-up time, typically several years.40 Airway 
 inflammation continues to persist for many years after smok-
ing cessation, and improvements in hospitalization are not 
generally seen until years after smoking cessation.12,41 There-
fore definitive data regarding COPD alone without smoking 
are difficult to obtain.
Pathogenesis and pathology  
of COPD
Knowledge about the pathogenesis of COPD will be helpful 
in understanding the causes of and ultimately treating the 
accelerated lung function decline. COPD is now recognized as 
a systemic inflammatory disease, not just affecting the airways 







































Figure 2 The decline in lung function with age, smoking, and smoking cessation. 
Note that the decline in lung function among “susceptible” smokers will be variable. 
Reproduced with permission from Fletcher C, Peto R. The natural history of chronic 
airflow obstruction. Br Med J. 1977;1(6077):1645–1648.13 Copyright © 1977 British 
Medical Association.
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Figure 2 The decline in lung function with age, smoking, and smoking cessation. 
Note that the decline in lung function among “susceptible” smokers will be variable. 
Reproduced with permission from Fletcher C, Peto R. The natural history of chronic 






Chronic exposure to cigarette smoke induces pathological changes in the lungs of mouse 
models, such as an inflammatory response in the small and large airways, destruction of 
alveolar walls and structural changes of the airways [56, 57]. Although the pathological 
and functional changes in these animal models are not fully comparable to the human 
situation, chronic smoking does lead to similar changes in humans. First, due to smoking 
an inflammatory reaction occurs, as presented in Figure 3. In classically described ‘chronic 
bronchitis’, the airways, mucosa and submucosa are infiltrated with inflammatory cells (see 
below in the paragraph ‘Inflammatory cells in innate immunity’), which contributes to airway 
obstruction [58]. Furthermore, enlarged bronchial mucus glands with increased mucus 
production in the bronchi and an increase in mucus-producing goblet cells in the surface 
epithelium can be found, as well as increased proliferative activity of the epithelial cells to 
form squamous cell metaplasia [59]. Both in the large and small airways peribronchiolar 
fibrosis can be found, contributing to irreversible airflow obstruction [58]. In emphysematous 
lungs, destruction of the alveolar walls results in permanent abnormal enlargement of 
air spaces [60] and the loss of elastic recoil additionally contributes to airflow obstruction. 
However, as COPD is a heterogeneous disease, often these pathological changes are (to 
some extent) present in every COPD patient. The structural changes in the airways, also 
called remodeling, are more extensively discussed below.
Pathogenesis of COPD
Several mechanisms have been proposed to describe the pathogenesis of COPD. First, in 
response to tobacco smoke, an inadequate inflammatory response develops in the airways of 
smokers [63], of which neutrophils, CD8+ T-cells and macrophages are the most predominant 
cells. Secondly, an imbalance between oxidants and antioxidants in the lungs of COPD 
patients results in oxidative stress, thereby amplifying airway inflammation and inducing cell 
death of e.g. epithelial and endothelial cells [64]. Thirdly, an imbalance between proteinases 
(e.g. elastase produced by neutrophils) and proteinases inhibitors (such as α1-antitrypsin) 
contributes to lung tissue changes and destruction. The combination of increased numbers 
and activation state of inflammatory cells in the lungs, increased production of chemokines 
and cytokines as well as an impaired response to infection, all are likely to contribute to the 
pathogenesis of COPD. The inflammatory cells of the innate and adaptive immune system 
implicated in COPD will be discussed more extensively below.
16
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Figure 3: Pathological changes due to cigarette smoking in the airways in COPD. Reproduced from Barnes [61].
Tobacco smoke
The lungs of a 60-year old person who has smoked one pack of cigarettes per day starting at 
age of 20 will have inhaled smoke generated from approximately 290.000 cigarettes, which 
equals 40 packyears [59]. The chemical composition of tobacco smoke consists of over 5000 
chemicals, including alkanes, polycyclic aromatic hydrocarbons, sterols, alcohols, nitrils, 
acid, phenol(ic ethers), alkaloids (such as nicotine), carbohydrates, inorganics components, 
metals, tar, and others, some of them being radicals, oxidants and carcinogens [65], which 
makes it hard to define which component(s) lead(s) to smoking-related features of COPD 


































Increased proliferation of 
airway epithelial cells in chronic 
obstructive pulmonary disease, 
as a result of the release of 
epithelial-cell growth factors, 
which lead to increased 
thickness of the epithelial-cell 
layer.
Type I pneumocytes
Flat alveolar cells that make up 
most of the epithelial-cell layer 
of the alveolar wall and that are 
responsible for gas exchange in 
the alveoli.
Bronchoconstrictor
An agent that induces 
contraction of airway smooth 
muscle and thereby narrows 
the airways, thus reducing the 
flow of air.
mast cells24. Mast cells also release cytokines that are 
linked to allergic inflammation, including interleukin-4 
(Il-4), Il-5 and Il-13 (REF. 25). The presence of mast 
cells in the airway smooth muscle has been linked to 
airway hyper-responsiveness in asthma26, as patients with 
eosinophilic bronchitis have a similar degree of eosino-
philic inflammation to that found in asthmatics and 
also have subepithelial fibrosis, but they do not show 
airway hyper-responsiveness, which is the physiological 
hallmark of asthma. By contrast, mast cells do not seem 
to have a role in COPD, which may explain the lack of 
variable bronchoconstriction in this disease.
Granulocytes. The inflammation that occurs in asthma is 
often described as eosinophilic, whereas that occurring 
in COPD is described as neutrophilic. These differences 
reflect the secretion of different chemotactic factors in 
these diseases. In asthma, eosinophil chemotactic factors, 
such as CC-chemokine ligand 11 (CCl11; also known 
as eotaxin-1) and related CC-chemokines, are mainly 
secreted by airway epithelial cells. The functional role of 
eosinophils in asthma is not clear and the evidence that 
links their presence to airway hyper-responsiveness has 
been questioned by the finding that the administration of 
Il-5-specific blocking antibodies that markedly reduce 
the number of eosinophils in the blood and sputum 
does not reduce airway hyper-responsiveness or asthma 
symptoms27,28. As discussed above, eosinophilic bronchi-
tis is not associated with airway hyper-responsiveness, 
but subepithelial fibrosis does occur, which suggests a 
role for eosinophils in airway fibrosis. Interestingly, the 
presence of eosinophils seems to be a good marker of 
steroid responsiveness29.
neutrophils are increased in the sputum of patients 
with COPD and this correlates with disease severity30. 
The increase in neutrophils is related to an increase 
in the production of CXC-chemokines, such as CXC-
chemokine ligand 1 (CXCl1; also known as GROα) and 
CXCl8 (also known as Il-8), which act on CXCR2 that 
is expressed predominantly by neutrophils.
Macrophages. Macrophage numbers are increased in the 
lungs of patients with asthma and COPD, but their num-
bers are far greater in COPD than in asthma. These mac-
rophages are derived from circulating monocytes, which 
migrate to the lungs in response to chemoattractants such 
as CCl2 (also known as MCP1) acting on CCR2, and 
CXCl1 acting on CXCR2 (REF. 31). There is increasing 
evidence that lung macrophages orchestrate the inflam-
mation of COPD through the release of chemokines that 
attract neutrophils, monocytes and T cells and the release 
of proteases, particularly MMP9 (REF. 32).
The pattern of inflammatory cells found in the res-
piratory tract therefore differs in patients with asthma 
and those with COPD and some of these contrasts 
may be explained by differences in the immunological 
mechanisms that drive these two diseases.
Immune responses
The immune mechanisms that drive the different inflam-
matory processes of asthma and COPD are mediated by 
different types of immune cell, in particular by different 
T-cell subsets. An understanding of which immune cells 
are involved is now emerging and may lead to the devel-
opment of new and more-specific therapies for airway 
diseases in the future (FIGS 1,2).
T cells. In asthmatic patients, there is an increase in the 
number of CD4+ T cells in the airways and these are pre-
dominantly T helper 2 (TH2) cells, whereas in normal air-
ways TH1 cells predominate33. By secreting the cytokines 
Il-4 and Il-13, which drive Ige production by B cells, 
Il-5, which is solely responsible for eosinophil differen-
tiation in the bone marrow, and Il-9, which attracts and 
drives the differentiation of mast cells34, Th2 cells have a 
central role in allergic inflammation and therefore their 
regulation is an area of intense research.
The transcription factor GATA3 (GATA-binding pro-
tein 3) is crucial for the differentiation of uncommitted 
naive T cells into Th2 cells and it also regulates the secre-
tion of Th2-type cytokines
35,36. Accordingly, there is an 
increase in the number of GATA3+ T cells in the airways 
Figure 2 | inflammatory	and	immune	cells	involved	in	chronic	obstructive	
pulmonary	disease	(CoPD).	Inhaled cigarette smoke and other irritants activate 
epithelial cells and macrophages to release several chemotactic factors that attract 
inflammatory cells to the lungs, including CC-chemokine ligand 2 (CCL2), which acts on 
CC-chemokine receptor 2 (CCR2) to attract monocytes, CXC-chemokine ligand 1 
(CXCL1) and CXCL8, which act on CCR2 to attract neutrophils and monocytes (which 
differentiate into macrophages in the lungs) and CXCL9, CXCL10 and CXCL11, which act 
on CXCR3 to attract T helper 1 (TH1) cells and type 1 cytotoxic T (TC1) cells. These 
inflammatory cells together with macrophages and epithelial cells release proteases, 
such as matrix metalloproteinase 9 (MMP9), which cause elastin degradation and 
emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cells and 
macrophages also release transforming growth factor-β (TGFβ), which stimulates 
fibroblast proliferation, resulting in fibrosis in the small airways.
R E V I E W S
nATuRe RevIews | immunology	  vOluMe 8 | MARCh 2008 | 185
 f o c u S  o n  a l l E R g Y  a n d  a S t h m a





[66]. Tobacco smoke is an aerosol containing a mixture of both gaseous components and 
particles [67]. The particles have a diameter of approximately 0.1-0.8 µm, depending for 
instance on the puffing regimen of the smoker and presence in mainstream smoke (directly 
inhaled smoke) or sidestream smoke (smoke released from the burning tip of a cigarette) [68]. 
Each component has its own distribution between the gas and liquid phase. Exposure of the 
airways can take place in four different ways: 1) direct gas exposure; 2) evaporation of gas 
from the particle followed by exposure; 3) particle deposition, followed by evaporation from 
the particle; and 4) particle deposition followed by diffusion directly in the tissue [67]. As it 
is impossible to describe the effects of all separate components of cigarette smoke on the 
immune system, they are summarized by the term ‘cigarette smoke’ when discussed in the 
following paragraphs.
Innate immunity in COPD
The lung microbiome
The past opinion was that the lower airways are sterile [69]. However, with current techniques, 
such as 16S rRNA (ribosomal RNA) sequence analysis, it was discovered that micro-organisms 
from above the larynx can also be found in the lower respiratory tract [70]. This ‘microbiome’, 
which comprises (traces of ) living and dead micro-organisms and their components, 
contributes to the development of the immune system, thereby creating a symbiosis. Every 
individual, even when healthy, has his/her own (lung) microbiome, which varies in number 
and diversity and may change during lifetime [71]. The microbiome composition can be 
altered in several ways, such as by anatomical, pathological (smoking) and physiological 
changes or by a defective immune system [72]. An imbalance in the microbiome may 
contribute to several diseases, such as COPD. A reduction in microbial diversity is found in 
COPD patients, with more abundance of pathogenic bacteria (e.g. Haemophilus species), 
whereas non-pathogenic Bacteroides and Prevotella species are reduced [70, 73, 74]. In 
addition, some micro-organisms have increased microbial pathogenicity [72]. This disruption 
of the local microbiome may result in an imbalance between immune regulation and 
immune responses in the lungs, resulting in tissue destruction, emphysema and airflow 
limitation in COPD [75]. 
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The innate immune response
To prevent invasion of microbes or noxious effects of inhaled substances, such as cigarette 
smoke, the innate immune system is protecting our lungs. Several mechanisms of innate 
immunity are present in the respiratory tract: mucociliary clearance, the epithelial barrier, 
humoral factors and several innate and adaptive immune and inflammatory cells [59, 63]. 
Cigarette smoke impairs host defense against infections by decreasing epithelial barrier 
function, ciliary function and antimicrobial peptide production [76].
The airways are lined by a pseudostratified epithelium that functions as a barrier, and consists 
of basal cells that act as progenitors, and a variety of luminal cell types, including ciliated cells 
and mucin producing goblet cells [77]. The cilia promote sputum containing trapped inhaled 
particles to be moved towards the throat, and this mucociliary clearance forms the first line 
of defense against inhaled microparticles. A considerable proportion of smokers with and 
without COPD have increased sputum production by mucus gland hypertrophy and an 
increase in the goblet cells of the surface epithelium, which is accompanied by a decrease in 
cilia. As a result of this impaired clearance, mucostasis occurs in the airway lumen. 
In addition to this barrier function and role in mucociliary clearance, the airway epithelium is 
also involved in inflammation, immunity, host defense and tissue remodeling by producing a 
range of mediators. Due to long-term presence of noxious gases and particles, the epithelial 
cell layer of smokers with and without COPD is often characterized by squamous cell, goblet 
cell and basal cell hyper- or metaplasia [78]. Cigarette smoke affects epithelial cell function 
by various mechanisms, including direct oxidant activity, Toll-like receptor (TLR) signaling 
and may induce endoplasmic reticulum stress and an integrated stress response [79, 80]. In 
addition, the activity of adherent and tight junctions of epithelial cells, which normally form 
an impermeable barrier, is transiently decreased. This facilitates entering of macromolecules 
and microbes into the interstitium of the lung [81]. 
Antimicrobial peptides (AMP) are part of the innate immunity and are small peptides that 
have antimicrobial activity against bacteria, viruses and fungi [77]. Besides this, they are 
important players in e.g. inflammation, repair and regeneration. Defensins and cathelicidins 
(in humans there is only one cathelicidin: hCAP-18 or LL-37) are the most commonly studied 
AMP in humans. β-Defensins and cathelicidins are mainly expressed in airway epithelial cells, 
whereas α-defensins and cathelicidins are also produced by neutrophils, macrophages and 
other cells [82]. Although the exact role of β-defensins beyond their direct antimicrobial 
activity is unknown, they also attract immune cells and activate dendritic cells, thus playing 
a role in innate and adaptive host defense [83]. Cathelicidins act in angiogenesis, wound 




antimicrobial function of LL-37 and increased pro-inflammatory activity [85].
Inflammatory response in innate immunity
When a microbe enters the airways, a cascade of innate immunity reactions starts. First, the 
microbe must be recognized, which is done by pathogen-associated molecular patterns 
(PAMPs). Several pattern recognition receptors (PRRs) contribute to microbial recognition, 
for instance membrane-bound Toll-like receptors (TLRs), cytosolic NOD-like receptors (NLRs) 
and RIG-I-like receptors (RLRs). These PRRs are expressed on various cell types, including 
alveolar macrophages, dendritic cells and epithelial cells [86]. PRRs are also activated by 
specific endogenous, often intracellular molecules, which are released after cell damage, 
called damage-associated molecular patterns (DAMPs). The recognition of PAMPs and DAMPs 
are crucial to start the inflammatory response and to help shaping the adaptive immune 
responses. 
Cigarette smoke also leads to activation of several PRRs, both directly (effect of e.g. 
lipopolysaccharide [LPS] present in cigarette smoke) and indirectly (by damage on epithelial 
cells, which release DAMPs) [87]. Both the hydrophilic constituents as well as the tar fraction 
of cigarette smoke contribute to cell injury [88]. Activation of PRRs like TLRs and RAGE 
(receptor for advanced glycation end products) lead to increased expression of the pro-
inflammatory cytokine pro-interleukin-1β [89, 90]. The contribution of this event to lung 
injury was demonstrated in a mice study with IL-1R knock-out mice, showing less pulmonary 
inflammation and protection against emphysema after exposure to cigarette smoke [91]. 
When the inflammatory response starts, several pro-inflammatory cytokines and chemokines 
such as tumor necrosis factor α (TNFα) or IL-8/CXCL8 are released from airway epithelial 
cells and alveolar macrophages. This leads to the recruitment of neutrophils and monocytes, 
[63], which explains why neutrophils and macrophages are present in higher numbers 
in the lungs of COPD patients compared to non-smokers. When activated, these cells 
release oxygen radicals and proteolytic enzymes such as neutrophil elastase and matrix 
metalloproteinases (MMPs) [92, 93]. Cigarette smoke and neutrophil elastase also stimulate 




Inflammatory cells in innate immunity
Macrophages
Macrophages play an important role in the pathogenesis of COPD and are essential in 
innate immunity and host defense [95, 96]. The number of alveolar macrophages in lung 
parenchyma and bronchoalveolar lavage (BAL) of patients with COPD is increased up to 
20-fold compared to healthy smokers and never-smokers [97, 98]. Increased numbers of 
macrophages have been found in small and large airways, lung parenchyma, BAL fluid 
and sputum of patients with COPD [99-103]. The number of macrophages in the airways is 
associated with the severity of COPD [58, 104]. After their activation by for instance cigarette 
smoke, macrophages release proteases, metalloproteinases (such as MMP-2, MMP-9, MMP-
12) and IL-8/CXCL8, which all contribute to destruction of the alveoli and the development of 
emphysema (Figure 3) [61, 105, 106].
Diverse macrophage subpopulations are present throughout the lung, such as alveolar 
macrophages and tissue macrophages. These macrophages constitute a heterogeneous cell 
population with substantial plasticity both in vivo and in vitro [95]. In vitro cultured human 
monocytes exposed to e.g. granulocyte or macrophage colony-stimulating factors (GM-
CSF and M-CSF, respectively) differentiate into MΦ1 and MΦ2 cells, respectively [107]. Due 
to environmental stimuli present in the lung, monocytes differentiate into a classical MΦ1 
(pro-inflammatory) or an alternatively activated MΦ2 (anti-inflammatory) phenotype. MΦ1 
cells are activated by exposure to TLR ligands and/or IFN-γ and are characterized by secretion 
of pro-inflammatory cytokines, such as IL-12, by promotion of Th1 response and by their 
antimicrobial activity. In contrast, MΦ2 cells promote tissue remodeling and phagocytic 
activity of apoptotic cells (efferocytosis), have a high expression of scavenger and mannose 
receptors, such as CD163 and produce anti-inflammatory cytokines, such as IL-10. However, 
the concept of this dichotomy in phenotypes is probably an oversimplification of the actual 
situation, which is even different between mice and men [108, 109]. It is plausible that in vivo 
macrophages with an intermediate phenotype exists [109]. A previous study showed that 
(small) MΦ1 macrophages, characterized by TNF-α and human leukocyte antigen (HLA)-DR 
were more abundant in induced sputum of COPD patients compared to large (possibly MΦ2) 
macrophages [110]. Another study investigating alveolar macrophage gene expression in 
COPD found that expression of genes related to MΦ1 macrophages in BAL is decreased and 
that of MΦ2 macrophages is increased in BAL of smokers with COPD compared to healthy 
smokers and non-smokers [111]. In this thesis, the subdivision between MΦ1 and MΦ2 is 
used (also called M1 and M2, respectively), which is an oversimplicifation of macrophage 
heterogeneity. This thesis further evaluates macrophage phenotypes and their distribution 




corticosteroids (ICS) on these phenotypes in patients with COPD. 
Macrophages play an important role in the defense against respiratory infections by bacteria 
such as (nontypeable) Haemophilus influenza, Moraxella catarrhalis and Streptococcus 
pneumoniae, which are all frequent pathogens in case of COPD exacerbations [112]. 
Although increased numbers of macrophages are present in the lung, the bacteria are not 
adequately phagocytosed. Studies have shown an impaired antimicrobial activity of alveolar 
macrophages in smoking and ex-smoking patients with COPD [113, 114]. The impaired 
phagocytic capacity of alveolar macrophages in smoking COPD patients is improved after 
smoking cessation [115] and after treatment with macrolide antibiotics, such as azithromycin 
[116].
Another way of improving phagocytic capacity of macrophages could be with (inhaled) 
glucocorticoids, which are frequently used as treatment in several airway diseases, including 
COPD. This has been confirmed in a study that showed that inhaled corticosteroids 
significantly increased efferocytosis in murine alveolar macrophages [117]. However, some 
studies suggest that these drugs are less effective in controlling pulmonary inflammation 
in COPD patients compared to other chronic inflammatory processes [118]. Steroids can 
reduce killing of pneumococci in in vitro cultured murine alveolar macrophages, partially by 
delaying phagolysosome acidification, without an effect on production of reactive oxygen or 
nitrogen species [119], supporting the observation that COPD patients treated with inhaled 
steroids have a slightly higher incidence of pneumonia [120]. Furthermore, there is a relative 
steroid resistance, which is associated with a decreased expression and activity of histone 
deacetylase 2 (HDAC2), a regulator of transcription during e.g. inflammation [121]. This 
reduced activity of HDAC2 is due to oxidative and nitrative stress, e.g. resulting from smoking, 
which combine to form peroxynitrite, resulting in inactivation and degradation of HDAC2, 
and thereby steroid insensitivity [122].
Neutrophils
The number of neutrophils in sputum [123] and BAL fluid [100] of patients with COPD is 
increased, but with various results in the lung parenchyma and the airway wall [101, 124, 
125], reflecting rapid passage of neutrophils through the lung tissue. A positive relation has 
been found between the number of sputum neutrophils and decline in lung function in 
patients with COPD [126], although other studies found that sputum neutrophils increased 
and bronchial neutrophils remained similar after smoking cessation in patients with COPD 
[127]. In addition, smoking cessation attenuated lung function decline in COPD [128].
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These data suggest divergent roles for neutrophils in the development and progression of 
emphysema, which may be explained by the fact that neutrophils are not a homogeneous 
group of cells. Furthermore, it is unclear to which extent neutrophils contribute to disease 
development, or are mostly increased as a result of e.g. tissue injury. This argument also holds 
for various other cell types associated with COPD.
Although neutrophils are present in increased numbers in the airways in COPD, clearance 
of bacteria is compromised probably due to disordered host-pathogen interactions [129]. 
Neutrophils and other inflammatory cells can be recruited by several chemotactic factors, 
such as IL-8, leukotriene B4 (LTB4) and other chemoattractants, which can be found in the 
airways of COPD patients [100]. Activated neutrophils secrete several proteases, including 
neutrophil elastase (NE), cathepsin G, proteinase-3 and matrix metalloproteinases (MMP)-
8 and 9. These proteases may contribute to the development of emphysema and stimulate 
mucus production [130, 131]. Cigarette smoke impairs efferocytosis of apoptotic neutrophils, 
which increase release of pro-inflammatory mediators, cytokines and chemokines from these 
neutrophils [129]. In addition, hypoxia in COPD prolongs survival of neutrophils in vitro [132], 
which impairs oxidase-dependent bacterial killing and promotes survival of bacteria [133]. 
It remains to be studied to what extent these described factors, as well as other cells of the 
immune system or remodeling of the airways in COPD contribute to the disordered function 
of neutrophils in COPD, compared to neutrophils of healthy smokers [129].
Eosinophils
COPD patients can present with marked eosinophilia in sputum, BAL and in the airway 
wall [134], even after exclusion of patient with asthmatic features. Sputum eosinophilia 
in COPD has been associated with more severe airflow obstruction [135], bronchial 
hyperresponsiveness to methacholine and adenosine 5’-monophosphate (AMP) and a 
higher number of exacerbations [136, 137]. In COPD patients, an elevated sputum eosinophil 
count is predictive for a better response to ICS on post-bronchodilator lung function, but 
does not result in a reduction in sputum eosinophils [138]. In addition, sputum eosinophils 
can be used as management strategy to reduce COPD exacerbations, eosinophilic airway 
inflammation and symptoms [139]. Elevated blood eosinophils can be found during COPD 
exacerbations; those patients with higher blood eosinophils and treated with ICS have a 






Mast cells play an important role in the airways of asthmatics, especially those in the airway 
smooth muscle [141, 142]. Smokers have more mast cells in sputum compared to ex-smokers 
with COPD [143]. Mast cells can secrete TNF-α, proteases and IL-8 and could therefore 
contribute to the pathogenesis of COPD as well [144]. Like macrophages, mast cells also 
constitute a heterogeneous cell population, with tryptase- and chymase-positive cells. With 
progression of COPD, the number, density, morphology and distribution of mast cells change 
[145]. The most predominant and important mast cell location in the airways in COPD is yet 
unclear, as mast cells have been found in all lung compartments [146]. A positive correlation 
has been found between the number of tryptase- and chymase-positive mast cells and lung 
function in COPD [147]. 
The cross-talk between innate and adaptive immunity
Dendritic cells
Dendritic cells function as antigen presenting cells in the airways and alveoli that link 
the innate and adaptive immune system. These cells present an antigen in a major 
histocompatibility complex (MHC) class I and II to naive CD8+ and CD4+ T-cells, respectively 
[63]. Cigarette smoke attracts dendritic cells to the respiratory tract especially in patients with 
COPD compared to healthy smokers, and their local numbers in lung tissue are associated 
with severity of airflow limitation [148]. The role of adaptive immunity is discussed elsewhere 
in this introduction.
Innate lymphoid cells 
Other cells which are involved in lung inflammation are the innate lymphoid cells (ILC), which 
are lymphocytes without expression of classical T-cell surface markers. Currently three ILCs 
have been described, although it is unclear whether these cells are stable, heritable cell 
lineages or stages of activation or differentiation [149]. ILC1 include natural killer (NK) cells 
and secrete IFN-γ, ILC2 are activated by epithelium-derived alarmins, including IL-25 and 
IL-33 and release Th2 cytokines, such as IL-4, IL-5, IL-13, which are involved in allergic lung 
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inflammation; and ILC3 release IL-17 and IL-22 which is involved in allergic asthma, virus-
induced lung disorders and airway remodeling in asthma [150, 151]. Especially ILC2s are 
involved in the cross-talk between innate and adaptive immune responses [151]. Recent 
studies have also suggested a role for ILC2s in the pathogenesis of COPD [152, 153], whereas 
the role of ILC1 and ILC3 is currently unclear. An accumulation of ILCs has been found in 
mouse lungs after a respiratory viral infection, and viral pathogens are thought to often 
contribute to acute exacerbations of COPD in humans [152]. Cigarette smoke decreases a 
specific receptor for IL-33 on ILC2s, but increased this receptor on NK cells. During infection, 
local IL-33 augmented type I pro-inflammatory responses via macrophages and NK cells 
[153].
The adaptive immune response
T-Lymphocytes
In the large and small airways as well as in the parenchyma in COPD, the cytotoxic CD8+ 
T-lymphocyte is the most predominant type of T-cell [99, 154-157]. The number of CD8+ 
cells is related to disease severity and airflow limitation in COPD [154, 158]. CD8+ T-cells 
(and natural killer cells of the innate immune system) release pore-forming and proteolytic 
enzymes such as perforin and granzyme B after activation, which cause cell death of target 
cells [154, 159]. Granzyme B expression in CD8+ T-cells and granulocytes is increased in small 
airways of patients with COPD, suggesting a possible role in the pathogenesis of COPD [160, 
161].
CD4+ T-cells are also important cells in the airways of smokers with COPD. Several subtypes 
of CD4+ cells are present of which Th1, Th17 and regulatory T-cells (Treg) cells are the most 
well-studied [162, 163]. CD4+ Th1 cells of COPD patients secrete more IFN-γ compared to 
healthy smokers, which promote attraction of other inflammatory cells to the lungs [164]. 
Th17 cells secrete IL-17A and IL-17F and mediate immunity against extracellular pathogens. 
They can induce epithelial cells to produce antimicrobial peptides, chemokines and growth 
factors (like GM-CSF), thereby regulating the inflammatory response [165]. IL-17A can also 
be secreted by macrophages, mast cells and epithelial cells [162]. Treg cells can regulate 
immune responses and suppress inflammation. Natural Treg have a main function in 
preventing auto-immunity, whereas adaptive or inducible Treg are mostly activated by 




mRNA encoding the transcription factor FOXP3 (forkhead box P3) and less IL-10 secretion 
(both markers of Treg) in the lungs compared to healthy smokers and never smokers [167]. 
However, the exact role of Treg cells in COPD needs to be elucidated.
B-lymphocytes
Increased numbers of B-cells, organized in lymphoid follicles, are found in both large and 
small airways and lung parenchyma during progression of COPD [58, 168-170]. The lymphoid 
follicles in COPD belong to inducible Bronchus-Associated Lymphoid Tissue (iBALT), which is 
an ectopic lymphoid tissue formed on infection and inflammation in mice and humans [171]. 
After contact with antigens from the airways, B-cell follicles initiate a local immune response 
and are maintained as memory cells in the lungs. One of the factors that regulate B-cells is 
B-cell activating factor (BAFF), which is present in healthy persons as well as in COPD and is 
associated with disease severity of COPD by promoting B-cell survival and lymphoid follicle 
expansion [172, 173]. When blocking the BAFF receptor in cigarette smoke-exposed mice, 
pulmonary inflammation and emphysema formation is attenuated [173]. The role of B-cells in 
the pathogenesis of COPD remains to be further clarified.
Is COPD an autoimmune disease?
Both T-cells and most B-cells need antigen-presenting cells, such as dendritic cells, before 
they are primed with an antigen. An intriguing question is which antigens that drive COPD 
development and progression are important in the case of COPD. Possible candidate 
antigens could be microbial, cigarette smoke components or auto-antigens from e.g. the 
extracellular matrix [174-176]. Examples of microbial antigens are for example viral epitopes 
or peptides. By slight modifications of the epitopes, such as oxidation or citrullination, they 
are still presented by the MHC, but lead to ineffective response by the host cells and may 
trigger autoimmunity instead [177]. Second, cigarette and wood smoke can both induce 
carbonylation and citrullination of lung proteins, which may serve as auto-epitopes [178, 
179]. In addition, an oligoclonal expansion of CD4+ and CD8+ T-cells has been found in the 
lungs after chronic cigarette exposure, which persists after smoking cessation [180]. Finally, 
breakdown products of elastin have been shown to induce proliferation and cytokine 
production by CD4+ T-cells in lungs of COPD and the presence of anti-elastin antibodies 
[167, 181], although anti-elastin autoantibodies were not found in another study [182]. 
Furthermore, anti-elastin antibodies are present in diseases that are not accompanied by 
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COPD [183]. Therefore, the presence of an autoimmune response is insufficient to define 
COPD as an autoimmune disease as this autoimmune response may not be causative for 
the disease. In addition, also anti-nuclear autoantibodies [184], as well as antibodies against 
rheumatoid factor (RF) and heat shock protein 70 (HSP70), have been found in COPD [185].
Remodeling and extracellular matrix
Remodeling takes place in the structural elements of the lungs, which are composed of 
several pillars, called together the extracellular matrix (ECM). This is a three dimensional 
structure, giving the lung its structural support and rigidity. The ECM is constantly changed 
by environmental stimuli, including mechanical forces, and is maintaining its functions such 
as cell adhesion, proliferation, cell trafficking, water balance and regulation of inflammatory 
mediators. Three major components of the ECM are collagens, proteoglycans and elastic 
fibers, which are produced by (myo)fibroblasts, epithelial cells and airway smooth muscle 
cells (Figure 4) [62, 186, 187]. The composition of the ECM in the lungs is different in healthy 
subjects versus COPD patients. Previous studies have shown that the airways of COPD 
patients contain less elastic fibers, reduced levels of the proteoglycan decorin but more of 
the proteoglycan versican and lower expression of collagen I and III is present [188-193]. 
This altered composition of the ECM, which is already present in mild and moderate COPD, 
contributes to the remodeling of the airways and lung parenchyma [59, 194].
Airway remodeling is a process that can result from repeated injury and repair and leads 
to structural changes in quantity, composition and organization of the airway structure. 
Remodeling is a process that has been linked to the presence of airflow limitation in COPD 
[59, 192, 195]. In COPD, it is mainly attributed to cigarette smoking, which induces structural 
changes due to chronic inflammation that occurs not only in the central, but also in the 
peripheral airways as well as the lung parenchyma. In both large and small airways of COPD 
patients, features of remodeling can be found. In the large airways epithelial metaplasia, 
goblet cell hyperplasia, mucus gland hypertrophy and thickening of the reticular basement 
membrane can be found [196]. In the small airways an increase in smooth muscle mass, 
angiogenesis, subepithelial collagen deposition and peribronchiolar fibrosis can be found, 
all contributing to reduced airway lumen and airflow limitation [58, 195, 197]. Emphysema 




alveolar integrity and emphysema. As a consequence gas exchange will be impaired, which 
can be measured as a lower diffusion capacity of carbon monoxide and ultimately hypoxemia.
The exact mechanism of airway remodeling has not been elucidated, but in addition to 
increased synthesis of matrix components, one of the possible mechanisms is the imbalance 
between an excess of matrix metalloproteinases (MMPs) and a shortage of tissue-inhibitor 
metalloproteinases (TIMPs), both produced by various cell types, including neutrophils, 
monocytes and macrophages [198]. The chronic inflammatory response in the airways 
causes chemotaxis of these cells. MMPs degrade collagens as well as proteoglycans [59, 199]. 
In addition, fragments of elastic fibers also have a chemotactic activity for monocytes and 
macrophages [200]. Fragments of proteoglycans such as versican, fibronectin and biglycan 
help to perpetuate inflammation through activation of Toll-like receptor (TLR)-2 and/or 
4. Cytokines such as TNF-α, transforming growth factor-β (TGF-β) and interferon (IFN)-γ, 
secreted by several inflammatory cells can also up- or downregulate ECM molecules or MMPs 
[201], thereby influencing ECM turnover. This thesis evaluates the effect of smoking and ICS 
on extracellular matrix components in large airways of patients with COPD.
Figure 4: Schematic presentation of the airway wall and its extracellular matrix components. Reproduced from 
Dunsmore [186].
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Basement membranes
Basement membranes are found wherever parenchymal 
cells juxtapose connective tissue (Figure 1). Basement 
membranes provide physical support for an organ and also 
regulate macromolecular diffusion. In the lung, the type 
I alveolar epithelial and capillary endothelial basement 
membranes are fused thus providing a minimal barrier 
for gas diffusion. At the biochemical level, specifi c base-
ment membrane components can modulate cell phenotype 
through direct interactions with cell surface recept rs. 
Integrins are the best characterized cell surface recep-
tors for matrix proteins and mediate both mechanical and 
chemical signals which activate a variety of intracellular 
signaling pathways to affect cell proliferation, survival, 
and differentiation (for review ee Hynes 2002; Danen and 
Sonnenberg 2003; Hynes 2004). Airway branching and 
alveolar epithelial cell localization are infl uenced by the 
interactions of basement membrane components such as 
type IV collagen, laminin, fi bronectin, and proteoglycans
with cell surface receptors.
The pulmonary interstitium
The pulmonary interstitium is located between the airspace 
epithelium and pleural mesothelium. Fibers of the matrix 
proteins, collagen and elastin, are the major components of 
the pulmonary interstitium. The primary function of these 
fi bers is to form a mechanical scaffold that maintains struc-
tural integrity during ventilation (Figure 2). It has long been 
recognized that devastating pathology can result from disrup-
tion of pulmonary interstitial matrix homeostasis. Increased 
extracellular matrix synthesis and deposition, particularly 
of types I and III collagen, epitomizes pulmonary fi brosis. 
In fi brotic lungs, gas exchange is adversely affected by the 
obliteration of capillary beds and decreased regional compli-
ance caused by the thickening of the pulmonary interstitium. 
Conversely, extracellular matrix degradati n is a character-
istic of pulmonary emphysema (Mandl et al 1977; Barnes 
2004). In this disease, ventilation is negatively affected by 
the decreased intrinsic recoil of the lung that results from 
proteolytic dest uction of elastic fi bers (Christie 1934; Stead 
et al 1952; Mead et al 1955; Cherniack 1956).
Figure 1 Basement membrane organization. Epithelial cells are linked to connective tissue via a network of matrix proteins. Laminin 5 connects integrins on the basal surface 
of epithelial cells to the type IV collagen network in the lamina densa of the basement membrane. Anchoring  brils composed of type VII and type XV collagen link the base-
ment membrane to the interstitial matrix where type I collagen, type III collagen and elastic  bers are found. Integrins located on the  broblast cell surface interact with many 
matrix proteins including type I collagen. Copyright © 2003, 2007. Modi ed with permission from Dunsmore SE, Chambers RC, Laurent GJ. 2003. Matrix Proteins. Figure 2.1.2. 
In: Respiratory Medicine, 3rd ed. London. Saunders, p. 83; Dunsmore SE, Laurent GJ. 2007. Lung Connective Tissue. Figure 40.1. In: Chronic Obstructive Pulmonary Disease: 
A Practical Guide to Management, 1st ed. Oxford. Wiley-Blackwell, p. 467.
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Smoking cessation is the intervention with the greatest capacity to influence the natural 
course of COPD, which has already been shown in the 1970’s (Figure 2) [30, 31]. Since 
nicotine is extremely addictive, smoking cessation should be supported by counseling 
combined with nicotine replacement therapy, varenicline (Champix) or bupropion (Zyban), 
which results in a cessation rate of roughly 50-60% after 3 months and 25-35% after 1 year 
[202, 203]. This clearly shows that the majority of people relapse. Therefore, active cigarette 
smoking should be seen as a chronic disease [204-206]. Smoking cessation has various 
beneficial effects, such as a slowing down of lung function decline [207], a decrease in 
respiratory symptoms and bronchial hyperresponsiveness [128] and increased survival [208]. 
In contrast, the effect of smoking cessation on airway inflammation in COPD is more difficult 
to interpret. Ex-smokers with COPD still have increased inflammatory cells after one-year 
smoking cessation, such as an increased percentage of sputum neutrophils and eosinophils, 
BAL percentage eosinophils and mucosal macrophages and eosinophils compared to healthy 
ex-smokers [209]. This may reflect a phase of repair. Some (cross-sectional) studies show 
a decrease in inflammation with increased levels of soluble TNF receptor-55 and -75 levels 
in sputum and blood in ex-smokers with mild to severe COPD [210, 211] and lower levels 
of neutrophil chemoattractant IL-8 in sputum [212]. These studies have been performed in 
small numbers of patients and some patients used steroids, which might have influenced the 
outcomes. Ex-smokers have lower mast cell numbers in the epithelium and lamina propria in 
bronchial biopsies [213]. Other studies show similar expression of pro-inflammatory markers 
(IL-8, MCP-1, TNFα, IL-1β, IL-2R and CCR2) and numbers of various inflammatory cells, like 
neutrophils, eosinophils, macrophages and lymphocytes in bronchial biopsies of current and 
ex-smokers with mild to severe COPD patients [214, 215]. With longer duration of smoking 
cessation (>3.5 years), bronchial CD8+ T-cells decrease, plasma cells increase and bronchial 
epithelial remodeling diminishes in moderate to severe COPD patients [216, 217]. These data 
suggest that bronchial inflammation (at least partially) persists after smoking cessation, but 
may depend on the duration of smoking cessation. However, a expression of a number of 
genes, such as SERPIND1, remain altered even years after smoking cessation, although that 
of other genes reverses to normal [218]. Although the exact mechanism for the ongoing 
inflammatory response is unknown, there are suggestions for self-perpetuating innate 
immune responses, decreased resolution of inflammation, airway wall remodeling, impaired 
macrophage clearance, microbial colonization of the lung, oxidative stress, hypoxia, genetic 
susceptibility and epigenetic changes [92, 158]. This thesis further studies the effect of 





Currently, there is no pharmacological treatment that modifies the long-term decline in lung 
function in COPD [207, 219-221], although some studies suggest that ICS may have beneficial 
effects on lung function decline [222, 223]. The goal for treatment of stable COPD is therefore 
to reduce symptoms, improve exercise tolerance and health status and to prevent disease 
progression, exacerbations and mortality [1]. The current management of COPD can be 
divided into non-pharmacological and pharmacological treatment modalities, which are 
discussed below.
Non-pharmacological treatment
Apart from smoking cessation, regular physical activity, pulmonary rehabilitation 
with attention for dietary status and influenza vaccination are also important non-
pharmacological strategies [224]. Pulmonary rehabilitation followed by maintenance and 
regular physical activity, improves exercise tolerance as well as reduction of dyspnea and 
fatigue in patients with COPD [225]. Benefits of rehabilitation diminish after ending of the 
program, but a patients’ health status remains better if exercise training is maintained 
[226, 227]. Yearly vaccination against influenza, but not pneumococcal vaccine, reduces 
the risk of hospitalization due to lower respiratory tract infections and mortality in patient 
with COPD [228, 229]. In case of hypoxemia (pO2 <8.0kPa), long-term supplemental oxygen 
therapy should be considered, as this reduces mortality [230]. In a selected group of patients 
with severe emphysema in the apical parts of the lungs and severe impairment of exercise 
tolerance lung volume reduction surgery (LVRS) can be considered, which increases exercise 
tolerance by improving the elastic retraction of the lungs and reduction of hyperinflation. In 
addition, these patients have a better survival compared to patients treated with pulmonary 
rehabilitation [231, 232]. Newer techniques using endobronchial lung volume reduction 
(BLVR) with one-way valves and coils for patients with severe COPD are currently developed 
[233, 234]. 
Pharmacological treatments
Preferentially, the pharmacological management of COPD patients should include 
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inhaled medications as this way of drug administration provides quick action mode in 
the lungs, requires a lower dose and therefore reduces the risk of (systemic) side effects 
[235]. The caveat of inhaled therapy in COPD is that some obstructed, peripheral regions 
of the tracheobronchial tree may not be accessible for inhaled aerosols. Pharmacological 
treatment is individualized, depending on the GOLD stage and/or combined COPD score 
(Table 1). The two main components of pharmacological treatment are bronchodilators and 
anti-inflammatory therapy: bronchodilators are given to relief complaints of dyspnea, anti-
inflammatory medications decrease inflammation and aim to achieve disease modification, 
by affecting the underlying pathophysiology of COPD. 
Table 1: Treatment options per COPD GOLD stage [1].*


































SABA: short-acting β2-agonists; LABA: long-acting β2-agonists; SAMA: short-acting anticholinergics; LAMA: 
long-acting anticholinergics; ICS: inhaled corticosteroids.
* Medication is presented in alphabetical orders and not order of preference.
** Medication in this column is only used in combination with other 1st choice options or with alternative 
choice options. 
Bronchodilators
Bronchodilators are important therapeutic options in COPD as they improve expiratory 




during exercise, and improving exercise tolerance [236]. Several variants of bronchodilators 
are currently available: short-acting β2-agonists (SABA), long-acting β2-agonists (LABA), 
short-acting anticholinergics (SAMA) and long-acting anticholinergics (LAMA), which can 
be used on an as-needed basis or a regular basis to prevent or reduce symptoms. LABA 
(e.g. salmeterol) have a better bronchodilating effect compared to SAMA (ipratropium), 
although no differences were found in dyspnea-scores, number of exacerbations, quality 
of life and exercise tolerance [237]. LAMA (tiotropium) treatment results in a higher lung 
function compared to LABA (salmeterol), but no differences were found in dyspnea-scores, 
number of exacerbations, quality of life and exercise tolerance [238, 239]. Compared to 
ipratropium, tiotropium reduces the risk of an exacerbation and improves quality of life [238]. 
Mortality is comparable between the different bronchodilators [240-242]. Very long-acting 
bronchodilators are currently available (both LABA and LAMA) and are applied in one inhaler 
(either LABA or LAMA alone, or combination). This combination of two very long-acting 
bronchodilators seems safe and effective [243, 244] and improves lung function even further 
compared to a separate LABA and LAMA [245]. However, results of studies regarding effect 
on exacerbations and quality of life are not yet available.
Inhaled corticosteroids (ICS)
ICS belong to one of the most prescribed medications for respiratory diseases, with 
approximately 30-40% use by patients with respiratory complaints in the United Kingdom 
and the Netherlands [246]. Of these patients, 50% use ICS for several months and 20-40% 
use ICS for more than 1 year [247]. The mechanisms by which corticosteroids may improve 
lung function in patients with COPD remain poorly understood, but 3 mechanisms of action 
of ICS have been described. First, bronchodilation may be enhanced by up-regulation of β2-
adrenergic receptors located in the airway walls and bronchial vessels, thereby potentiating 
its physiological effect [248]. It is known that in asthmatics fluticasone reduces bronchial 
blood flow within less than 2 hours after inhalation [249]. Second, the anti-exudative 
effects of ICS together with vasoconstriction of the bronchial circulation may reduce airway 
wall edema by the anti-exudative effects of ICS. Finally, ICS may reduce the release of 
inflammatory mediators and induce vasoconstriction of the pulmonary vasculature.
Many studies have evaluated the effect of ICS with and without LABA in COPD. Long-term 
ICS treatment (1 to 3 years) improves symptoms, quality of life and lung function (measured 
by FEV1) and decreases the number of exacerbations by about 30% in patients with COPD 
GOLD 2-3 [220, 221, 223, 250-253]. The GLUCOLD study group (see below in paragraph 
‘Aims of the present study’) has previously shown that 30-month treatment with inhaled 
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fluticasone propionate can attenuate decline in lung function [222]. However, meta-analyses 
(that did not include the (relatively small) GLUCOLD study) did not confirm this attenuated 
lung function decline [254, 255]. This suggests that efficacy of ICS depends on the cohorts 
investigated and thereby on COPD phenotype and/or severity of the patients in the study. 
Till now only a few trials have evaluated the anti-inflammatory effect of ICS in the airways 
in COPD [256]. Short term treatment with ICS with or without LABA showed no significant 
change in mucosal CD8+ cells, macrophages and neutrophils [257-259], while another 
study found a reduction in CD4+ and CD8+ cells in bronchial biopsies after treatment with 
fluticasone and salmeterol [260]. Furthermore, a meta-analysis showed that ICS may reduce 
sputum total cell counts, neutrophils and lymphocytes [261]. The GLUCOLD study group 
(see below in paragraph ‘Aims of the present study’) has previously shown that 30 months 
of treatment with inhaled fluticasone decreased the number of bronchial CD3+, CD4+ and 
CD8+ cells and mast cells and reduced the sputum neutrophil, macrophage and lymphocyte 
counts compared to placebo [222]. Furthermore, treatment with ICS in the GLUCOLD study 
was accompanied by a change in airway gene expression profiles [262]. 
As with every treatment, the benefits of ICS should be balanced against its adverse events. 
During the use of ICS with or without LABA, COPD patients have an increased risk of 
developing pneumonia, especially with use of fluticasone [120, 263-265], although they 
have fewer exacerbations. Other reported side effects are oropharyngeal candidiasis and 
hoarseness. Some studies found a decreased bone mineral density and cataract [252, 266-
268]; however as the systemic bioavailability is minimal, these findings are hard to interpret. 
Mortality risk in COPD patients of all stages is decreased after ICS treatment [269], although 
this was not found in other studies [223, 254]. Therefore, it is important to select the 
individual patient who will probably benefit most of ICS therapy [46]. ICS with or without 
LABA are currently recommended in COPD patients with GOLD 3-4 with many symptoms and 
more than two exacerbations per year [1, 270].
Withdrawal of ICS
Compliance to inhaled treatment, such as ICS, varies widely in patients with COPD and 
is dependent on GOLD stage [271]. Previous studies indicate that discontinuation of ICS 
induces a relapse in lung function decline in moderate to very severe COPD patients without 
an effect on the number of exacerbations [272]. However, other studies found an increased 




Effects of withdrawal of ICS in COPD on inflammatory parameters have been studied even 
more scarcely. The GLUCOLD study showed that after withdrawal following a 6-month 
treatment period the number of CD3+ cells, mast cells and plasma cells increased in bronchial 
biopsies, without an effect on sputum cell counts [222]. Others showed that the percentage 
of sputum neutrophils increased after 6 weeks of withdrawal of ICS [277], but this has not 
been confirmed in another study [275]. As ICS are frequently discontinued and only a few 
studies are available investigating the effects of withdrawal of ICS, this warrants careful 
monitoring of disease outcomes after withdrawal of ICS in COPD [278]. In this thesis the long-
term effects of withdrawal of ICS is studied on lung function decline and inflammatory cells 
in sputum and bronchial biopsies after a previous prolonged treatment with ICS in patients 
with moderate to severe COPD.
Aims of the present study
This thesis describes the cellular, pathological, and clinical changes during and after 
treatment with ICS in patients with COPD, with respect to the heterogeneity of the disease. 
Data from the GLUCOLD (Groningen and Leiden Universities Corticosteroids in Obstructive 
Lung Disease) study were used to analyze this. 
The GLUCOLD study
The GLUCOLD study is an investigator-initiated project (ClinicalTrials.gov registration number 
NCT00158847) and is a placebo-controlled, double-blind, randomized trial. The trial was 
initiated to study the effect of short- and long-term treatment with ICS with and without 
long-acting bronchodilators on lung function decline, airway inflammation and quality of 
life in patients with moderate to severe COPD. Patients were steroid naive, which implicates 
that they were not allowed to have used ICS 6 months prior to start of the study, to exclude 
unknown previous benefits of ICS and avoid selective drop-out in the placebo group. A 
total of 109 out of the 114 patients had never used ICS before enrollment in the study; 
only seven patients had ever received a short course of oral corticosteroids. Further in- and 
exclusion criteria are presented in Table 2. Lapperre et al. showed in the GLUCOLD study that 
ICS use decreased airway inflammation, attenuated lung function decline and improved 
quality of life in this group of COPD patients [222]. This thesis will continue to study airway 
inflammation, with a focus on macrophages and their heterogeneity, airway wall remodeling 




Table 2: In- and exclusion criteria of the GLUCOLD study.
Inclusion criteria
Age 45-75 years
>10 packyears of smoking
≥1 of the following symptoms: chronic cough, sputum production, frequent exacerbations or dyspnea 
on exertion
No course of oral steroids during the last 3 months, no maintenance treatment with inhaled or oral 
steroids during the last 6 months
Post-bronchodilator FEV1/IVC radio below 90% confidence interval (CI) of the predicted FEV1/IVC ratio 
and post-bronchodilator FEV1 (after 400ug salbutamol) <90% of predicted value (90% CI) [279]
Post-bronchodilator FEV1 >1.3liter and >20% of predicted value.
Exclusion criteria
Prior or concomitant history of asthma
α1-antitrypsin deficiency (SZ, ZZ, or zero phenotype)
Other active lung disease except for mild bronchiectasis
Contra-indications for elective bronchoscopy, such as oxygen saturation <90%, abnormal coagulability, 
anti-coagulant therapy which cannot be temporarily withheld during bronchoscopy, history of 
pneumothorax, uncontrolled angina pectoris
Other diseases likely to interfere with the purpose of the study
Inability to keep diary and to understand written and oral instructions in Dutch
During the first part of the study (GL1) patients were randomized to one out of four 
treatment options (Figure 5):
• 6-month inhaled fluticasone propionate 500µg twice daily, followed by 24-month 
placebo (F6)
• 30-month inhaled fluticasone propionate 500µg twice daily (F30)
• 30-month inhaled fluticasone propionate with salmeterol 500/50µg twice daily in a 
single inhaler (FS30)
• 30-month placebo 
Patients visited the outpatient clinic in Leiden University Medical Center (LUMC) or 
University Medical Center Groningen (UMCG) every 3 months during which lung function 
and quality of life were recorded. During the second part of the GLUCOLD study (follow-




spirometry was performed. During the follow-up study, patients were treated by their own 
pulmonary physician or general practitioner according to the current guidelines [1]. Airway 
hyperresponsiveness was recorded at baseline, after 6 and 30 months (GL1) and after 2 and 5 
years of follow-up (GL2). A bronchoscopy with bronchial biopsies was performed at baseline, 
after 6 and 30 months (GL1) and after 7.5 years (5 years of follow-up, GL2). 114 COPD 
patients started with the first part of the study, 85 patients started with GL2 and 61 patients 
completed 7.5 years of follow-up.
Figure 5: Study design during first (GL1) and second (follow-up, GL2) part of the GLUCOLD study.
Placebo 
FS30 





GLUCOLD follow-up study [GL2] 
3.5 7.5 6.5 5.5 4.5 
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Relation between smoking, treatment and macrophage heterogeneity in COPD
Chapter 2: Does smoking cessation have an effect on macrophage heterogeneity in 
bronchoalveolar lavage (BAL) and sputum of patients with COPD? 
The anti-inflammatory marker CD163 for anti-inflammatory macrophages (MΦ2) was used on 
sputum and BAL of current and ex-smokers with COPD. In addition, we measured the pro-
inflammatory mediators interleukin (IL)-6 and IL-8 and the anti-inflammatory mediators elafin, 
and Secretory Leukocyte Protease Inhibitor (SLPI) in BAL and sputum. 
Chapter 3: Do (inhaled) corticosteroids have an effect on macrophage polarization in in 
vitro cultured monocyte-derived macrophages as well as in serum and sputum of COPD 
patients? 
The novel pro-inflammatory MΦ1 marker YKL-40 was examined, and the effect of 
corticosteroids on secretion and expression of YKL-40 by in vitro cultured monocyte-derived 
macrophages was studied, and YKL-40 levels in serum and sputum of COPD patients were 
measured.
Effect of treatment on airway remodeling in COPD
Chapter 4: What is the effect of smoking and long-term treatment with ICS on 
composition of extracellular matrix components in large airways of COPD? 
Percentage and density of stained area with collagen I and III, the proteoglycans versican and 
decorin and elastic fibers were quantified and compared between smokers and ex-smokers 




Effect of withdrawal of inhaled corticosteroids treatment on clinical and 
pathological outcomes in COPD
Chapter 5: What is the effect of 5-year discontinuation of ICS on lung function decline, 
airway hyperresponsiveness and quality of life after 2.5-year treatment with ICS in 
patients with moderate to severe COPD?
Patients included in the randomized treatment during the first part of the GLUCOLD study 
(2.5 years, GL1) were followed for 5 consecutive years (GL2), and lung function and quality of 
life were measured annually. Airway hyperresponsiveness was measured after 2 and 5 years 
of follow-up. During the follow-up study, patients were treated by own physician according 
to the current guidelines.
Chapter 6: What is the effect of 5-year withdrawal of ICS after previous 2.5-year 
treatment with ICS on the inflammatory cells in the large airways of patients with 
COPD? 
After 2 and 5 years of follow-up during GL2, a sputum induction was performed; after 5 years 
of follow-up bronchial biopsies were obtained. Outcomes were number of inflammatory cells 
in sputum and bronchial biopsies. 
General discussion
Chapter 7: A summary is presented of the main results. Furthermore, implications of the 
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Background: Macrophages have been implicated in the pathogenesis of COPD. M1 and M2 
macrophages constitute subpopulations displaying pro- and anti-inflammatory properties. 
We hypothesized that smoking cessation affects macrophage heterogeneity in the lung of 
patients with COPD. Our aim was to study macrophage heterogeneity using the M2-marker 
CD163 and selected pro- and anti-inflammatory mediators in bronchoalveolar lavage (BAL) 
fluid and induced sputum from current smokers and ex-smokers with COPD.
Methods: 114 COPD patients (72 current smokers; 42 ex-smokers, median smoking cessation 
3.5 years) were studied cross-sectionally and underwent sputum induction (M/F 99/15, age 
62±8 [mean±SD] years, 42 (31-55) [median (range)] packyears, post-bronchodilator FEV1 
63±9% predicted, no steroids past 6 months). BAL was collected from 71 patients. CD163+ 
macrophages were quantified in BAL and sputum cytospins. Pro- and anti-inflammatory 
mediators were measured in BAL and sputum supernatants.
Results: Ex-smokers with COPD had a higher percentage, but lower number of CD163+ 
macrophages in BAL than current smokers (83.5% and 68.0%, P=0.04; 5.6 and 20.1 x104/ml, 
P=0.001 respectively). The percentage CD163+ M2 macrophages was higher in BAL compared 
to sputum (74.0% and 30.3%, P<0.001). BAL M-CSF levels were higher in smokers than ex-
smokers (571pg/ml and 150pg/ml, P=0.001) and correlated with the number of CD163+ BAL 
macrophages (Rs=0.38, P=0.003). No significant differences were found between smokers 
and ex-smokers in the levels of pro-inflammatory (IL-6 and IL-8), and anti-inflammatory 
(elafin, and Secretory Leukocyte Protease Inhibitor [SLPI]) mediators in BAL and sputum. 
Conclusions: Our data suggest that smoking cessation partially changes the macrophage 
polarization in vivo in the periphery of the lung towards an anti-inflammatory phenotype, 
which is not accompanied by a decrease in inflammatory parameters.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung function 
decline and an abnormal inflammatory response in the airways, mainly caused by cigarette 
smoke [1]. The inflammation response in the small airways in COPD is characterized by the 
accumulation of macrophages, neutrophils, CD8+-lymphocytes and B-cells and is associated 
with the severity of COPD [2, 3]. Smoking cessation is an effective treatment to reduce 
lung function decline [1]. Nevertheless, airway inflammation in bronchial biopsies, sputum 
and bronchoalveolar lavage (BAL) of COPD patients (predominantly) persists one year 
after smoking cessation [4-6]. We previously showed that the number of macrophages and 
neutrophils in bronchial biopsies are comparable in current and ex-smokers with COPD [7]. 
However, the effects of smoking on macrophage phenotypes in COPD are incompletely 
understood.
Macrophages play an important role in innate and adaptive immunity and form a 
heterogeneous population [8, 9]. Macrophages display polarized phenotypes by which they 
can be divided into subpopulations. Pro-inflammatory, or classically activated macrophages 
(M1) display pro-inflammatory and cytotoxic properties and can eradicate intracellular 
pathogens. In contrast, anti-inflammatory or alternatively activated macrophages (M2) 
display anti-inflammatory properties and are implicated in repair [8, 10]. Granulocyte-
macrophage colony stimulating factor (GM-CSF) can generate M1 in vitro from human 
peripheral blood monocytes, and macrophage colony stimulating factor (M-CSF) can 
generate M2 [11]. M1 secrete pro-inflammatory cytokines, like IL-(interleukin)-12 and 
tumor necrosis factor (TNF)-α, have good antigen presenting capacity and promote Th1 
immunity. In contrast, M2 secrete anti-inflammatory mediators, such as IL-10, show poor 
antigen presenting capacity and promote development of T-regulatory cells [11-13]. 
Alveolar macrophages show anti-inflammatory M2-characteristics [14-16], which can be 
distinguished from pro-inflammatory macrophages using M2 markers such as the scavenger 
receptor CD163 [17, 18]. Compared to M1 cells, M2 macrophages are highly phagocytic. 
The phagocytic capacity of alveolar macrophages is decreased in smoking COPD patients 
and improves with smoking cessation [19]. This suggests a phenotypic alteration and a 
role of macrophage heterogeneity in COPD, which has also been proposed in e.g. tumor 
progression [20], atherosclerosis [21] and renal diseases [22]. 
Although inflammation persists, smoking cessation shows positive clinical effects [1]. This 
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suggests that other mechanisms play a beneficial role, for instance regulation of macrophage 
polarization. We hypothesize that in moderate to severe COPD patients a) ex-smokers have 
more M2 and anti-inflammatory mediators in BAL and induced sputum compared to current 
smokers; b) M2 and anti-inflammatory mediators are relatively higher in the peripheral 
airways (as sampled by BAL) than in the central airways (as sampled by induced sputum).
METHODS
Subjects and study design
Patient characteristics and methods have been described previously [7, 23, 24]. In short, we 
studied 114 clinically stable moderate to severe COPD patients [GLUCOLD study (Groningen 
Leiden Universities Corticosteroids in Obstructive Lung Disease)] cross-sectionally. They 
were aged 45-75 years, smoked ≥10 packyears and were current or ex-smokers (quit ≥1 
month). Patients diagnosed with asthma, α1-antitrypsin deficiency and those who used 
corticosteroids in the past six months were excluded; they were allowed to use short-acting 
bronchodilators. Approval of the medical ethics committees of both centers was obtained 
and all patients provided written informed consent [23]. Spirometry was performed 
according to international guidelines [25]. All patients underwent a bronchoscopy with BAL 
and a sputum induction on separate visits.
Bronchoscopy, BAL and sputum induction
Fiberoptic bronchoscopy was performed in all patients and processed using a standardized 
protocol, as previously described [7, 24, 26, 27]. The BAL procedure was discontinued during 
the study due to ethical considerations, since four of 71 patients experienced a serious 
adverse event that was considered to be possibly related to the BAL procedure (pleural 
pain, fever, pneumonia, short-term cardiac ischemia). Sputum induction was achieved using 
hypertonic sodium chloride aerosols (w/v 4.5%) for a maximal duration of three times five 
minutes and processed according to the whole sample method.
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BAL and sputum processing
BAL was filtered through a nylon gauze and centrifuged for 10 minutes at 450*g at 4°C. If 
erythrocytes were macroscopically present, the cell pellet was resuspended in lysisbuffer 
(100 ml phosphate buffered saline (PBS) containing 0.83 gram NH4Cl, 0.1 gram KHCO3 and 
0.004 gram Ethylenediaminetetra Acetic Acid (EDTA), pH 7.4) for 5 minutes and centrifuged 
(450*g, 4°C). The cell pellet was resuspended in 0.1% glucose (w/v) in PBS and centrifuged 
again under the same conditions. BAL processing and differential cell counts were performed 
analogous to the methods described for sputum processing, except that no dithiothreitol 
was used for homogenization. The viability of the non-squamous cells in BAL was similar in 
smokers and ex-smokers (82 ± 12% versus 82 ± 9%, P=0.96).
Sputum was processed according to the whole sample method and all samples were treated 
with dithiothreitol 0.1% (DTT, Sputolysin, Calbiochem) [28]. Cell free supernatants of both BAL 
and sputum were stored at -80°C. 
From both BAL and sputum samples cytospins were centrifuged on apex-coated slides [28]. 
A sputum sample was considered adequate when the percentage squamous cells was less 
than 80%. After drying for 1 hour, the cytospins were wrapped in aluminum foil and stored 
at -80ºC pending immunocytochemical staining. 
Immunocytochemical staining
Frozen cytospins of BAL and sputum were brought to room temperature in one hour. BAL 
cytospins were fixed in acetone at -20°C for 10 minutes, dried and endogeneous peroxidase 
activity was blocked by incubation in methanol and 0.3% hydrogen peroxide for 10 minutes. 
Sputum cytospins were fixed in 4% paraformaldehyde in PBS 0.9% (w/v) for 1 hour, rinsed 
with PBS and endogenous peroxidase activity was blocked with sodium azide 0.1% (w/v) 
and hydrogen peroxide 0.18% (w/v) in PBS for 30 minutes. Non-specific binding was blocked 
in PBS, 1% bovine serum albumin (BSA) and 5% normal human serum (NHS) for 45 minutes 
for the sputum cytospins only. Mouse-anti-human CD163 (clone GHI/61, BD Pharmingen) 
was used as a primary antibody to stain M2-type macrophages [17] at the dilution of 1:75 
for BAL cytospins and 1:50 for sputum cytospins, and both were incubated for one hour at 
room temperature. The primary antibody was diluted in PBS/1% BSA for BAL cytospins 
and in PBS/1%BSA/1%NHS for sputum cytospins. The horseradish peroxidase conjugated 
anti-mouse Envision system (DAKO, Glostrup, Denmark) was used as a secondary antibody 
and was incubated for 30 minutes, the chromogen NovaRed (Vector, Burlingame, CA) for 
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7 minutes. All washing steps were with PBS. All slides were counterstained with Mayer’s 
hematoxylin (Klinipath, Duiven, The Netherlands) and mounted afterwards with Pertex 
mounting medium (HistoLab, Gothenburg, Sweden).
We considered the possibility that DTT used to liquefy the induced sputum samples affects 
detection of CD163. To this end we generated M1 and M2 by culture of monocytes for six 
days in the presence of GM-CSF and M-CSF respectively [11], and treated these cells with DTT 
prior to FACS-based analysis of CD163 expression and preparation of cytospins followed by 
immunocytochemical staining for CD163. 
Analysis of cytospins
Two cytospins per sample were stained for differential cell counts with May-Grünwald 
Giemsa (MGG). Differential cell counts were expressed as a percentage of nucleated 
cells, squamous cells excluded. The median percentage squamous cells was 7.5% (2.1-
13.3%). CD163+ and CD163- macrophages were enumerated based on morphology by two 
independent, experienced researchers at 400x magnification (Figure 1). To avoid observer 
bias, slides were coded without knowledge of clinical data. The mean number of CD163+ 
macrophages divided by the total counted number of macrophages was used to calculate 
the percentage of CD163+ macrophages. The total number of CD163+ macrophages per 
volume was calculated by the percentage of CD163+ macrophages multiplied by the total 
number of macrophages. Repeatability between the two observers (LIK and SVW) was good, 
as measured by the intraclass coefficient (ICC), with the two way random model and absolute 
agreement. For BAL CD163+ and CD163- macrophages the ICC were both 95%; for sputum 
CD163+ and CD163- macrophages the ICC were 97% and 93% respectively. 
Figure 1: Photomicrograph of membrane-bound CD163 staining on BAL and sputum cells. A BAL cytospin is 
shown in the left photograph and a sputum cytospin in the right photograph. Scale bar= 20 μm.
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Enzyme-linked Immunosorbent Assay (ELISA)
Commercially available kits were used to detect GM-CSF (Bender Medsystems), M-CSF 
(R&D systems), IL-6, IL-8, IL-10 (Sanquin), IL-12 (IL-12/IL-23p40, R&D systems) and elafin 
(HBT) in sputum and BAL supernatants. SLPI ELISA was developed in our laboratory at the 
Leiden University Medical Center [29]. The absorbance was measured at 450nm using a 
Microplate reader (model 680; Bio-Rad, Hercules, CA) and Microplate Manager software 
(version 5.2.1, Bio-Rad). The lower limits of detection for sputum were 300 pg/ml (SLPI), 2.5 
ng/ml (elafin), 38 pg/ml (IL-6) and 400 pg/ml (IL-8). The lower limits of detection for BAL 
were 150 pg/ml (M-CSF), 0.2 ng/ml (SLPI), 5.5 pg/ml (IL-6) and 15 pg/ml (IL-8). In BAL and 
sputum supernatants, IL-10, IL-12, GM-CSF levels were below the lower limit of detection. 
Furthermore, elafin and M-CSF were undetectable in BAL and sputum supernatants 
respectively. In case more than 10% of the samples were below the detection limits, the 
value of these samples was set at the lower limit of detection (M-CSF and IL-6 in BAL).
Statistical analysis
Mean values and standard deviations (SD) or medians with interquartile ranges (IQR) are 
presented. When appropriate, variables were logarithmically transformed before statistical 
analysis. Differences between smokers and ex-smokers were explored using χ2-tests, two-
tailed unpaired t-tests and Mann-Whitney tests. We used the Spearman (Rs) correlation 
coefficient to analyze correlations. Multiple linear regression was used to correct for the 
recovery of BAL. The statistical analysis was performed with SPSS 16.0 software (SPSS Inc., 
Chicago, IL). Statistical significance was inferred at P≤0.05.
RESULTS
Characteristics
In total, 114 COPD patients participated in the study, 72 current smokers and 42 ex-smokers, 
as presented in Table 1. All steroid-naive patients had moderate to severe COPD (GOLD stage 
2-3) based on a mean (SD) post-bronchodilator FEV1 of 63 (9)% predicted and had a median 
(25th and 75th percentile) smoking history of 42 (31-55) packyears. The total group of 
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patients and the unselected group in which BAL was performed were comparable. Of the BAL 
samples (first 71 patients), 62 were suitable for analysis. 106 out of 109 sputum inductions 
were suitable for analysis. BAL and sputum cell differentials and cell concentrations are 
presented in Figures 2 and 3. The percentage and number of macrophages in BAL were 
significantly higher in current smokers than in ex-smokers (95.8% and 74.2%, P<0.001; 
34.0 and 7.6x104/ml, P=0.008 respectively). The mean recovery of BAL was 41 (18)%; the 
recovery in smokers was higher compared to ex-smokers (45 (16)% and 35 (19)%, P=0.039, 
respectively). 
Table 1: Patient characteristics for current and ex-smokers with COPD.
Smokers (n=72) Ex-smokers (n=42)
Males (n (%)) 59 (81.9) 40 (95.2)*
Age (years) 60.1 (7.7) 64.1 (7.2)*
Packyears 43.3 (32.4-55.6) 36.8 (27.5-53.1)
Smoking cessation (years) 3.5 (1.0-9.8)
FEV1 post-bronchodilator (L) 2.02 (0.46) 2.05 (0.46)
FEV1 post-bronchodilator (%pred) 63.3 (8.3) 62.5 (9.6)
FEV1/IVC% post-bronchodilator 49.5 (8.5 46.0 (8.3)
*
KCO (%pred) 73.3 (25.1) 80.4 (25.9)
Data are presented as mean (SD) or median (IQR) unless otherwise stated. These patient characteristics have 
been previously described [7].
pred= predicted; FEV1= forced expiratory volume in one second; IVC= inspiratory vital capacity; KCO= carbon 
monoxide transfer coefficient.
* P<0.05 compared with smokers with COPD (χ2 test for sex differences, two tailed unpaired t-tests for other 
data).
Smoking status and CD163+ macrophages in BAL and induced 
sputum
DTT used to liquefy the induced sputum did not affect detection of CD163 by FACS and 
immunocytochemical staining (data not shown). Ex-smokers with COPD had a significantly 
higher percentage of anti-inflammatory CD163+ macrophages in BAL than current smokers 
(83.5% and 68.0%, P=0.04, respectively) (Figure 4), independent of BAL recovery. However, 
ex-smokers had a lower number of anti-inflammatory macrophages in BAL compared 
to current smokers (5.6 and 20.1x104/ml, P=0.001, respectively). The percentage CD163+ 
macrophages was higher in BAL compared to sputum (74.0% and 30.3%, P<0.001, 
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respectively). Ex-smokers had a similar percentage and number of anti-inflammatory 
macrophages in induced sputum compared to current smokers with COPD (25.0% and 31.1%, 
P=0.89; 10.1 and 6.8 x104/ml, P=0.24 respectively). 
Figure 2: BAL differential cell counts expressed as percentage and cell concentrations of COPD patients. 
Percentage is shown in the left panel, cell concentrations in the right panel. Open circles represent ex-smokers, 
closed circles represent current smokers. Horizontal bars represent medians. P-values are corrected for 
recovery of BAL fluid using multiple linear regression.
Figure 3. Sputum differential cell counts expressed as percentage and cell concentrations of COPD patients. 
Percentage is shown in the left panel, cell concentrations in the right panel. Open circles represent ex-smokers, 













































































































Figure 4. The percentage and number of CD163+ macrophages in BAL and induced sputum in COPD patients. 
The percentage (left panel) and number of CD163+ macrophages (right panel) in BAL and induced sputum 
between ex-smokers (open symbols) and smokers (closed symbols) with COPD. Horizontal bars represent 
medians. P-values are corrected for recovery of BAL fluid using multiple linear regression.
Smoking status and soluble mediators in BAL and induced sputum 
supernatants
BAL M-CSF levels were lower in ex-smokers than current smokers (P=0.001) (Figure 5 and 
Table 2). This difference was neither explained by differences in BAL recovery between both 
groups, nor by the ratio of M-CSF to anti-inflammatory macrophages. No correlation was 
found between recovery and BAL M-CSF levels. The anti-inflammatory mediator SLPI in BAL 
was inversely correlated with recovery. The pro-inflammatory mediators IL-6 and IL-8 in BAL 
were comparable between smokers and ex-smokers and were independent of recovery. No 
difference was found in induced sputum for the pro-inflammatory IL-6, IL-8 levels and the 
anti-inflammatory mediator elafin. The levels of SLPI, IL-6 and IL-8 in sputum were higher 
than the levels in BAL (all P<0.001). M-CSF was below the lower limits of detection in induced 
sputum and elafin was undetectable in BAL.
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Table 2: Soluble mediators measured in BAL and induced sputum supernatants of smokers and ex-smokers 
with COPD.
Soluble mediator Ex-smokers Smokers
BAL
   SLPI (ng/ml) 156 (72-386) 87 (48-154)
   M-CSF (pg/ml) 150 (150-159) 571 (150-927)
   IL-6 (pg/ml) 6 (6-6) 6 (6-6)
   IL-8 (pg/ml) 83 (43-193) 64 (37-122)
Sputum
   SLPI (ng/ml) 5897 (4406-8628) 6643 (4321-8862)
   Elafin (ng/ml) 44 (20-102) 44 (12-101)
   IL-6 (pg/ml) 23 (10-36) 30 (11-58)
   IL-8 (pg/ml) 3454 (1178-5212) 2571 (805-5900)
Data are presented as medians (IQR 25-75th percentile).
Figure 5. Soluble mediators measured in BAL and induced sputum supernatants of COPD patients. Ex-smokers 
are represented by open symbols and smokers by closed symbols. Horizontal bars represent medians. P-values 
are corrected for recovery of BAL fluid using multiple linear regression.




































Correlation between cells, mediators and lung function
The number of CD163+ macrophages in BAL correlated with FEV1 post-bronchodilator 
(%predicted) (Rs=0.255; P=0.05) and FEV1/IVC% (Rs=0.374; P=0.004). No correlations were 
found between the number and percentage CD163+ macrophages in BAL and sputum and 
the number of packyears or the duration of smoking cessation. No correlations were found 
between the number of packyears or duration of smoking cessation and concentrations of all 
soluble mediators in BAL and induced sputum.
BAL M-CSF correlated with the number of CD163+ macrophages in BAL (Rs=0.379; P=0.003). 
BAL SLPI was negatively correlated with the number and percentage of macrophages and 
positively correlated with the number and percentage of neutrophils in BAL (all P<0.05). 
BAL SLPI and the number of CD163+ macrophages correlated inversely (Rs=-0.353; P=0.008). 
Sputum SLPI correlated with the number and percentage of CD163+ macrophages in 
sputum (Rs=0.377; P<0.001 and Rs=0.236; P=0.021, respectively). Both BAL and sputum IL-8 
correlated inversely with percentage macrophages, but positively with the percentage and 
number of neutrophils (all P<0.05). This relation was not seen for IL-6. A trend was seen for 
a correlation between sputum IL-8 and the percentage of CD163+ macrophages (Rs=-0.189; 
P=0.061). The percentage, but not the number, of CD163+ macrophages in BAL showed a 
trend for correlation with sputum (Rs=0.267, P=0.053).
DISCUSSION
This study is the first to show that the percentage of macrophages with anti-inflammatory, 
M2-type characteristics (as shown by CD163 expression) is significantly higher in BAL 
from ex-smokers than in current smokers with COPD. In addition, the percentage of anti-
inflammatory macrophages was higher in BAL than in induced sputum, indicating a 
predominance of this macrophage phenotype in the periphery of the lung. BAL M-CSF 
correlated with the number of CD163+ macrophages in BAL. The results together are 
in line with the hypothesis that smoking cessation causes a shift in the phenotype of 
luminal macrophages towards a more anti-inflammatory phenotype, which is restricted 
to the periphery of the lung. Although we did observe a higher percentage of M2-
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type macrophages in BAL from ex-smokers, this was not accompanied by a decrease in 
inflammatory parameters such as neutrophils and pro-inflammatory mediators. 
Our study shows that ex-smokers with COPD have a higher percentage of anti-inflammatory 
macrophages in BAL than current smokers. Our findings on pulmonary macrophage 
polarization further extend previous observations. First, we discovered that macrophages 
recovered from induced sputum have less anti-inflammatory features than from BAL. A 
previous study showed that induced sputum of COPD patients contains a majority of pro-
inflammatory macrophages, based on their HLA-DR expression and capacity to produce 
TNFα, in contrast to control subjects [30]. However, these authors only analyzed markers of 
pro-inflammatory macrophages and most patients used corticosteroids which may have 
affected the macrophage phenotype [17]. Second, we showed that ex-smokers have more 
anti-inflammatory macrophages in BAL than current smokers. This is in line with a recent 
paper, showing that never smokers compared to current smokers had higher BAL levels of 
CCL18, a chemokine expressed by alternatively activated macrophages [31]. Furthermore, 
previous studies have shown that anti-inflammatory macrophages have a higher phagocytic 
capacity [8, 10]. Therefore our findings are in line with another study demonstrating that 
alveolar macrophages of current smokers with COPD show reduced phagocytosis compared 
to ex-smokers [19]. In addition, active smoking, but also the presence of COPD itself, may be 
associated with an impaired phagocytic capacity of alveolar macrophages (and therefore a 
predominance of pro-inflammatory macrophages) [32-34]. However, in contrast to these and 
our findings, a recent study indicated that smoking may enhance macrophage differentiation 
into an anti-inflammatory phenotype, since cigarette smoking polarized human alveolar 
macrophages of COPD patients in vivo towards an enhanced expression of M2-related 
genes and a suppression of M1 genes [35]. This study included only 12 COPD patients with 
predominantly GOLD stage 1. A possible explanation for this apparent difference with 
our observations is therefore that the direction of the effect of smoking on macrophage 
differentiation may be determined by disease severity. 
Previously, several studies have evaluated the effect of smoking on soluble mediators. We 
found comparable SLPI levels in BAL between current smokers and ex-smokers with COPD, in 
line with results from a study of 25 smoking, ex-smoking and never smoking COPD patients 
with GOLD stage 2-3 [36]. We did not find a difference in BAL IL-6 and IL-8 and sputum IL-6 
between current smokers and ex-smokers with COPD, in line with two previous studies [37, 
38].
We believe that our study has several strengths. We studied a large cohort of well-
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characterized COPD patients in which sputum (n=114) and BAL (n=71) were collected, 
whereas previous studies were of smaller size [30, 31, 36, 39]. In addition, we studied 
steroid-naive patients, excluding possible influences of inhaled corticosteroid therapy 
on CD163 expression. This is important, since it has been shown in previous studies that 
dexamethasone induces CD163 expression on monocytes and macrophages in vitro [17]. 
The BAL and sputum cytospins were counted manually by two independent researchers 
simultaneously (LIK and SVW). CD163- macrophages as well as CD163+ macrophages were 
readily recognized. Repeatability between the observers was good, as measured by the 
intraclass correlation coefficient. 
A number of limitations needs to be taken into account when interpreting our results. First, 
this was a cross-sectional study and it cannot be ruled out that our group of ex-smokers 
quit smoking because they experienced more smoking related symptoms and they may 
have had different macrophage phenotypes before quitting. In addition, we did not confirm 
smoking status by laboratory tests which is in line with other cross-sectional studies [4,5] and 
therefore cannot exclude the possibility that some ex-smokers were still smoking. Second, 
BAL samples were not available from all subjects in our study due to ethical considerations. 
As this was not anticipated, it is unlikely that a selection bias for the BAL results was 
introduced. Nevertheless, a significant difference in anti-inflammatory macrophages in BAL 
was found between smokers and ex-smokers. Further studies are needed to investigate 
whether the observed differences in CD163 staining on macrophages are also observed 
when comparing current or ex-smokers without COPD to non-smokers and whether CD163 
expression is a specific feature of COPD. Third, we only focused on the marker CD163 for M2 
macrophages, which can result in an oversimplification of our conclusions. Furthermore, it 
appears that the M2 macrophage population is more heterogeneous than the M1 population 
[9] and M2 subpopulations were not taken into account in our analysis. Obviously, it is of 
interest to evaluate whether the use of pro-inflammatory or other anti-inflammatory markers 
(like arginase or iNOS) can confirm our results and whether associated functional differences 
can be detected. Currently, there is no general agreement on well defined markers for M1 
macrophages. 
Fourth, we found that the percentage CD163+ cells is higher in ex-smokers with COPD 
whereas the number of CD163+ cells is higher in current smokers with COPD. In addition, we 
observed a higher percentage and number of macrophages in BAL from smokers compared 
to ex-smokers, which likely results from more active recruitment of monocytes from the 
circulation. Therefore, it is not surprising that smokers have a higher number of CD163+ cells 
in BAL, since they have more macrophages in BAL. We hypothesize that percentages and 
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numbers provide different and complimentary information: percentages better reflect the 
environment during differentiation, whereas cell numbers result from both recruitment and 
differentiation. Fifth, several soluble mediators were below the lower limits of detection in 
sputum and BAL supernatants. Finally, analysis of cytospins using immunocytochemistry is a 
semi-quantitative measurement and could therefore result in incorrect interpretations. Using 
e.g. FACS analysis ideally combined with functional analysis of e.g. the phagocytic capacity of 
the macrophages, could have been more accurate to evaluate the equilibrium between pro- 
and anti-inflammatory macrophages in our samples. Unfortunately, fresh samples were not 
available at the time of this research.
How can we explain our results? Macrophages in the periphery of the lung in healthy 
individuals display mainly anti-inflammatory characteristics that may be involved in 
suppressing inflammation in this area of the lung. Our study, as well as recent data from 
others [19, 40], suggest that the anti-inflammatory environment may change into a pro-
inflammatory environment as COPD develops in smokers. This is in line with the observation 
that IL-10 levels are lower and GM-CSF and Matrix Metalloproteinase (MMP)-12 levels are 
higher in sputum and BAL from COPD patients compared to healthy controls [39, 41, 42]. 
Inflammatory lung diseases, including COPD [43], are characterized by increased local 
production of GM-CSF which may contribute to development of a pro-inflammatory 
macrophage phenotype in addition to its established effect on neutrophil survival [44]. 
Macrophages maintain their plasticity even when differentiated into M1 or M2 cells and 
can switch their phenotype dependent on the presence of appropriate stimuli [45, 46]. 
In this study we add to the field that smoking cessation may skew alveolar macrophage 
heterogeneity towards a more anti-inflammatory phenotype as characterized by the M2 
marker CD163. Pro-inflammatory macrophages are the predominant phenotype in the 
central airways, which may be explained by high exposure to pathogens and environmental 
stimuli compared to macrophages in the peripheral airways. The higher percentage 
and number of neutrophils in sputum samples are in line with this observation. The 
predominance of anti-inflammatory macrophages in the periphery of the lung may help to 
keep this area, which is central to gas exchange, free from excessive inflammation.
Our results suggest that smoking cessation can change macrophage polarization from a 
pro-inflammatory towards a CD163 expressing anti-inflammatory phenotype, which may 
decrease inflammation and enhance repair. Our findings of a positive association between 
a better lung function and more anti-inflammatory M2 macrophages are in line with this. We 
hypothesize that a shift in macrophage phenotype contributes to further clinical effects of 
smoking cessation. Therefore, the plasticity of the macrophage phenotype and the possibility 
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to modulate this phenotype may be relevant to the treatment of chronic inflammation, 
including COPD. 
CONCLUSION
This study shows that previous smoking cessation may contribute to the anti-inflammatory 
phenotype of intraluminal macrophages in BAL of ex-smoking COPD patients in vivo. 
Additional research is needed to further characterize this phenotype and to demonstrate its 
impact on local inflammation. Furthermore, studies are needed to investigate whether it is 
restricted to luminal macrophages or is also present in lung tissue. Prospective studies are 
required to show whether anti-inflammatory treatment contributes to the anti-inflammatory 
macrophage phenotype in vivo, and whether this contributes to treatment effects on 
inflammation and clinical outcomes such as lung function decline.
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Background: Macrophages constitute a heterogeneous cell population with pro- (MΦ1) 
and anti-inflammatory (MΦ2) cells. The soluble chitinase-like-protein YKL-40 is expressed in 
macrophages and various other cell types, and has been linked to a variety of inflammatory 
diseases, including COPD. Dexamethasone strongly reduces YKL-40 expression in peripheral 
blood mononuclear cells (PBMC) in vitro. We hypothesized that: a) YKL-40 is differentially 
expressed by MΦ1 and MΦ2, b) is decreased by corticosteroids and c) that long-term 
treatment with inhaled corticosteroids (ICS) affects YKL-40 levels in serum and sputum of 
COPD patients. 
Methods: Monocytes of healthy subjects were cultured in vitro for 7 days with either GM-
CSF or M-CSF (for MΦ1 and MΦ2, respectively) and stimulated for 24h with LPS, TNFα, or 
oncostatin M (OSM). MΦ1 and MΦ2 differentiation was assessed by measuring secretion 
of IL-12p40 and IL-10, respectively. YKL-40 expression in macrophages was measured by 
quantitative RT-PCR (qPCR) and ELISA; serum and sputum YKL-40 levels were analyzed by 
ELISA. 
Results: Pro-inflammatory MΦ1 cells secreted significantly more YKL-40 than MΦ2, which 
was independent of stimulation with LPS, TNFα or OSM (P<0.001) and confirmed by qPCR. 
Dexamethasone dose-dependently and significantly inhibited YKL-40 protein and mRNA 
levels in MΦ1. Serum YKL-40 levels of COPD patients were significantly higher than sputum 
YKL-40 levels but were not significantly changed by ICS treatment.
Conclusions: YKL-40 secretion from MΦ1 cells is higher than from MΦ2 cells and is 
unaffected by further stimulation with pro-inflammatory agents. Furthermore, YKL-40 release 
from cultured monocyte-derived macrophages is inhibited by dexamethasone especially 
in MΦ1, but ICS treatment did not change YKL-40 serum and sputum levels in COPD. These 
results indicate that YKL-40 expression could be used as a marker for MΦ1 macrophages in 
vitro, but not for monitoring the effect of ICS in COPD.
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INTRODUCTION
YKL-40 (or chitinase 3-like-1 [CHI3L1], breast regression protein [BRP]-39 or human 
cartilage glycoprotein-39 [HCgp-39]) is a chitinase-like protein which is found in humans 
[1]. It is expressed by various cell types, including neutrophils and macrophages [2-4], 
while macrophages have been identified as its main cellular source [2, 5]. Monocytes do 
not express YKL-40, and YKL-40 expression appears to be associated with later stages of 
macrophage differentiation [2, 6]. Although its biological function is largely unknown, YKL-
40 has been suggested to play a major role in a variety of processes, including epithelial-
mesenchymal transition, migration and proliferation of (malignant) cells, angiogenesis, tissue 
remodeling and inflammation [7-9]. Furthermore, YKL-40 has been implicated in several 
acute and chronic inflammatory diseases, including asthma and COPD [10, 11]. Several 
studies have shown that YKL-40 levels are higher in sputum and serum of COPD patients 
compared to asymptomatic smokers [12, 13].
These data suggest that macrophages may also be a major source of YKL-40 in inflammatory 
lung diseases such as COPD, a disease in which macrophages play an important role [14]. It is 
however unknown whether YKL-40 expression is restricted to a subset of macrophages. This 
is a relevant question, since macrophages constitute heterogeneous cell populations with 
various functions. Pro-inflammatory, or classically activated macrophages (type I, MΦ1), show 
pro-inflammatory properties by secreting pro-inflammatory cytokines such as interleukin-12 
(IL-12), have antigen presenting capacity and promote Th1 immunity. In contrast, anti-
inflammatory, or alternatively activated macrophages (type II, MΦ2), demonstrate anti-
inflammatory characteristics with expression and secretion of anti-inflammatory cytokines, 
such as IL-10 and promote development of regulatory T cells [15]. Furthermore, Di Rosa et al. 
observed higher expression of YKL-40 in monocyte-derived MΦ1 [16]. 
Dexamethasone strongly suppresses YKL-40 expression in cultured monocyte-derived 
macrophages [17]. In line with these findings, rheumatoid arthritis patients treated with 
methotrexate and prednisolone had lower serum YKL-40 concentrations compared to 
patients treated without prednisolone [18]. However, it is unknown if YKL-40 levels are 
influenced by treatment with inhaled corticosteroids (ICS) in COPD and could therefore be 
used to monitor treatment response. Furthermore, it is not known whether modulation by 




Based on these observations we hypothesized that YKL-40 expression is directed by 
macrophage polarization, with a higher expression in monocyte-derived MΦ1 compared to 
MΦ2. Furthermore, we hypothesized that steroids decrease YKL-40 secretion and expression 




Monocytes were isolated from buffy coats of healthy blood donors (Sanquin Blood Bank, 
Leiden, The Netherlands) using anti-CD14 microbeads (Miltenyi Biotec, Auburn, CA, USA) 
according to the manufacturer’s protocol. MΦ1 and MΦ2 were derived as described 
previously [23, 24]. Briefly, cells were cultured for six days in RPMI 1640 medium in 48 well 
plates (Invitrogen, Life Technologies, Bleiswijk, The Netherlands) containing 10% fetal calf 
serum (FCS, Invitrogen), 2mM L-glutamine, 100U/ml penicillin and 100μg/ml streptomycin 
(all Bio Whittaker, Walkersville, MD, USA) at 37°C in 5% CO2 atmosphere with either GM-CSF 
(5ng/ml, Invitrogen) or M-CSF (50ng/ml, R&D Systems, Minneapolis, MN, USA) to obtain 
MΦ1 and MΦ2, respectively (13, 14). Differentiated macrophages were stimulated with the 
pro-inflammatory stimuli lipopolysaccharide (LPS, from Pseudomonas aeruginosa, 100ng/
ml, Sigma-Aldrich, St. Louis, MO, USA), TNF-α (10ng/ml, Peprotech, Rocky Hill, NJ, USA) or 
oncostatin M (OSM, 100ng/ml, R&D Systems) for 24 hours. Dexamethasone (0.1, 0.3 and 1nM, 
Sigma) was added during differentiation at day 0, 3 and/or day 7. The demethylating agent 
5-AZA-2’-deoxycytidine (5-AZA, 0.1, 1 and 10 μM, Sigma) was added during differentiation. 
Every day 100 μl per well was removed and replaced by fresh medium containing growth 
factors and 5-AZA. 
GLUCOLD study
Serum and sputum supernatants were obtained from patients with moderate to severe 
COPD who participated in the GLUCOLD (Groningen and Leiden Universities Corticosteroids 
in Obstructive Lung Disease) study [25]. Patients were steroid-naive at baseline and were 
subsequently randomized to one of four inhaled treatments, all twice daily: 6- or 30-month 
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fluticasone propionate dry-powder inhaler (500µg, group 1 and 2, respectively), 30-month 
fluticasone with salmeterol (500/50µg, group 3) or 30-month placebo (group 4). In this 
mechanistic study, we only used data from the compliant patients (≥70% of the prescribed 
dose of treatment) of groups 2 and 3 combined to increase power, and group 4. At baseline 
and after 30 months of treatment, serum and sputum samples were collected. Sputum 
induction and processing were performed as previously described [26, 27]. Cell free 
supernatants of serum and sputum were stored at -80°C. The ethics committees of Leiden 
University Medical Center and University Medical Center Groningen approved the study and 
all patients provided written informed consent.
Enzyme-linked Immunosorbent Assay (ELISA)
Commercially available ELISA kits were used to detect IL-12p40 (IL-12/ IL-23p40, R&D 
Systems; sensitivity 62.5 pg/ml) and IL-10 (Sanquin, Amsterdam, The Netherlands; sensitivity 
4.1 pg/ml), to confirm that the monocytes were adequately differentiated towards MΦ1 and 
MΦ2, respectively (Figure 1A). YKL-40 ELISA (R&D Systems; sensitivity 16 pg/ml [10]) was 
performed on cell culture supernatant, serum and sputum supernatant. The absorbance was 
measured at 450nm using a Microplate reader (model 680; Bio-Rad, Hercules, CA, USA) and 
Microplate Manager software (version 5.2.1, Bio-Rad). 
Flow cytometry
Cell surface markers were assessed by standard flow cytometry using a FACS Calibur 
cytometer (Becton and Dickinson, La Jolla, CA, USA) and CellQuest Pro software after staining 
with specific APC-conjugated CD163 and CD14 (both BD Biosciences/ Pharmingen (Temse, 
Belgium), FITC-conjugated CD68 (eBioscience, Vienna, Austria) and/or goat-anti-human 
YKL-40 (R&D systems) detected by Alexa Fluor 594 F(ab’)2 fragment of goat anti-mouse 
(Invitrogen) as secondary antibody. Cells were incubated with the antibodies for 30 minutes 
on ice in PBS containing 0.5% BSA (w/v) and 0.2% sodium azide (w/v) (both Sigma). After 
fixation with Cytofix/ Cytoperm buffer, intracellular staining was performed in Perm/ Wash 
buffer (both BD Biosciences). Flow cytometric analysis confirmed that the differentiated 
monocytes were CD14+ and CD68+, and that the majority of MΦ2 were CD163+ (Figure 1B). 




Figure 1: Characterization of differentiated MΦ1 and MΦ2. Figure 1A: IL-12p40 (left panel) and IL-10 (right 
panel) in supernatants of MΦ1 and MΦ2, respectively, stimulated with LPS for 24 hours. Data represent means 
with SEM of 6 donors. Figure 1B: Flow cytometry analysis for CD68, CD14 and CD163 (left, middle and right 
panel, respectively) for MΦ1 and MΦ2 (upper and lower panel, respectively). 
Immunofluorescence staining
YKL-40 and CD68 expression in sputum cytospins was demonstrated using 
immunofluorescence. Cytospins were fixed in 4% formaldehyde in PBS for 30 minutes, 
followed by antigen retrieval in citrate solution pH6.0 (DAKO, Glostrup, Denmark) for 30 
minutes and cooled on ice. The primary antibodies goat-anti-human YKL-40 (R&D systems, 
dilution 1:25) and mouse-anti-human CD68 (clone PG-M1, DAKO, dilution 1:50), diluted in 
PBS/ 1% BSA (w/v) were incubated together overnight. Alexa Fluor568 donkey-anti-goat 
and Alexa Fluor 488 donkey-anti-mouse (Invitrogen, Eugene, OR, dilution of both 1:200) 
were incubated in a dark environment for 30 minutes. The cytospins were covered with 
Vectashield with DAPI (Vector Laboratories, Inc. Burlingame, CA, USA). Photographs were 
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Quantitative reverse-transcriptase polymerase chain reaction (qPCR)
RNA was isolated using Qiagen RNeasy mini kit (Qiagen, Venlo, The Netherlands) and cDNA 
was synthesized in equal amounts per experiment. Quantitative reverse-transcriptase 
polymerase chain reaction (qPCR) was performed with the primers for YKL-40 and LL-37 as 
presented in Table 1. QPCR was performed on the iCycler PCR device using iQ SYBR Green 
Supermix (Bio-Rad) for 40 cycles at 58°C. Relative mRNA concentrations of ACTB and ATP5B 
(GeNorm, PrimerDesign Ltd., Southampton, UK) were used as housekeeping genes for 
human genes.




CTG TGG GGA TAG TGA GGC AT CTT GCC AAA ATG GTG TCC TT
LL-37 (CAMP) 
(249 base pairs)
TCA TTG CCC AGG TCC TCA G TCC CCA TAC ACC GCT TCA C
Statistical analysis
Differences within one cell type and between cell types were analyzed by one-way and two-
way ANOVA, respectively. Paired and unpaired tests were used for evaluating YKL-40 levels 
in serum and sputum within and between treatments, respectively, using only data from 
subjects with availability of samples from both baseline and 30 months. Statistical analysis 
was performed with SPSS 22.0 software (SPSS Inc., Chicago, IL). Data are presented as means 
with standard error of the mean (SEM) for in vitro experiments and means with standard 





MΦ1 produce more YKL-40 compared to MΦ2
Secretion of YKL-40 by MΦ1 was markedly higher compared to MΦ2 (P<0.001) and not 
further increased by stimulation for 24 hours with 100ng/ml LPS compared to medium 
(P<0.001; Figure 2A, left panel). qPCR confirmed these results, i.e. MΦ1 express more YKL-40 
than MΦ2 with and without LPS stimulation (10-fold higher in MΦ1 vs MΦ2, P<0.001; Figure 
2A, right panel), with a trend towards more YKL-40 expression in LPS-stimulated MΦ1 (P<0.1). 
Flow cytometry analysis also showed that MΦ1 cells express more YKL-40 compared to MΦ2 
(Figure 2B). In addition, MΦ1 secreted more YKL-40 compared to MΦ2 which was irrespective 
of further stimulation with TNF-α, and OSM for 24 or 48 hours, respectively (all P<0.001, 
Figure 2C). Immunofluorescence staining showed that only a minority of macrophages in 
sputum of COPD patients was positive for YKL-40 as shown by co-staining with CD68 (Figure 
2D).
YKL-40 expression is inhibited by dexamethasone
To investigate the effect of steroids on macrophage YKL-40 expression, we first assessed 
its effect on expression of the MΦ1 and MΦ2 markers IL-12p40 and IL-10. Whereas 
dexamethasone did not affect IL-10 secretion, it inhibited IL-12p40 secretion, especially when 
added at day 0 (Figure 3A and B, respectively). In line with these findings, dexamethasone 
also dose-dependently inhibited YKL-40 expression and secretion mainly in MΦ1 (Figure 
4A and B, respectively). Again this effect was most pronounced when dexamethasone was 
added from the start of the differentiation at day 0 (Figures 4A and B, left panel). Adding 
dexamethasone at later time points (day 3 or day 7) showed a trend for lower YKL-40 
expression and secretion (Figures 4A and B, middle and right panel, respectively), but failed 
to reach significance. 
We have previously demonstrated that the human cathelicidin antimicrobial peptide 
hCAP/LL-37 directs macrophage differentiation towards MΦ1 cells [28]. In the course of 
the latter studies we also noted that hCAP18/LL-37 is preferentially expressed in MΦ1 
cells (unpublished results). In the present study, we therefore used LL-37 expression 
for a comparison with YKL-40 expression. In line with the findings for IL-12p40 and YKL-
40, the expression of LL-37 was also dose-dependently reduced by increasing doses of 
dexamethasone when added on day 0, but not on day 3 or day 7 (Figure 4C). 
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D
Collectively these data indicate that dexamethasone inhibits YKL-40 expression, but that 
this effect is most likely explained by a more generic effect on MΦ1 development and is not 













































































































































































































Figure 2: MΦ1 produce more YKL-40 compared to MΦ2. Figure 2A: YKL-40 secretion measured by ELISA 
(left panel, 6 donors) and mRNA levels (normalized expression, right panel, 5 donors) in MΦ1 and MΦ2 after 
medium and LPS stimulation for 24 hours. Figure 2B: Flow cytometry analysis of MΦ1 and MΦ2 with and 
without anti-YKL-40 and secondary antibody. Left panel: MΦ1 with secondary antibody (pink) and MΦ1 with 
anti-YKL-40 and secondary antibody (black); middle panel: MΦ2 with secondary antibody alone (pink) and 
MΦ2 with anti-YKL-40 and secondary antibody (black); right panel: MΦ1 and anti-YKL-40 with secondary 
antibody (red) and MΦ2 and anti-YKL-40 with secondary antibody (blue). Figure 2C: YKL-40 secretion in 
MΦ1 and MΦ2 after 24 and 48 hours of stimulation with medium, LPS, TNF-α and oncostatin M (OSM). Data 
represent mean and SEM of 4 and 3 donors (24 and 48 hours, respectively). *: P<0.001 between MΦ1 and MΦ2 
for corresponding stimulus and time. $: P<0.001 between corresponding stimulus at different time points. 
Figure 2D: Immunofluorescence staining on sputum cytospin of a COPD patient (blue: DAPI; red: YKL-40; green: 
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YKL-40 expression is not affected by the demethylating agent 5-AZA
Epigenetic mechanisms may contribute to CHI3L1 expression. This is supported by the 
finding of a single-nucleotide polymorphism (SNP) localized near the CpG island in the 
promoter region of the CHI3L1 gene, which is associated with YKL-40 expression [19, 20]. 
To evaluate whether YKL-40 expression in monocyte-derived macrophages is influenced by 
the methylation status of the CHI3L1 gene, macrophages were generated in the presence of 
the demethylating agent 5-AZA. We first observed that 5-AZA inhibited IL-12p40 secretion, 
and to a smaller extent also IL-10 secretion (Figures 5A and B, respectively). In contrast, YKL-
40 protein secretion and expression was not significantly affected by 5-AZA, although it 
needs to be noted that the highest concentration resulted in cell toxicity (Figures 5C and D, 
respectively).
Figure 4: YKL-40 expression and protein secretion is inhibited by dexamethasone. YKL-40 mRNA levels 
(normalized expression) and YKL-40 protein secretion (figure 4A and B, respectively) in MΦ1 and MΦ2 with 
addition of dexamethasone at day 0, 3 and 7 of differentiation (0.1, 0.3 and 1nM) (left, middle and right 
panel, respectively). LL-37 mRNA levels (normalized expression) after 0, 3 and 7 days of differentiation with 
dexamethasone (0.1, 0.3 and 1nM) (figure 4C left, middle and right panel, respectively). Data represent means 
and SEM (n= 3 donors). * P≤0.05, ** P<0.01 or *** P<0.001 compared to MΦ2 with corresponding stimulus. $= 
p≤0.05, $$ P<0.01 or $$$ P<0.001 compared to corresponding unstimulated cells. ##: P<0.01 or ### P<0.001 
compared to corresponding LPS stimulated cells.
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Figure 5: YKL-40 protein secretion and mRNA expression is inhibited by the demethylating agent 5-AZA. IL-
10 and IL-12p40 secretion after stimulation with 5-AZA (concentration 0.1, 1 and 10µM) (Figures 5A and 
B, respectively). YKL-40 protein secretion and mRNA expression in MΦ1 and MΦ2 after culturing with 5-AZA 
(concentration 0.1, 0.3 and 1nM) (Figure 5C and D, respectively). Differentiated cells are stimulated with 100ng/
ml LPS for 24 hours. Data represent mean and SEM (n=3 donors). * P≤0.05, ** P<0.01 or *** P<0.001 compared 
to MΦ2 with corresponding stimulus. # P≤0.05, ##: P<0.01 or ### P<0.001 compared to corresponding LPS 
stimulated cells. 
YKL-40 levels in serum and sputum of COPD patients are not changed 
by treatment with inhaled corticosteroids 
We next used samples of the GLUCOLD study to investigate the effects of ICS treatment 
on serum and sputum YKL-40 levels in COPD patients. Baseline characteristics between 
the group of moderate to severe COPD patients treated with ICS and placebo were not 
significantly different as shown in Table 2. Of the 75 compliant patients, 70 serum samples 
and 59 induced sputum samples at baseline were available and suitable for analysis. Serum 
YKL-40 levels at baseline were significantly higher compared to sputum levels at baseline 
(respectively median 71 ng/ml versus 29 ng/ml, P<0.001). ICS treatment did not significantly 
change YKL-40 levels in serum and sputum compared to placebo (both p>0.05; Figure 6).
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Table 2: Patient characteristics of compliant patients at baseline of the GLUCOLD study. The ICS group is a 
combination of the original 30-month fluticasone and 30-month fluticasone with salmeterol groups.
Data represent mean with SD, median with interquartile range or numbers.
GLUCOLD: Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease. ICS: Inhaled 
corticosteroids. FEV1: Forced Expiratory Volume in 1 second. IVC: Inspiratory vital capacity. Pred: predicted.
ICS (n=51) Placebo (n=24)
Gender (M/F) (n) 45/6 20/4
Age (yr) 61.7 (7.8) 59.4 (8.1)
Smoking (y/n) (n) 33/18 17/7
Packyears (yr) 48 (31-56) 42 (34-54)
Post-bronchodilator FEV1 (% pred) 62.5 (9.2) 61.2 (8.3)
Post-bronchodilator FEV1 (L) 2.02 (0.41) 2.00 (0.55)
Post-bronchodilator FEV1/IVC (%) 47.3 (8.8) 46.7 (9.0)
Serum YKL-40 (ng/ml) 66 (49-119) 78 (60-118)
Sputum YKL-40 (ng/ml) 52 (20-79) 18 (12-40)
Figure 6: Sputum and serum YKL-40 protein levels of COPD patients before and after ICS treatment. YKL-40 
levels in sputum and serum at baseline (0) and after 30 months (30m) of inhaled corticosteroids (ICS) and 
placebo. For comparison of the levels between baseline and 30 months, we only included patients from whom 
samples were available at both time points (paired data). Each dot represent a single patient, red horizontal 
bars represent medians. 




























This study shows that secretion and expression of YKL-40, a chitinase-like protein, is higher 
in in vitro generated monocyte-derived MΦ1 than in MΦ2, and that YKL-40 expression is 
not further increased upon stimulation with several pro-inflammatory stimuli. In addition, 
YKL-40 release in vitro is strongly inhibited by dexamethasone especially in MΦ1, most 
likely due to an effect on differentiation. Addition of the demethylating agent 5-AZA did 
not significantly decrease YKL-40 release, but did decrease IL-12p40 production by MΦ1 and 
to a smaller extent IL-10 production by MΦ2 cells. YKL-40 levels in serum were significantly 
higher in serum than in sputum of COPD patients. Treatment of these patients for 2.5 years 
with inhaled corticosteroids did not significantly change serum and sputum YKL-40 levels 
compared to placebo. These results suggest that YKL-40 is a promising pro-inflammatory 
marker in in vitro cultured pro-inflammatory macrophages, but is less suitable for monitoring 
in vivo effect of treatment with steroids on YKL-40 in serum and sputum of COPD patients.
We show that YKL-40 is a novel marker of in vitro cultured monocyte-derived MΦ1, which 
is independent of LPS, OSM and TNF-α. This is an important observation, since many 
established MΦ1 markers require additional stimulation to induce expression. Our data 
confirm and extend previous results [16, 17, 29], reporting higher CHI3L1 expression in 
classically activated macrophages compared to alternatively activated macrophages. In 
the latter studies, in contrast to our study, interferon-gamma (IFN-γ) and IL-4 were used for 
MΦ1 and MΦ2 polarization, respectively [16, 17]. We extended these data by differentiating 
monocytes with GM-CSF and M-CSF into MΦ1 and MΦ2, respectively, and explored the effect 
of further stimulation after differentiation with several pro-inflammatory stimuli. We found 
that dexamethasone efficiently suppressed YKL-40 expression and secretion in MΦ1, but that 
this was mainly explained by an inhibitory effect of dexamethasone on MΦ1differentiation, 
thus extending previous results [17].
We found that YKL-40 levels in serum were higher than in sputum of COPD patients. Serum 
YKL-40 levels of our group of patients were comparable with previous studies [13, 30, 31]. 
However, sputum YKL-40 levels with sputum processed using the whole sample method, 
were considerably lower than in studies using the selected plug method [12]. This is most 
likely due to dilution which is inherent to the whole sample method. After long-term 
treatment with ICS, we did not detect a significant change in YKL-40 levels in serum and 
sputum compared to placebo. To our knowledge, this is the first study that evaluates the 
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long-term effect of ICS in serum and sputum YKL-40 levels of COPD patients. Therefore, this 
study presents new in vitro and in vivo data that may help to provide insight in the function of 
YKL-40.
The mechanisms that regulate YKL-40 expression in health and disease are partly 
understood. It has been demonstrated that YKL-40 expression is absent in monocytes, and 
markedly induced during macrophage differentiation, especially during the later stages 
of differentiation [2]. Promotor analysis of the CHI3L1 gene revealed that especially Sp1, 
an ubiquitous transcription factor, is important for CHI3L1 gene expression [6]. Possibly 
epigenetic mechanisms also contribute to CHI3L1 expression. This is supported by the 
finding of a SNP localized near the CpG island in the promoter region of the CHI3L1 gene, 
which is associated with YKL-40 expression [19, 20, 32]. Furthermore, hypomethylation of the 
CHI3L1 gene in rheumatoid arthritis is associated with increased expression of YKL-40 [33, 34]. 
Therefore, CHI3L1 gene expression may be regulated by transcription factors such as Sp1 and 
by DNA methylation status. Our observations with 5-AZA treatment do not support a role for 
DNA methylation in the expression of YKL-40 in MΦ1. Further studies into methylation status 
of the promotor of YKL-40, the role of histone modification and microRNAs are needed to 
define a role of epigenetic mechanisms in the expression of YKL-40 in (lung) macrophages.
The strength of our study is that it describes a thorough evaluation of a novel, potential 
pro-inflammatory macrophage marker using both in vitro and in vivo approaches. Well-
characterized patients with COPD used long-term, randomized, placebo-controlled 
treatment with ICS. However, we were unable to detect an effect of a randomized treatment 
with ICS on YKL-40 serum and sputum levels. Nevertheless, our study has some limitations. 
First, we used in vitro cultured monocyte-derived macrophages from whole blood of healthy 
subjects that were differentiated towards MΦ1 and MΦ2 instead of lung-derived (e.g. 
alveolar) macrophages that were differentiated under the influence of the local environment. 
Since the culture systems do not fully reflect in vitro differentiation of macrophage subsets 
[35, 36], it needs to be noted that the effect of steroids on lung macrophages may differ 
from that on in vitro differentiated macrophages. Furthermore, in vivo a heterogeneous and 
intermediate macrophage population exists [37], which complicates the comparison with 
in vitro generated MΦ subsets. We therefore cannot formally exclude the possibility that this 
has contributed to our inability to detect an effect of inhaled corticosteroids on serum and 
sputum YKL-40 levels. Second, the demethylating agent 5-AZA demonstrated cell toxicity 
which might have influenced our results. However, we found a dose-dependent inhibition of 
YKL-40 expression and secretion, suggesting that DNA methylation status may contribute to 
regulation of YKL-40 expression in MΦ1, which is in line with studies posing that methylation 
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of a part of the CpG island of the CHI3L1 gene is associated with YKL-40 levels [19, 32].
How can we explain that serum and sputum YKL-40 levels of COPD patients were 
not significantly changed after long-term ICS treatment compared to placebo? This is 
unexpected since serum YKL-40 levels of rheumatoid arthritis patients rapidly decreased 
after one week of prednisolone [18]. However, the amount of inhaled fluticasone that reaches 
the systemic circulation is low [38], which could explain why serum YKL-40 levels did not 
significantly change with ICS therapy. In addition, lung macrophages in COPD have reduced 
glucocorticoid sensitivity [39, 40]. 
CONCLUSION
YKL-40 is mainly expressed and secreted by MΦ1 and is not further increased by pro-
inflammatory stimuli. YKL-40 release is inhibited by dexamethasone in MΦ1 in vitro, whereas 
long-term treatment of COPD patients with inhaled corticosteroids did not significantly 
change YKL-40 levels in serum and sputum. This suggests that YKL-40 is a potential marker 
for in vitro cultured pro-inflammatory macrophages and is not a valuable biomarker in serum 
and sputum of patients with COPD treated with inhaled corticosteroids. 
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Background: Smoking and inflammation contribute to the pathogenesis of chronic 
obstructive pulmonary disease (COPD), which involves changes in extracellular matrix. This 
is thought to contribute to airway remodeling and airflow obstruction. We have previously 
observed that long-term treatment with inhaled corticosteroids can not only reduce 
bronchial inflammation, but can also attenuate lung function decline in moderate to 
severe COPD. We hypothesized that inhaled corticosteroids and current smoking modulate 
bronchial extracellular matrix components in COPD. 
Objective: To compare major extracellular matrix components (elastic fibers; proteoglycans 
[versican, decorin]; collagens type I and III) in bronchial biopsies a) after 30-months inhaled 
steroids treatment or placebo; and b) between current and ex-smokers with COPD. 
Methods: We included 64 moderate to severe, steroid-naive COPD patients (24/40 (ex)-
smokers, 62±7 years, 46 (31-54) packyears, post-bronchodilator forced expiratory volume 
in one second (FEV1) 62±9% predicted) at baseline in this randomized, controlled trial. 19 
and 13 patients received 30-months treatment with fluticasone or placebo, respectively. 
Bronchial biopsies collected at baseline and after 30 months were studied using (immuno)
histochemistry to evaluate extracellular matrix content. Percentage and density of stained 
area were calculated by digital image analysis. 
Results: 30-Months inhaled steroids increased the percentage stained area of versican (9.6% 
[CI 0.9 to 18.3%]; P=0.03) and collagen III (20.6% [CI 3.8 to 37.4%]; P=0.02) compared to 
placebo. Increased collagen I staining density correlated with increased post-bronchodilator 
FEV1 after inhaled steroids treatment (Rs=0.45, P=0.04). There were no differences between 
smokers and ex-smokers with COPD in percentages and densities for all extracellular matrix 
proteins.
Conclusions: These data show that long-term inhaled corticosteroids treatment partially 
changes the composition of extracellular matrix in moderate to severe COPD. This is 
associated with increased lung function, suggesting that long-term inhaled steroids 
modulate airway remodeling thereby potentially preventing airway collapse in COPD. 
Smoking status is not associated with bronchial extracellular matrix proteins.
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INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is characterized by an abnormal 
inflammatory response and structural alterations of the bronchial wall and parenchyma [1]. 
This pulmonary remodeling has been linked to airflow limitation in COPD [2, 3]. Changes 
in the extracellular matrix (ECM), produced by (myo)fibroblasts, epithelial cells and airway 
smooth muscle cells, contribute to this remodeling process and alter airway mechanics and 
dynamics [4, 5]. The ECM consists of three major components: elastic fibers, proteoglycans 
and collagens, which are involved in cell migration, proliferation, adhesion, water balance 
and regulation of inflammatory mediators [4].
The composition of the pulmonary ECM is different in subjects with and without COPD. 
Fewer elastic fibers are found in small airways and alveoli of COPD patients than in healthy 
controls [6, 7]. Furthermore, versican, a large proteoglycan is more abundant, while the small 
proteoglycan decorin is reduced in small airways in COPD compared to healthy subjects 
[8-10]. Collagens are the main component of the ECM, and collagen composition differs 
between COPD patients and healthy controls as shown by the observation that collagen type 
I is lower in the large and small airways [11] and collagen type III expression is lower in the 
small airways of COPD patients than in healthy controls [3]. 
Since smoking is a risk factor for COPD, this may also influence ECM composition. Indeed, 
cigarette smoke has been shown to induce secretion of several profibrotic growth factors, 
including transforming growth factor-beta (TGF-β), both in human lung fibroblasts and in 
lung tissue of COPD patients [12, 13]. Rodent models exposed to cigarette smoke had less 
lung elastic fibers, but more collagens than sham-smoked animals [14]. Others even reported 
an increased elastic fibers gene expression in lung tissue of severe COPD patients [15]. Smoke 
exposure decreased proteoglycan expression as demonstrated by a study with pulmonary 
fibroblasts from moderate and very severe COPD patients [16].
Although generally (neutrophil dominated) inflammation in COPD is considered to be 
resistant to steroids treatment, we recently observed that long-term inhaled corticosteroids 
(ICS) treatment partially decreased bronchial inflammation (CD3+, CD4+, CD8+ and mast cells, 
without effects on neutrophils, and attenuated lung function decline in moderate to severe 
COPD patients participating in the GLUCOLD (Groningen Leiden Universities Corticosteroids 
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in Obstructive Lung Disease) study [17]. ICS may affect ECM through various mechanisms, 
including modulation of inflammation by profibrotic mediators and targeting ECM genes 
directly. This may explain differences in the effects of steroids that are observed in in vivo 
and in vitro studies. Whereas steroid treatment of asthmatics did not change elastic fibers 
and collagens in bronchial biopsies [18], steroids did inhibit serum-induced proteoglycan 
production in fetal lung fibroblasts [19]. In contrast to asthma, to the authors’ knowledge, 
effects of ICS on ECM composition in COPD patients have not been described. 
We hypothesized that inhaled steroids treatment modulates bronchial ECM components in 
COPD. In addition, we hypothesized that current smoking affects bronchial ECM. 
MATERIALS AND METHODS
Subjects and study design
The current study is a substudy of the GLUCOLD (Groningen Leiden Universities 
Corticosteroids in Obstructive Lung Disease) study, a double-blind, placebo-controlled 
randomized trial in which 114 moderate to severe COPD steroid-naive patients were included 
[17]. Clinically stable subjects participating in the GLUCOLD study were aged 45-75 years, 
smoked ≥10 packyears, were current or ex-smokers with ≥1 month of smoking cessation 
and were allowed to use short-acting bronchodilators. Exclusion criteria were asthma and 
ICS use in the previous 6 months. Patients were randomly assigned to receive one of four 
treatments for 30 months: 1) fluticasone propionate 500 μg bid; 2) fluticasone/salmeterol 
500/50 μg bid; 3) fluticasone 500 μg bid (6 months) and followed by placebo (24 months); 
or 4) placebo bid. Diskus dry-powder inhalers (GlaxoSmithKline, Zeist, The Netherlands), were 
used for inhalation of the study medication and placebo, and both had equal appearance. 
For the current study we used tissue and data of group 1 and 4. Spirometry, reversibility to 
salbutamol and airway hyperresonsiveness (PC20) were determined according to international 
guidelines [20, 21]. Approval of the medical ethics committees of both centers was obtained: 
all subjects provided written informed consent [17].
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Bronchoscopy and bronchial biopsies
A fiberoptic bronchoscopy was performed at baseline and after 30 months according to 
standardized protocols [22]. Six bronchial biopsies per patient per visit were collected at the 
3rd-5th bronchial level, one with the best morphology being used. Tissue of 64 out of 114 
patients was available due to use in previous studies [17, 22, 23].
(Immuno)histochemical stainings
Processing and analysis of bronchial biopsies was performed in line with the 
recommendations of the ATS/ERS task force [24] by using an internal reference parameter in 
the analysis. We did not take specific precautions to orientate the samples during processing 
to assure that the orientation of the biopsies is randomized [25]. However, since biopsies 
tend to curl after sampling, a random orientation of the tissue structures is favored during 
embedding [26]. Sections of 4 μm thickness of paraffin-embedded bronchial biopsies were 
used for histochemistry (elastic fibers) and immunohistochemistry for proteoglycans and 
collagens. Elastic fibers were stained according to Weigert’s protocol [27]. Versican, decorin, 
collagen I and III antibodies were used after appropriate antigen retrieval, followed by 
horseradish peroxidase-conjugated anti-mouse or anti-rabbit EnVision system (DAKO, 
Glostrup, Denmark) and the chromogen NovaRed (Vector, Burlingame, CA). Images of stained 
biopsies are presented in Figure 1. 
Digital image analysis
Tissue samples were analyzed in a blinded manner by independent observers, unaware 
of the subjects’ clinical data (LK, JS). Total biopsy images were acquired using a color 
camera (200x magnification) and analyzed with image analysis software (CellD, Olympus, 
Zoeterwoude, The Netherlands). The lamina propria was selected per biopsy (minimum 
area 0.09 mm2). The percentage stained area for a specific ECM component was calculated 
dividing the stained area by the total selected area (volume fraction; used as an internal 
reference parameter; [24]). Staining intensity was further analyzed by densitometry 
(weighted mean per biopsy) and presented as gray value (black: gray value=0; white: gray 
value=255). Only immunohistochemical stainings can represent density, therefore density 





Figure 1: Examples of (immuno)histochemical stainings. 
The same bronchial biopsy section is shown for the histochemical staining for elastic fibers (A) and the 
immunohistochemical stainings for versican (B), decorin (C), collagen type I (D) and collagen type III (E). 
Original magnification 200x. Scale bar represents 500 µm.
Statistical analysis
Only biopsies from compliant subjects using ≥70% of the prescribed dose were analyzed 
(per-protocol analysis). Means with standard deviations (SD) and 95% confidence intervals 
(CI) or medians with interquartile range (IQR) are presented. Differences between smokers 
and ex-smokers were explored using Mann-Whitney tests. Paired and independent 
t-tests were used for evaluating the effect of ICS on ECM proteins within and between 
treatments, respectively. Correlations were analyzed using Spearman correlation coefficient 
(Rs). Statistical analysis was performed with SPSS 17.0 software (SPSS Inc., Chicago, IL). 
Significance was inferred at P≤0.05.
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At baseline, bronchial biopsies of 64 of 114 unselected moderate to severe COPD patients 
[24/40 (ex-)smokers] were included. Patient characteristics of the whole group have 
previously been published [17, 22, 28]. 33 Patients were treated with either fluticasone 
or placebo for 30 months (19/19 and 13/14 adherent in fluticasone and placebo group, 
respectively). Mean post-bronchodilator FEV1 was 62% predicted (SD 9.9%). Ex-smokers were 
older at baseline compared to current smokers, as is shown in Table 1. Baseline characteristics 
of the entire group, groups with available and unavailable bronchial biopsies, and the 
number of available biopsies were not significantly different between both treatment arms. 
During the study, six patients changed their smoking habits (balanced among groups).  
Inhaled corticosteroids and extracellular matrix proteins
Adjusted for baseline values, we found that ICS significantly increased percentage versican 
(9.6% [CI 0.9 to 18.3%]; P=0.03) and collagen III (20.6% [CI 3.8 to 37.4%]; P=0.02) compared 
to placebo (Figure 2); a trend was seen for the density of decorin (3.9 [CI -0.7 to 8.6]; P=0.09) 
and collagen III (8.4 [CI -1.1 to 17.9]; P=0.09). Baseline percentage and density of versican 
(17% [CI 3.5 to 30.6%]; P=0.02 and 8.0 [CI 2.7 to 13.3]; P=0.006, respectively) and collagen III 
(10.7% [0.1 to 21.4%]; P=0.03 and 7.9 [CI 0.9 to 15.0]; P=0.05, respectively) and percentage of 
decorin (2.0% [CI 0.5 to 3.5%]; P=0.02) were significantly higher in the placebo group than 
the fluticasone group. Change in smoking status was not included into our analysis, because 
current and ex-smokers with COPD had similar ECM composition. An increase in density 
of collagen I was associated with improvements in post-bronchodilator FEV1 (l) (Rs=0.45, 
P=0.037) when we analyzed both fluticasone and placebo treated groups combined (Figure 
3). No correlations were found for other ECM proteins and lung function. 
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Figure 2: Percentage and density of stained area for placebo and fluticasone for all ECM proteins. 
Percentage (upper panel) and density (lower panel) of stained area in bronchial biopsies is presented. Open 
figures: baseline percentage stained area, closed figures: percentage stained area after 30 months. Horizontal 
bars represent medians. 
Smoking status and extracellular matrix proteins at baseline
No significant differences in percentage of the area being positively stained and density of 
ECM proteins were found between current smokers and former smokers with COPD (Figure 
4). Long-term ex-smokers (≥5.5 years, our median value) had similar percentage and density 
of all ECM proteins compared to short term ex-smokers (<5.5 years) and current smokers (all 
P>0.05). Furthermore, no relation was found between packyears and percentage or density 
of all ECM proteins.
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Table 1: Patient characteristics at baseline. Patient characteristics for current smokers and ex-smokers with 
COPD and groups treated with placebo and fluticasone (only compliant patients). Bronchial biopsies were 
available at baseline of 64 (elastic fibers), 56 (versican), 61 (decorin), 61 (collagen I) and 64 (collagen III) patients. 
After 30 months, bronchial biopsies of 32 compliant patients were available, tissue from 29 (elastic fibers), 26 
(versican), 27 (decorin), 28 (collagen I) and 28 (collagen III) patients had sufficient surface area for analysis 
(≥0.09 mm2) (fluticasone and placebo groups combined). 
Data are presented as mean (SD) or median (IQR), unless otherwise stated. Methacholine PC20: provocative 
concentration of methacholine that causes a 20% decrease in FEV1, expressed as mean doubling doses. Part of 









Males [n (%)] 37 (92.5) 23 (95.8) 12 (92.3) 17 (89.5)
Age (years) 60.9 (7.2) 65.1 (6.6)* 62.5 (7.9) 62.0 (7.4)
Current/ ex-smoker (n) 9/4 11/8
Packyears 46.8 (30.9-55.0) 37.5 (32.1-52.5) 42.0 (28.4-58.0) 44.9 (31.2-51.0)
Smoking cessation (years) 5.5 (1.3-10.0) 0.0 (0.0-1.5) 0.0 (0.0-5.0)
FEV1 post-bronchodilator 
(l)
2.05 (0.44) 1.94 (0.46) 1.95 (0.61) 2.03 (0.42)
FEV1 post-bronchodilator 
(%pred)
63.0 (8.7) 59.6 (9.9) 59.9 (9.8) 62.5 (9.5)
FEV1/IVC% post-
bronchodilator
48.7 (8.9) 44.2 (8.9) 44.3 (9.5) 47.7 (8.6)
Geometric mean 
methacholine PC20 (mg/ml)
0.76 (2.9) 0.39 (3.0) 0.67 (1.9) 0.41 (2.4)
* P<0.05 compared to current smokers (two tailed unpaired t-tests).
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Figure 3: Correlation between change in post-bronchodilator FEV1 (L) and change in density of collagen I.
Both values represent values after 30 months minus values at baseline. 
Closed circles represent fluticasone treated subjects, open circles represent placebo treated subjects.
Correlations between extracellular matrix and lung function at 
baseline
Correlations between extracellular matrix and lung function at baseline percentage collagen 
I correlated positively with FEV1 (% predicted) post-bronchodilator (Rs=0.31, P=0.015) (Figure 
5, left panel) and FEV1/IVC% (Rs=0.38, P=0.003). In addition, percentage collagen type I and III 
correlated with PC20 (Rs=0.33, P=0.012; Rs=0.37, P=0.004, respectively) (Figure 5, right panel). 
Percentage collagen I, but not collagen III, was significantly lower in GOLD stage III (n=9) 
than GOLD stage II (n=55) (medians 5.5% and 17.7%, respectively, P=0.01). No significant 
correlations were found between lung function at baseline and densities of all ECM proteins.
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Figure 4: Percentage and density of stained area at baseline of ex-smokers and smokers with COPD. 
Percentage (upper panel) and density (lower panel) of stained area in bronchial biopsies is presented. Ex-
smokers are presented as open circles, current smokers as closed circles. Horizontal bars represent medians. No 
significant differences were found for all studied extracellular matrix proteins (both percentage stained area 
and density).
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Collagen I (% stained area)
Figure 5: Correlation between percentage collagen type I at baseline and lung function parameters. 
Panel A presents post-bronchodilator FEV1 (% predicted) and panel B shows PC20 (in doubling dose). Each dot 
represents a single patient.
DISCUSSION
Our results show that 30-month treatment with inhaled corticosteroids increases the 
percentage stained area of versican and collagen III, indicating that long-term treatment 
possibly influences the remodeling process in the airways. Furthermore, lung function is 
weakly, but positively correlated with collagen I both at baseline and with regard to changes 
in FEV1 and collagen I that occurred after treatment. In addition, we show that the content 
of ECM proteins in bronchial biopsies did not significantly differ between smokers and ex-
smokers with moderate to severe COPD.
This study shows that the content of elastic fibers, major proteoglycans and collagens 
in the bronchial mucosa are similar in current and ex-smokers with COPD. Our findings 
extend previous observations, showing no difference in the percentage elastic fibers in 
COPD patients and smokers without airway obstruction [11, 29]. We observed no significant 
difference in versican and decorin content between current and ex-smokers with COPD, 
which is in line with an in vitro study with cultured lung fibroblasts of moderate COPD 
patients and control subjects. Cigarette smoke extract (CSE) exposure of these cells did not 
affect versican gene expression, but decreased decorin gene expression [16]. This apparent 
difference with our findings could be explained by the fact that smoke-exposed fibroblasts 
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are only selectively triggered compared to a multifactorial environment in vivo. Finally, in our 
study collagen type I and III were not significantly different between current and ex-smokers 
with COPD, which is similar to recent observations in cultured fibroblasts of COPD and non-
COPD patients [30].
The percentage of versican and collagen III increased with long-term ICS treatment 
compared to placebo, without significant changes in elastic fibers, decorin and collagen I. In 
line with this, ICS for four weeks or 3.5 years did not affect elastic fibers content in bronchial 
biopsies of asthmatics compared to healthy controls [18]. Notably, we found a significant 
increase in collagen III, but not collagen I, after 2.5 years of ICS treatment compared to 
placebo, which was associated with lung function. Previous studies in COPD patients showed 
that gene expression of collagen 1α1 and collagen 3α1 in small airways and parenchyma was 
decreased in association with lower FEV1 [3, 31]. Thus, collagen may have stabilizing effects 
on the collapsible airways in patients with COPD, which could be further enhanced by long-
term use of ICS. 
Our study has various strong points. We included only steroid-naive COPD patients, 
excluding possible influences of steroids on ECM components at baseline. Both the 
percentage and density of the stained area in bronchial biopsies were analyzed: the 
percentage corresponds to the presence of the ECM protein, whereas density represents the 
local amount of ECM protein. For the analysis of the percentage, we used the total selected 
tissue area for analysis as an internal reference parameter according to the recommendations 
of the Joint ATS/ERS Task Force [24]. We considered the possibility that part of our changes is 
explained by an effect of ICS on edema. However, less edema resulting from ICS treatment 
would probably have increased percentage and density all studied ECM proteins, whereas 
in our study the percentage of only some ECM proteins was affected. Furthermore, we 
previously found lower numbers of selected bronchial inflammatory cells after ICS treatment 
in the current study [17]. We did not find correlations between the effect of ICS treatment on 
inflammatory cells and ECM components (data not shown). 
There are some considerations when interpreting our results. Matched bronchial biopsies 
both at baseline and follow-up were available from approximately half of our COPD patients, 
because part of the tissue was no longer available. This could have negatively affected the 
power of our study. Still, the number of available biopsies was similar among both groups. 
Furthermore, since one biopsy per patient per visit was studied, we cannot exclude that 
local heterogeneity of ECM proteins has affected our results. To minimize selection bias, we 
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only selected biopsies with the largest lamina propria. Lung tissue specimens from healthy 
or never-smokers were not available, but comparisons with these groups were beyond the 
objectives of this study. Furthermore, features of remodeling in COPD are different between 
large and small airways, nevertheless we evaluated the ECM in the central airways only 
[2] and important correlations with lung function could still be observed. Finally, despite 
treatment randomization, we accidentally found that the percentage and densities of 
versican, decorin and collagen III at baseline were significantly higher in the placebo than 
the fluticasone group. Not withstanding this, when still adjusted for the baseline values, we 
observed effect of ICS therapy. Taken together, we do not believe that the above limitations 
largely affected our results.
How can we explain that smoking has no effect on ECM? Exposure of cultured pulmonary 
fibroblasts of moderate and very severe COPD patients to CSE resulted in downregulation of 
decorin, but not versican and collagen type I and III expression [16, 30]. In addition, collagen 
I and tropoelastin were dose-dependently inhibited by CSE in rat fetal lung fibroblasts 
[32]. Mice with long-term exposure to cigarette smoke showed a decrease in elastic fibers 
and collagen type III, without significant effect on collagen I [33]. We could only partially 
confirm these in vitro and animal studies. Inflammation and remodeling in the lung in vivo 
are simultaneous and complex ongoing processes and may not be mimicked by studies in 
isolated fibroblasts and inbred animals kept under specific conditions. Furthermore, after 
smoking cessation bronchial inflammation (at least) partially persists [22], which is in line 
with our finding of similar ECM composition between smokers and ex-smokers.
We showed a positive correlation between the content of collagen and lung function 
after treatment with inhaled steroids. However, the current opinion of remodeling is that 
airway wall thickening is strongly associated with progression of COPD [2], suggesting that 
increased ECM deposition is related to a decreased lung function. How can we explain this 
apparent contradiction? In COPD, an imbalance between proteases and anti-proteases is 
present, as shown by an excess of matrix metalloproteinases (MMP) and a relative shortage 
of tissue inhibitor of metalloproteinases (TIMP) [34]. MMP degrade both collagens and 
proteoglycans [2, 34, 35]. Dexamethasone can reduce MMP-9 and increase TIMP-1 release 
from alveolar macrophages of COPD patients [36], which may result in a decreased capacity 
to degrade ECM. This is in line with our observation that ICS increase collagen and versican. 
Also the observation from Annoni et al [11], showing that patients with COPD have lower 
collagen I densities in their airways, is in line with the speculation that an increase in collagen 
I induced by ICS could stabilize the airways. Furthermore, the observed positive correlation 
between collagen with lung function and PC20 before and after long-term ICS therapy also 
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suggests that increased airway wall fibrosis is actually preventing both airway collapse 
and attenuating airway smooth muscle contractions in COPD. Besides airway remodeling, 
emphysema might also influence airway collapse, which could contribute to the airflow 
obstruction. Unfortunately, no data were collected to quantify the extent of emphysema in 
our cohort of COPD patients.
Although smoking cessation shows positive clinical effects [1], smoking status was not 
significantly correlated with our studied ECM components. Treatment with ICS increased the 
percentage versican and collagen III. We found positive correlations between ECM proteins 
and several lung function parameters at baseline and after treatment with ICS. Therefore, our 
data may implicate that steroids alter airway structure by increasing ECM content in COPD 
which is associated with preserved lung function. This suggests that increased presence ECM 
proteins do not by themselves lead to detrimental consequences, but instead can prevent 
airway collapse. 
In conclusion, we showed that treatment for 30 months with inhaled corticosteroids 
increased the relative content of versican and collagen III in the large airways of patients 
with moderate to severe COPD. Our data suggest that steroids not only prevent bronchial 
inflammation but possibly also alter airway structure by increasing specific ECM proteins in 
COPD that are associated with improvements in lung function. Further studies are needed to 
confirm these findings in other studies, and to understand the possible implications of these 
findings for current treatment strategies and for the development of future, targeted anti-
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Background: We previously observed that 30 months of inhaled corticosteroids (ICS) can 
attenuate FEV1-decline in COPD, but it is unclear whether withdrawal induces a relapse. We 
hypothesized that FEV1-decline, airway hyperresponsiveness (AHR) and quality of life (QOL) 
deteriorate after ICS cessation even after prolonged use. 
Methods: 114 moderate to severe COPD patients finished randomized treatment with 
6-month (F6) or 30-month fluticasone (F30) (500µg, bid), 30-month fluticasone/salmeterol 
(FS30) (500/50µg, bid) or placebo during GLUCOLD-1 (GL1). The subsequent 5 years 
[GLUCOLD-2 (GL-2)], patients were prospectively followed annually, treated by their physician. 
Post-bronchodilator FEV1, AHR and QOL were initially recorded at baseline, 30 months (GL1) 
and annually during GL2. Analysis was performed by linear mixed-effects models. 
Results: Amongst 101 adherent patients during GL1, 79 patients started and 58 completed 
GL2. Patients using ICS during GL1, but only using ICS 0-50% of time during GL2 (n=56/79) 
had significantly accelerated annual FEV1-decline compared to GL1 (difference GL2-GL1 
[95%CI]: FS30 -68ml/year [-112 to -25], P=0.002; F30 -73ml/year [-119 to -26], P=0.002), 
accompanied by deterioration in AHR and QOL. 
Conclusions: ICS discontinuation after 30-month in COPD can worsen lung function decline, 
AHR and QOL during 5-year follow-up. This suggests that ICS treatment lacks sustained 
disease modifying effect after treatment cessation.
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INTRODUCTION
Patients with stable Chronic Obstructive Pulmonary Disease (COPD) are currently treated 
with long-acting bronchodilators and in case of frequent exacerbations with inhaled 
corticosteroids (ICS) [1]. In these patients, ICS use reduces exacerbations, the rate of decline 
in quality of life (QOL) and the risk of death and hospitalization [2, 3]. However, the effect of 
ICS on lung function decline remains controversial.
Several studies in COPD presented transient improvements in lung function with ICS, 
whereas others failed to show benefits on FEV1, QOL and frequency of exacerbations [4-6]. 
We have previously reported that 30-month treatment with fluticasone and salmeterol in 114 
well-characterized, moderate to severe COPD patients decreased inflammation, attenuated 
lung function decline and improved QOL [7]. 
In contrast, long-term effects after ICS withdrawal on lung function and QOL have been little 
studied. Recent research indicates that discontinuation after 6 weeks of ICS in severe-to-very-
severe COPD patients leads to a greater decrease in FEV1 without effect on the number of 
exacerbations during a 1-year follow-up compared to the ICS continuation group [8]. Other 
ICS withdrawal studies found a deterioration in lung function, increased frequency of 
exacerbations and a lower QOL during 6-12 month follow-up compared to the non-ICS group 
[9, 10]. Thus, there is a clinical need for careful monitoring disease outcomes after withdrawal 
of long-term ICS treatment in COPD [11].
We hypothesized that lung function decline, airway hyperresponsiveness (AHR) and health-
related QOL deteriorates after withdrawal of ICS in COPD patients who had previously been 
randomized to 30-month ICS treatment, but had no or reduced ICS treatment during 5 
subsequent years of prospective follow-up. 
MATERIALS AND METHODS
Patients and design
For the first interventional part of the GLUCOLD [Groningen Leiden Universities 
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Corticosteroids in Obstructive Lung Disease] study (GL1), a double-blind, placebo-controlled 
randomized trial, 114 stable, moderate to severe, steroid-naive COPD patients were included 
[7]. Participants were randomized to receive one of the following twice daily treatments 
as dry-powder inhaler: 6-month (F6) or 30-month fluticasone propionate (F30; 500µg), 
30-month fluticasone with salmeterol (FS30; 500/50µg; single Diskus), or 30-month placebo. 
During the present observational, prospective GLUCOLD follow-up study (GL2), participants 
visited the outpatient clinic annually for 5 consecutive years. At the start of GL2, the 
participants’ physicians were recommended to treat the patients according to the guidelines 
[12]. This implies that some patients stopped using ICS, whereas others intermittently or 
continuously used ICS during GL2. 
After completion of GL2, the patients’ pharmacy presented an overview of delivered 
medications during the past 5 years of inhaled/oral steroids and antibiotics. Treatment 
adherence to the prescribed medication during GL2 was not checked.
Post-bronchodilator spirometry and measures of QOL were recorded at baseline and after 30 
months (GL1) and subsequently yearly during follow-up (GL2) [7]. AHR to methacholine (PC20) 
was measured at baseline, after 30 months, 2 and 5 years follow-up. The ethics committees 
of Leiden University Medical Center and University Medical Center Groningen approved the 
original and follow-up study. All patients provided new written informed consent for GL2.
Outcomes 
The primary outcome was the difference in the annual decline in post-bronchodilator FEV1 
during 5-year of follow-up (GL2) compared to the first 30 months (GL1). Secondary outcomes 
were differences between GL2 and GL1 in AHR and QOL, measured by the MRC dyspnea 
score (Medical Research Council), St. George’s Respiratory Questionnaire (SGRQ) and Clinical 
COPD Questionnaire (CCQ) [13-14].
Statistical Analysis
We used only data of adherent patients in GL1 (using ≥70% of the prescribed dose) [7]. Data 
of participants who did not complete GL2 were also used for analysis and analyzed with SPSS 
22.0 software (SPSS Inc. Chicago, IL). The analysis was stratified for original treatment group 
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and ICS use during GL2. We used linear mixed-effect models with a random intercept for 
each subject using all FEV1 measurements during the entire study as outcome variable and 
an unstructured covariance matrix. To assess the difference in FEV1-decline between GL1 and 
GL2 we included two time variables in the models; time1: time since start of GL1 (range 0-7.5 
years); time2: time since start of GL2 (range 0-5 years, during GL1 this value is zero). ICS use 
during GL2, based on delivered prescriptions by the pharmacies, was divided in the following 
groups: all (compliant) patients; patients without ICS use; patients with 0-50% of the time ICS 
use (which included the group without ICS use) and patients with 50-100% of the time ICS 
use. The daily dose of ICS (in µg, in beclomethasone dipropionate (BDP) equivalents) during 
5 years was calculated as daily sum of the different doses of ICS (in µg/day) divided by the 
total time that ICS were used (days). For selected analyses, we combined the original FS30 
and F30 groups to increase power. Given the limited sample size of patients completing the 
7.5 years of prospective follow-up, possible confounders (smoking, age, sex and center) were 
not included in the model. A previous post-hoc analysis showed that smoking was unlikely 
to be a major confounder [7]. Baseline patient characteristics and daily dose of ICS dose were 
analyzed by Kruskal-Wallis tests, analysis of variance or χ2 tests. Data are presented as change 
in estimates between GL2 and GL1 with 95% confidence interval (CI), means with standard 
deviations or medians with interquartile range. Statistical significance was inferred at P≤0.05 
(two-sided). 
RESULTS
At the start of the GLUCOLD study (GL1), 114 patients had been randomized to receive one 
of the above mentioned randomized 30-month treatments; 101 participants were adherent 
during GL1 [7]. Eighty-six patients completed GL1, 79 started the GLUCOLD follow-up study 
(GL2) and 58 patients completed GL2 (Figure 1). Patient characteristics at baseline and at start 
of GL2 (Table 1) were similar among the original treatment groups, except for a significantly 
higher post-bronchodilator FEV1 after 30-month treatment among the FS30 and F30 groups, 
compared to the F6 and placebo groups [7]. Most patients (56/79 patients) did not use any 
or used 0-50% of the time ICS during GL2. The mean daily ICS dose during 5 years was 960µg 
(SD 496µg, in BDP equivalents, Table 2), which was not significantly different between the 
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55Figure 1: Study flow diagram. Number of randomly assigned patients who were adherent to the original 
therapy (used ≥70% of prescribed dose during GLUCOLD study (GL1)). After 2.5 years, the GLUCOLD follow-up 
study (GL2) started. The number of patients who remained in GL2 and those withdrawn are presented.
Lung function decline
Annual FEV1-decline was significantly faster during GL2 than GL1 in patients who used ICS 
0-50% of the time during GL2 in the original FS30 group (difference in FEV1-decline between 
GL2 and GL1 (95% CI)) (-68 ml/year [-112 to -25 ml/year]; P=0.002) and F30 group (-73 ml/
year [-119 to -26 ml/year]; P=0.002) (Table 3 and Figure 2). When analyzing patients without 
ICS use during GL2, FEV1-decline during GL2 compared to GL1 was even more pronounced 
(original FS30 group: -106 ml/year [-171 to -41 ml/year]; P=0.002; F30 group: -84 ml/year 
[-149 to -18 ml/year]; P=0.01). Patients in the original combined FS30/F30 groups using ICS 
50-100% of the time during GL2 had a decline in FEV1 of -59 ml/year ([-106 to -11 ml/year]; 
P=0.02) in GL2 compared to GL1. 
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Withdrawn n= 2
n= 16  
Withdrawn n= 2
n= 14n= 12  
Withdrawn n= 2
n= 16  
Withdrawn n= 3
n= 16                  
Placebo              
30 months n= 24
Fluticasone/ 
Salmeterol           
30 months n= 25
Fluticasone       
30 months n= 26
Fluticasone       





Table 2: Number of compliant patients at the start of the GLUCOLD follow-up study (GL2) using ICS and daily 
dose of ICS (in µg) during 5 years in those patients who used ICS during GL2. 
The daily dose of ICS (in µg, in BDP equivalents) during 5 years was calculated by the sum of the different doses 
of ICS per day (in µg/day), divided by the total time that ICS were used (in days). Doses were based on data 




No ICS use ≤50% use of 
ICS (n)
>50% use of 
ICS (n)




F6 8 7 6 0 671 (383)
F30 10 5 3 2 1025 (590)
FS30 5 6 5 3 1132 (490)
Placebo 11 4 3 1 1049 (418)
Total 34 22 17 6 960 (496)
Daily dose of ICS is presented as means with standard deviations. F6: 6 months treatment with fluticasone 
and 24 months with placebo; F30: 30 months treatment with fluticasone; FS30: 30 months treatment with 
fluticasone and salmeterol.
Airway hyperresponsiveness
Patients of the combined original FS30/F30 groups without ICS use and patients who used 
ICS 0-50% of time during GL2 showed a deterioration in methacholine PC20 in GL2 compared 
to GL1 (-1.3 doubling dose/year [-2.0 to -0.5], P=0.002; -1.1 doubling dose/year [-1.8 to -0.5], 
P=0.001, respectively). Patients in the original placebo group who used 50-100% of the time 
ICS during GL2 had an increase in PC20 in GL2 compared to GL1 (1.5 doubling dose/year [0.06 
to 2.9]; P=0.04). 
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Table 3: Annual decline in post-bronchodilator FEV1 (ml/year) during GL2 compared to GL1. Treatment in GL1 
(first column) and use of inhaled corticosteroids (ICS) during GL2 (upper row). * P<0.05
Treatment in GL1 all patients 
(n=79)
no ICS use 
(n=34)
0-50% ICS use 
(n=56)


































Data presented as estimates and 95% CI. F6: 6 months treatment with fluticasone and 24 months with placebo; 
F30: 30 months treatment with fluticasone; FS30: 30 months treatment with fluticasone and salmeterol.
Health-related quality of life
Complete withdrawal of ICS during GL2 in the original combined FS30/F30 groups was 
accompanied by worsening of the MRC dyspnea score in GL2 by 0.2 points/year (0.06 to 0.3 
points/year, P=0.006), SGRQ total score by 2.5 points/year (0.2 to 4.7 points/year, P=0.03), 
CCQ total score by 0.1 point/year (0.008 to 0.2 points/year, P=0.03) and CCQ symptom score 
by 0.2 points/year (0.05 to 0.3 points/year, P=0.008) compared to GL1. 
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Figure 2: Mean post-bronchodilator FEV1 (L) and 95% CI during GL1 and GL2 over time for all compliant 
patients (A, upper part) and those using 0-50% ICS during GL2 (B, lower part) of the four original treatment 
groups.
F6: 6months treatment with fluticasone and 24 months with placebo; F30: 30 months treatment with 
fluticasone; FS30: 30 months treatment with fluticasone and salmeterol.
DISCUSSION
This study shows that discontinuation of ICS after long-term use in COPD seems to accelerate 
lung function decline during subsequent follow-up together with deterioration in AHR and 
health-related QOL. This indicates that the initial benefits of 30-month ICS treatment on 
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This is the first observation that lung function decline significantly accelerates during 5-year 
follow-up in moderate to severe COPD patients who did not use or intermittently continued 
ICS after 30-month randomized ICS treatment. Our results on FEV1 decline are in line with 
those of previous trials [8-10, 15]. However, different study designs, follow-up time, disease 
severities, sample sizes and definitions of ICS withdrawal makes it difficult to compare the 
annual decline in FEV1 between these studies. Furthermore, QOL measured by MRC, SGRQ 
and CCQ, deteriorated during long-term follow-up compared to the previous randomized 
treatment period, although the minimal clinically important difference was not reached [16, 
17]. SGRQ total score gradually declines over time after withdrawal of ICS in patients who 
previously used long-term ICS, which is similar to the decline in SGRQ found in the ISOLDE 
trial [15]. Our data extends previous observations, showing a deterioration in QOL after 
discontinuation of ICS compared to salmeterol or placebo during follow-up in COPD patients 
[9, 10]. Finally, we observed a deterioration in AHR during 5 years after ICS cessation, which 
thus far had only been described in asthmatics and after short-term treatment in COPD [7, 18, 
19]. In contrast to asthma, where AHR is mostly related to the degree of inflammation [20], we 
previously showed that AHR in this group of COPD patients is associated with both airflow 
limitation and airway inflammation [7, 21]. Taken together, the present study provides novel 
data on relapse of FEV1 decline and AHR after discontinuation of ICS after long-term use in 
COPD patients.
The strength of our study is represented by its long-term prospective design with repeated 
monitoring during 5 years of observational follow-up. In addition, the concordance of the 
currently observed changes in lung function decline, AHR and QOL further contributes to 
the confidence in our data. Nevertheless, this study had some limitations. First, only half of 
the patients randomized at baseline completed the entire 7.5-year follow-up, mostly due 
to the natural course of the disease with associated mortality and comorbidities. This could 
have led to a loss of statistical power compared to GL1 and a selection bias, even though the 
number of withdrawn patients during GL2 was similar among the original treatment groups. 
Second, only few patients used ICS 50-100% of the time during GL2 (n=23). Although only 
adherent patients during GL1 were used for the follow-up analysis, compliance to inhalation 
medication was not checked during GL2, thereby reflecting adherence in daily practice 
[22]. Creating small subgroups of patients using steroids during GL2 made it difficult to 
detect a difference in annual decline of FEV1 in the FS30 group between those who used ICS 
0-50% and 50-100% of the time during GL2. Third, pneumonia and exacerbation rates were 
not recorded during GL2, though prolonged use of ICS in COPD may have adverse effects, 
like the risk of serious pneumonia, especially with high-dose fluticasone [23]. However, 
retrospectively retrieved rates of antibiotics and prednisolone courses were similar between 
the groups. Amongst the 26 patients who died during the 7.5-year follow-up only one 
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patient in the original F6 group (not participating in GL2) died of a pneumonia, yet occurring 
as complication of a lung carcinoma. Furthermore, overall survival was not statistically 
different between the original treatment groups. Hence, our data do not allow conclusions 
on the incidence of pneumonia or exacerbations during or after ICS usage. 
How can we interpret our results? Effects of ICS in COPD are affected by the complexity of 
this heterogeneous disease, classified by clinical, physiologic, pathological and radiologic 
variables and varies by host susceptibility and/or cigarette smoking [24, 25]. Previously, we 
described that ICS treatment attenuates lung function decline and decreases inflammation 
in this group of COPD patients [7]. The present study shows a relapse in lung function decline 
after discontinuation of ICS. The presently observed rate of decline is higher compared to 
that in the recent WISDOM study [8]. Moderate to severe COPD patients as in our study are 
representing a pathophysiological distinct group and thereby potentially more responsive 
to ICS [4]. The annual rate of decline after ICS discontinuation could therefore be larger 
compared to severe airflow obstruction [9, 10, 15]. This suggests (at least) temporary disease 
modification of COPD, especially during active and prolonged periods of ICS use. Future 
analyses should focus on inflammatory outcomes to determine whether our previously 
observed anti-inflammatory effects of ICS in COPD are also ablated.
Our results may have consequences for future treatment of COPD patients. Although meta-
analyses show limited benefits of ICS in COPD [3], the original GLUCOLD study suggests that 
maintenance use of ICS can lead to attenuated lung function decline at least in this subset 
of COPD patients [7]. Notably, the current long-term follow-up study indicates that such 
benefits are not maintained after prolonged cessation of treatment. Though these data may 
suggest that ICS treatment in COPD should not be discontinued, this study was not designed 
to show evidence of any continued benefits of prolonged ICS therapy. 
CONCLUSIONS
The present data indicate that discontinuation after 30-month use of ICS in this group of 
moderate to severe COPD deteriorate lung function decline during 5-years follow-up. This 
is accompanied by worsening in AHR and a small drop in QOL. These results suggest that, 
whereas initial long-term ICS use can have a disease modifying effect in particular COPD 
patients, such benefits disappear when ICS are discontinued.  
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Background: Long-term treatment with inhaled corticosteroids (ICS) might attenuate 
lung function decline and decrease airway inflammation in a COPD subset, whereas ICS 
discontinuation relapses lung function decline. We hypothesized that airway inflammation 
increases after ICS withdrawal following long-term ICS treatment in COPD.
Methods: In the GLUCOLD-1 study (GL1) 114 patients with moderate to severe COPD were 
treated randomized to 6-month or 30-month fluticasone propionate (500µg bid), 30-month 
fluticasone/salmeterol (500/50µg, bid) or placebo. In the follow-up study (GL2), patients were 
followed prospectively for 5 consecutive years, treated by their physician. Bronchial biopsies 
and induced sputum were collected at baseline (GL1), 30-month (end GL1) and 7.5-year (end 
GL2) to assess inflammatory cell counts. Analysis was performed by linear mixed-effects 
models.
Results: In patients using ICS during GL1 and using ICS 0-50% of time during GL2 (n=61/85), 
bronchial cells increased in GL2 significantly: CD3+ (fold change/year GL2-GL1 [95%CI] 2.68 
[1.87-3.84]), CD4+ (1.91 [1.33-2.75]), CD8+ cells (1.71 [1.15-2.53]) and mast cells (1.91 [1.36-
2.68]). Additionally, sputum total cell counts increased significantly in GL2 (1.90 [1.42-2.54]), 
macrophage (2.10 [1.55-2.86]) neutrophil (1.92 [1.39-2.65]) and lymphocyte counts (2.01 
[1.46-2.78]). 
Conclusions: ICS discontinuation increases airway inflammation in moderate to severe COPD 
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INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic inflammation 
in the airways, with neutrophils, macrophages and CD8+ T-cells as major inflammatory cell 
types [1]. More severe airflow limitation is associated with more severe airway inflammation. 
As the progressive course of the disease continues to more severe airflow limitation, airway 
inflammation increases over time [2-4]. Except for smoking cessation, there is currently no 
therapy that halts the inflammatory process in the airways.
According to current guidelines, treatment with inhaled corticosteroids (ICS) is 
recommended for severe and very severe COPD patients in case of frequent exacerbations. 
Up to now only a few trials have evaluated the anti-inflammatory effect of ICS in bronchial 
biopsies and bronchoalveolar lavage (BAL) in COPD. A recent meta-analysis showed that 
12- to 26-week ICS treatment in COPD reduced CD4+ and CD8+ cells in bronchial biopsies 
[5-10]. In addition, ICS reduced neutrophil and lymphocyte counts in BAL, but increased 
macrophage counts [9, 11-13]. Our study group has previously shown that 30-month 
treatment with inhaled fluticasone decreased the number of bronchial CD3+, CD4+, CD8+ cells 
and mast cells, and reduced the sputum neutrophil, macrophage and lymphocyte counts [8]. 
Discontinuation of ICS may increase the number of exacerbations [14-16] and accelerate lung 
function decline in patients with COPD [17-22]. However, little is known about the effect of 
ICS discontinuation on airway inflammation. An increase in percentage sputum neutrophils 
was found in COPD patients randomized to ICS withdrawal when compared to neutrophils 
in case of 6-week ICS continuation [23]. We previously showed that discontinuation after 
6-month ICS increased bronchial CD3+ cells, mast cells and plasma cells at 2.5 years compared 
to continued therapy, without significant effect on sputum inflammatory cells [8]. However, 
the effects of withdrawal of ICS after long-term treatment on airway inflammation have not 
been investigated, but are highly relevant to evaluate the sustained reductions in bronchial 
inflammation and possible disease-modifying effects. 
We hypothesized that inflammatory cell counts in bronchial biopsies and sputum increase 
after withdrawal of ICS in COPD patients who had previously been randomized to 30-month 
ICS treatment during 5 subsequent years of prospective follow-up. Additionally, we 
examined whether the changes in inflammation after ICS withdrawal were associated with 
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changes in lung function decline.
MATERIALS AND METHODS
Study design and participants
Patients of the GLUCOLD (Groningen and Leiden Universities Corticosteroids in Obstructive 
Lung Disease) study (GL1) were enrolled in the observational, follow-up study (GL2). Details 
of the study design were previously described [8, 21]. In short, in GL1 114 moderate to 
severe, steroid-naive COPD patients were randomized to one of the four treatment arms, 
with Diskus dry-powder inhalers (GlaxoSmithKline, Zeist, The Netherlands) each twice daily 
for 30 months: 1) fluticasone propionate (FP) 500µg (F30); 2) FP with salmeterol, 500/50µg, 
single inhaler (FS30); 3) 6-month FP followed by 24-month placebo (F6); and 4) placebo. 
During GL2, patients were treated by their own physician according to current guidelines 
[24], which implied that the majority of patients intermittently used or did not use ICS. At the 
end of GL2, a list of delivered medications was provided by the patients’ pharmacy. The ethics 
committees of Leiden University Medical Center and University Medical Center Groningen 
approved both GL1 and GL2. Separate written informed consent for GL2 was provided by all 
patients.
Outcomes and measurements
The primary outcome of the present study was the effect of ICS withdrawal on inflammatory 
cell counts in the lamina propria of bronchial biopsies. Therefore, a fiberoptic bronchoscopy 
was performed after 5 years of follow-up (GL2) according to standardized protocols, 
consistent with bronchoscopies in GL1 [25]. Processing of bronchial biopsies was performed 
according to present recommendations [26], and two biopsies per patient were selected 
based on the largest lamina propria by evaluaton of hematoxylin-eosin stained sections. 
Immunohistochemical stainings on 4µm sections of paraffin-embedded bronchial biopsies 
were performed with specific antibodies against T-lymphocytes (CD3, CD4, and CD8), 
macrophages (CD68), neutrophil elastase (NE), mast cell tryptase (AA1) and eosinophils (EG2), 
according to the previous protocols [25]. Due to a lack of significant ICS-induced changes in 
plasma cells in GL1, we did not include these cells in our current analysis. Bronchial cells were 
counted using image analysis software (ImageJ, version 1.48i, National Institutes of Public 
Health). Subepithelial cells were calculated as weighted means and expressed as number 
of cells per 0.1mm2. The minimal selected area of lamina propria for analysis per biopsy 
was 0.02mm2. Data from bronchial cell counts of baseline and after 30 months (GL1) were 
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previously reported [8]. 
The secondary outcome was the effect of ICS discontinuation on inflammatory cell counts in 
induced sputum. A sputum induction was performed at year two and five of GL2. For safety 
reasons, sputum was only induced in patients with a post-bronchodilator FEV1 ≥1.2l. Induced 
sputum was processed according to the full sample method [27]. Two cytospins per sample 
were stained with May-Grünwald Giemsa (MGG) to obtain differential cell counts. A sputum 
sample was considered adequate if ≤80% squamous cells were present. Differential cell 
counts were expressed as cell count per 104ml non-squamous nucleated cells. Sputum cell 
counts at baseline and after 30 months (GL1) were previously reported [8].
Statistical analysis
Data from all patients were used for the analysis and the statistical analysis was performed 
with SPSS 22.0 software (SPSS Inc., Chicago, IL). Because there were no differences in 
inflammatory cell counts after 30 months of treatment in the F6 and placebo groups, and 
in the FS30 and F30 groups [8], we combined these to increase power into two groups: F6/
placebo and FS30/F30. ICS use during GL2 was retrospectively divided into the following 
groups: patients who used ICS 0-50% or 50-100% of the time. For the analysis of GL2, we 
focused on those patients using 0-50% ICS during GL2, being the largest subgroup (61 out of 
85 patients). Based on the information of the patients’ pharmacy, the daily dose of ICS (in µg, 
in beclomethasone dipropionate [BDP] equivalents) during 5 years was calculated as daily 
sum of the different doses of ICS (in µg/day) divided by the total time that ICS were used 
(days). 
A linear mixed-effect model with a random intercept for each subject was applied, using all 
natural-log transformed inflammatory measurements from GL1 and GL2 as outcome variable 
and an identity covariance matrix. The analysis was stratified for original combined treatment 
groups and ICS use during GL2. The change in inflammatory cell counts in GL2 compared to 
GL1 (GL2 minus GL1) was assessed by two time variables in the models: time 1 (time since 
start of GL1: range 0-7.5 years) and time 2 (time since start of GL2: range 0-5 years; during 
GL1 this value is zero). To assess the change in cell counts between the original FS30/F30 
groups compared to the original F6/placebo groups, a linear mixed-effect model with the 
same time variables was used including an interaction term between these time variables 
with the original combined treatment groups. Given the limited sample size of patients 
completing the 5 years of prospective follow-up, possible confounders (age, sex and center) 
were not included in the model. Smoking was unlikely to be a major confounder as shown in 
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a previous post-hoc analysis [8]. By Spearmans’ correlation coefficient, we assessed whether 
the changes in inflammation in GL2 versus GL1 were associated with change in lung function 
in the same period.
Since the number of cells decreased during GL1 and increased at the end of GL2, and 
therefore represent a difference in slope, we calculated the rate of change. Therefore, data are 
presented as fold change per year between GL2 minus GL1 with 95% confidence interval (CI), 
calculated by taking the antilog of estimates from the linear mixed-effects models. Statistical 
significance was inferred at P≤0.05. 
Table 1. Patient characteristics at baseline of randomized treatment (GL1) and at the start of 5 years of follow-
up (GL2) for the original FS30/F30 and F6/placebo groups.









Gender (M/F) (n) 51/9 48/6 41/5 42/4
Age (yr) 61 (7.7) 62 (7.8) 64 (7.7) 64 (7.3)
Smoking (y/n) (n) 36/24 36/18 22/24 26/20
Packyears (yr) 41 (31-54) 47 (31-56) 43 (31-58) 49 (34-57)
Post-bronchodilator FEV1 (% pred) 64 (8.3) 62 (9.3) 61 (11.1) 63 (11.7)
Post-bronchodilator FEV1 (L) 2.05 (0.5) 2.06 (0.4) 1.92 (0.6)* 2.03 (0.5)
Post-bronchodilator FEV1/IVC (%) 49 (8.5) 47 (8.6) 46 (10.6) 47 (9.9)
Data of the 2 combined groups are derived from the original 4 treatment groups in GL1 are presented 
as means and standard deviation, median with interquartile range (packyears) or numbers. F6: 6 months 
treatment with fluticasone, followed by 24 months of placebo; FS30: 30 months treatment with fluticasone 
and salmeterol; F30: 30 months treatment with fluticasone. Data for the individual 4 treatment groups have 
been previously reported [21].
* P≤0.001 compared to original combined F6/placebo groups at baseline GL1 (calculated with paired samples 
T-test).
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RESULTS 
Data from 114 patients were used for the analysis of GL1, 92 patients completed GL1, 85 
patients started and 61 completed GL2 [8, 21]. Patient characteristics at both baseline and 
at start of GL2 were similar among the original combined treatment groups, except for 
post-bronchodilator FEV1, which was significantly lower at the start of GL2 in the original 
combined F6/placebo groups compared to the original combined FS30/F30 groups (Table 1).
Most patients (61/85) used ICS 0-50% of time during GL2, with a mean daily ICS dose of 
1019µg (SD 554µg) in BDP equivalents during GL2 (Table 2), which was not significantly 
different between the original combined treatment groups. Bronchial biopsies of 29 patients 
were available at the end of GL2 (Table 3), and 21 of these 29 patients used 0-50% of time 
ICS during GL2. Sputum samples suitable for analysis were available from 47 and 33 patients 
after 2 and 5-year follow-up, respectively (Table 3). A diagram with the number of patients 
per group and available number of samples is presented in Figure 1.
Figure 1: Diagram presenting the number of patients and available bronchial biopsies and sputum samples in 
GL1 and GL2 in the original combined treatment groups.




46 patients      































GL1: GLUCOLD 1 study, first part of the study. GL2: GLUCOLD 2 study, follow-up study. F6: 6 months treatment 
with fluticasone, followed by 24 months of placebo; FS30: 30 months treatment with fluticasone and 
salmeterol; F30: 30 months treatment with fluticasone.
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Table 2: Number of patients at the start of the GLUCOLD follow-up study (GL2) using ICS and daily dose of ICS 
(in µg) during 5 years in those patients who used ICS during GL2.
Original 
treatment group
No ICS use (n) ≤50% use of 
ICS (n)
>50% use of 
ICS (n)
100% use of 
ICS (n)
Daily dose ICS 
(µg) 
F6/placebo 20 12 10 1 875 (479)
FS30/F30 15 14 8 5 1141 (591)
Total 35 26 18 6 1019 (554)
The daily dose of ICS (in µg, in BDP equivalents) during 5 years was calculated by the sum of the different doses 
of ICS per day (in µg/day), divided by the total time that ICS were used (in days). Doses were based on data 
provided by the patients’ pharmacy. 
Daily dose of ICS is presented as means with standard deviations. F6: 6 months treatment with fluticasone 
and 24 months with placebo; FS30: 30 months treatment with fluticasone and salmeterol; F30: 30 months 
treatment with fluticasone.
Bronchial biopsies
Compared to GL1, patients within the combined original FS30/F30 groups, who used ICS 
0-50% of time during GL2 showed an increase in bronchial CD3+ [GL2-GL1, expressed a fold 
change/year: 2.68 (1.87-3.84); P<0.001], CD4+ [1.91 (1.33-2.75); P=0.001], CD8+ cells [1.71 
(1.15-2.53); P=0.008] and mast cells [1.91 (1.36-2.68); P<0.001] at the end of GL2 (Figure 2). 
Discontinuation of ICS or use of ICS 0-50% of time during GL2 in the original combined FS30/
F30 groups increased the number of CD3+ cells (expressed as fold change/year) [1.78 (1.21-
2.64); P=0.04], CD8+ cells [1.73 [1.05-2.85); P=0.033] and mast cells [1.52 (1.06-2.17); P=0.023] 
compared to the original combined F6/placebo groups.
147
Airway Inflammation in COPD after Withdrawal of Inhaled Corticosteroids
66
Table 3: Sputum samples and bronchial biopsies at year 2 and year 5 of GL2, presented by original combined 
treatment groups and use of ICS during GL2.








Year 2 F6/placebo 10 10 3 1 24
FS30/F30 8 7 5 3 23
Year 5 F6/placebo 12 7 1 0 20
FS30/F30 4 5 3 1 13
Bronchial 
biopsies
Year 5 F6/placebo 10 5 3 1 19
FS30/F30 3 3 4 0 10
Sputum samples were collected from 63 and 51 patients after 2 and 5 years of follow-up (suitable for analysis 
47 and 33), respectively. Data presented as number of samples. 
GL2: follow-up study; ICS: Inhaled corticosteroids. F6: 6-month ICS followed by 24-month placebo. FS30: 
30-month fluticasone with salmeterol; F30: 30-month fluticasone.











































































Figure 2: Geometric mean cell counts in bronchial biopsies (per 0.1 mm2 lamina propria) for those patients 
who used ICS 0-50% of the time during GL2 in the original combined treatment groups FS30/F30 and F6/
placebo. Error bars represent 95% confidence interval. Data of bronchial CD3+ cells (Figure 2A), CD4+ cells (2B), 
CD8+ cells (2C) and mast cells (2D) are presented. Data were calculated by taking the antilog of the means of 
natural log-transformed number of cells. The group of patients who used ICS 50-100% of time during GL2 was 




At the end of GL2, patients of the original FS30/F30 groups who used 0-50% of time during 
GL2 had a higher total sputum cell count [GL2-GL1, expressed as fold change/year: 1.90 (1.42-
2.54); P<0.001], as well as higher counts of sputum macrophages [2.10 (1.55-2.86)]; P<0.001), 
neutrophils [1.92 (1.39-2.65)]; P<0.001) and lymphocytes [2.01 (1.46-2.78)]; P<0.001), at the 
end of GL2 compared to during GL1 (Figure 3). Discontinuation of ICS or use of ICS 0-50% 
of time during GL2 in the original combined FS30/F30 groups increased the total number of 
sputum cells (expressed as fold change/year) [1.66 (1.12-2.46); P=0.012], sputum neutrophils 
[1.68 [1.09-2.58); P=0.018], macrophages (1.90 [1.26-2.85]; P=0.002) and lymphocytes [1.73 
(1.09-2.74); P=0.020] compared to the original combined F6/placebo groups.










































































Figure 3: Geometric mean sputum cell counts (x 104 per ml) for original combined treatment groups FS30/
F30 and F6/placebo. Error bars represent 95% confidence interval. Data of patients who used ICS 0-50% of 
the time during GL2 are presented for total sputum cells (Figure 3A), neutrophils (3B), macrophages (3C) and 
lymphocytes (3D). Data were calculated by taking the antilog of the means of natural log-transformed number 
of cells. The group of patients who used ICS 50-100% of time during GL2 was too small, and is therefore not 
shown in the figures.
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Relation between lung function decline and inflammatory cells
The accelerated rate of decline in post-bronchodilator FEV1 during GL2 was associated 
with an increase in sputum macrophages in patients of the original FS30/F30 groups (Rs=-
0.63, P=0.04) and with a trend towards an increase in bronchial neutrophil counts (Rs=-0.60, 
P=0.07) (Figures 4A and B, respectively). 
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Figure 4: Correlation between change (end GL2-end GL1) in post-bronchodilator FEV1 (L) and change in 
natural log-transformed sputum macrophages (end GL2-end GL1, expressed as number of cells x 104 per ml) 
(Figure 4A, left panel) and changes in natural log-transformed bronchial neutrophils (per 0.1 mm2 lamina 
propria, Figure 4B, right panel). Each dot represents a single patient.
DISCUSSION
The present study shows that withdrawal of ICS after previous long-term ICS treatment 
in patients with moderate to severe COPD, is accompanied with increased bronchial 
T-lymphocytes and mast cells as well as several sputum cell counts. In addition, we found an 
association between the accelerated rate of lung function decline and increase in sputum 
macrophages during GL2, and a trend with bronchial neutrophils. These results suggest that 
airway inflammation is suppressed during active treatment with ICS and might relapse after 
long-term discontinuation of ICS.
We observed that several inflammatory cells in bronchial biopsies and sputum significantly 
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increased during 5-year follow-up in patients with moderate to severe COPD who did not 
use or only intermittently used ICS after previous 30-month randomized ICS treatment. 
These unique data confirm and extend previous findings of our study group, showing that 
withdrawal of ICS after 6-month ICS treatment increases bronchial CD3+ cells, mast cells and 
plasma cells when followed up to 30 months compared to those who continued ICS therapy, 
without a significant effect on sputum inflammatory cells [8]. Another open-labelled pilot 
study with only 6-week ICS withdrawal showed an increase in the percentage of sputum 
neutrophils compared to ICS continuation [23]. Taken together, the present study provides 
novel data on a relapse of airway inflammation after prolonged ICS discontinuation with 
previous long-term ICS use in COPD.
In this longitudinal study, we found that lung function decline seems to be related to an 
increase in sputum macrophage counts in moderate to severe COPD patients, the majority 
being without ICS treatment. Furthermore, a trend for an association with higher bronchial 
neutrophils was found. A previous study showed that higher sputum neutrophils were 
associated with faster FEV1 decline in patients with severe COPD using ICS [3]. Furthermore, 
a weak association between sputum percentage neutrophils and FEV1 percentage predicted 
was found in a cross-sectional study [4]. These findings in sputum neutrophils are likely not 
only explained by differences in study design, but also by differences among the studies 
in number of patients, severity or phenotype of COPD, and duration of treatment and 
withdrawal of ICS. A recent study by Barnes et al. found that COPD patients treated with 
fluticasone and a high percentage blood eosinophils at baseline have a slower rate of FEV1 
decline compared to placebo treated patients [28]. However, we could not detect a relation 
between baseline blood eosinophilia and lung function decline during GL2 in those who 
stopped or continued using ICS during GL2. Taken together, until now, this is the only long-
term study that suggests an association between lung function decline and change in 
inflammation after prolonged ICS withdrawal. 
A strength of our study is the long-term follow-up with monitoring of lung function and 
availability of sputum and bronchial biopsies during 5-year follow-up. This is unique, since 
no previous studies had such a prolonged treatment period as well as long follow-up period 
with treatment according to the current guidelines in a real life setting. It needs to be noted 
that the effect of ICS withdrawal in the present study was more pronounced in bronchial 
biopsies than in sputum, stressing the importance to not only study sputum cell counts 
when investigating COPD. Nevertheless, our study has some limitations. First, expectedly, the 
number of patients that finished the complete study is limited, particularly when considering 
the original treatment groups separately. Therefore, we chose to combine the original FS30/
151
Airway Inflammation in COPD after Withdrawal of Inhaled Corticosteroids
66
F30 and F6/placebo groups to increase power as there were no differences between the 
F6 and placebo groups at the start of the GL2 but only following first 6-months treatment 
during GL1. The small groups of patients from whom bronchial biopsies and sputum samples 
were available, make the correlation with lung function decline less strong. Despite these 
relatively low numbers, we still detected associations between clinical and histological 
outcomes. Second, GL2 was a prospective, (non-randomized) observational study and the 
majority of patients (61 of 85) discontinued their ICS or used 0-50% of time of observation 
ICS during GL2 (Table 2). Adherence to medication was not checked, reflecting daily practice. 
This could have led to a misclassification of ICS use during GL2 and therefore might have 
influenced out outcomes. Nevertheless, when only compliant patients during GL1 were 
included in the current analysis, similar results were found (data not shown). Due to the 
limited number of patients in whom a bronchoscopy was performed (Figure 1), a comparison 
between those with continuous ICS use versus ICS withdrawal during GL2 was not possible. 
Third, inflammatory cells were stained by immunohistochemistry with different batches of 
antibodies and counted using a different camera and image analysis software compared to 
GL1 [28]. We cannot rule out that these differences could have influenced our data. However, 
the bronchial inflammatory cell counts found in GL1 and GL2 were in a comparable range 
and cannot explain the observed difference found between and within the groups. Finally, 
bronchial inflammation is unequally distributed along the airways [29]. Since we were only 
able to collect samples from the central airways, the effect of ICS withdrawal in the small 
airways could not be investigated in this study. Taken into account these considerations, we 
are nevertheless confident that our data provide a novel view on relevant changes in airway 
inflammation after long-term cessation of prolonged ICS treatment.
How can we interpret our results? In the first part of the study (GL1), we found a reduction 
in bronchial inflammation and attenuation of lung function decline during 30-month 
ICS treatment in patients with moderate to severe COPD [8]. In the current study (GL2), 
we observed the expected opposite in that ICS withdrawal after previous long-term 
treatment resulted in an increase in CD3+, CD4+, CD8+ T-cells and mast cells in this selected 
group of patients, which further extends our previous observation that withdrawal of ICS 
relapses lung function decline [21]. The opposite outcome of ICS therapy in the first phase 
when compared to the effects of ICS withdrawal on airway inflammation in the second 
observational phase of our study can be regarded as a validation and strongly supports the 
plausibility of our findings. Taken together, our data suggest that during active treatment 




During the past 25 years numerous studies have been published concerning the question 
whether or not ICS are beneficial in COPD patients [30]. Our study shows that in this group of 
moderate to severe COPD, patients experience transient positive effects on lung function and 
on airway inflammation during ICS therapy, which are not maintained after ICS withdrawal 
[21]. The present selection of COPD patients may be representative of a particular phenotype 
that is responsive to steroid treatment [31], in whom long-term ICS therapy may need to be 
continued to maintain the observed beneficial effects on the course of lung function and 
airway inflammation over time. 
CONCLUSION
In conclusion, the present data indicate that ICS discontinuation during 5 years following 
30 months use of ICS, in a group of moderate to severe COPD patients, induces a relapse 
in bronchial and sputum inflammatory cells which is partially accompanied by a more 
rapid decline in lung function. These data suggest that ICS do not have a sustained disease 
modifying activity after ICS withdrawal in this group of COPD patients which is in line with 
observations in asthmatic patients. 
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Chronic obstructive pulmonary disease (COPD) is a common disease, which is currently the 
third leading cause of death worldwide [1], and is mainly caused by cigarette smoking. It 
is characterized by a progressive airflow limitation in most patients with COPD, structural 
changes in lung tissue (remodeling) and chronic airway inflammation. Anti-inflammatory 
treatment, such as inhaled corticosteroids (ICS), is currently recommended for patients 
with severe and very severe COPD with frequent exacerbations with the aim to inhibit 
the airway inflammation to prevent exacerbations. Previously, our study group showed 
that ICS treatment causes attenuation of lung function decline in a subgroup of moderate 
to severe COPD patients, accompanied by less airway inflammation and a better quality 
of life [2]. Although many patients use inhaled treatments, compliance to any long-term 
prescribed therapy is unfortunately poor [3]. Therefore it is important that both the treating 
physician and patient are informed about the clinical benefits of the particular treatment and 
understand what occurs after treatment withdrawal.
This thesis focusses on airway inflammation in COPD, with a specific focus on macrophages, 
macrophage phenotypes and their markers and airway remodeling in COPD. Another 
focus is the effects of long-term discontinuation of ICS on lung function decline and airway 
inflammation following 30 months of treatment with ICS in patients with moderate to severe 
COPD. 
For the studies described in this thesis, data and samples from the GLUCOLD (Groningen 
and Leiden Universities Corticosteroids in Obstructive Lung Disease) study were used. The 
GLUCOLD study is a randomized, double-blind, placebo-controlled trial with four treatment 
arms. During the first part of the study, moderate to severe COPD patients were randomized 
to receive an inhaled treatment with 30-month fluticasone propionate with or without 
salmeterol, 6-month fluticasone (followed by 24-month placebo) or 30-month placebo. 
During the second part of the study (GLUCOLD follow-up study), patients were followed 
annually for 5 years while being treated by their own physician. During this period the 
majority of the patients were not at all or intermittently treated with ICS. 
In this chapter, first the conclusions of the separate studies are presented below, followed by 
a general discussion and directions for future research.
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CONCLUSIONS OF THIS THESIS
Relation between smoking, ICS and macrophage heterogeneity 
in COPD
• Smoking cessation changes the macrophage phenotype in vivo in the peripheral lungs, 
sampled by bronchoalveolar lavage (BAL), towards an anti-inflammatory phenotype, 
which is not associated with a decrease in pro-inflammatory mediators in patients with 
COPD (Chapter 2). 
• The pro-inflammatory biomarker YKL-40 is mainly secreted by pro-inflammatory MΦ1 
macrophages derived from in vitro cultured monocyte-derived macrophages, and its 
release is dose-dependently inhibited by dexamethasone (Chapter 3).
• Serum and sputum YKL-40 levels of COPD patients are not affected by 30 months of 
treatment with ICS (Chapter 3).
Effect of smoking and ICS on airway remodeling in COPD
• No differences are observed in bronchial extracellular matrix proteins, such as collagen 
I and III, the proteoglycan versican and decorin and elastic fibers between current and 
ex-smokers with COPD (Chapter 4).
• Long-term ICS treatment in COPD increases the percentage stained area of versican 
and collagen III compared to placebo (Chapter 4).
• Increased density of collagen type I is associated with an increase in lung function in 
patients with moderate to severe COPD (Chapter 4).
Clinical and pathological outcomes after long-term withdrawal of ICS 
in COPD
• Discontinuation of ICS after 30-month ICS treatment relapses lung function decline, 
airway hyperresponsiveness and quality of life during 5 years of follow-up in patients 
with COPD (Chapter 5).
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• Withdrawal of ICS after 30-month treatment in patients with COPD increases bronchial 
CD3+, CD4+, CD8+ T-cells and mast cells, together with a higher total sputum cell counts, 
sputum macrophages, neutrophils and lymphocytes. Increased sputum macrophages 
are associated with an accelerated lung function decline (Chapter 6).
GENERAL DISCUSSION
Macrophage heterogeneity is a complex phenomenon
Macrophages have important functions in innate and adaptive immunity and play a 
central role in the pathogenesis of COPD. They constitute a heterogeneous cell population 
with classically activated or pro-inflammatory MΦ1 cells and alternatively activated or 
anti-inflammatory MΦ2 cells, analogous to the Th1 and Th2 dichotomy [4, 5]. MΦ1 secrete 
pro-inflammatory cytokines, such as TNF-α and IL-12, promote Th1 immunity and have a 
good antigen presenting capacity. In contrast, MΦ2 cells are characterized by a role in Th2 
immunity, promote T-regulatory cells and efferocytosis (removal of apoptotic cells), have a 
poor antigen presenting capacity and secrete anti-inflammatory cytokines, such as IL-10 
[6, 7]. Monocyte-derived macrophages differentiated into MΦ1 or MΦ2 can switch from 
a certain subtype into another due to local environmental stimuli, a feature which is called 
plasticity [8, 9]. MΦ2 cells can even be further divided in three subsets: MΦ2a facilitate 
parasite encapsulation and destruction; MΦ2b are important for immunoregulation; and 
MΦ2c promote tissue remodeling and matrix deposition [10]. In this thesis, the subdivision 
between pro- and anti-inflammatory macrophages is used. Various well-validated various 
macrophage markers have thus far been identified mainly based on in vitro studies. However, 
skewing of macrophage phenotypes depends on activation after a certain environmental 
condition and stimulation, which is different in in vitro and in vivo conditions. CD163 is 
considered as a specific marker for M-CSF generated MΦ2, whereas CD80 seems a marker 
for IFN-γ polarized MΦ1 [11]. Although there are suggestions that macrophage markers in 
humans are different compared to murine markers [12-14], one study found that there are at 
least some similarities in macrophage markers between humans and mice [15].
A positive relation has been found between the increasing severity of COPD and an 
increased percentage of macrophages in the small airways of COPD compared to smokers 
and ex-smokers with a normal lung function [16], which even (partially) persists after 
smoking cessation [17, 18]. Although the above-mentioned characteristics of macrophage 
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phenotypes suggest a MΦ1 predominance in COPD, the role of macrophage phenotypes 
in COPD is still not fully clear. Some authors even suggest that in COPD patients in vivo an 
intermediate phenotype of macrophages, with characteristics of both MΦ1 and MΦ2 
cells, can be found [19, 20]. In this thesis we evaluated the MΦ2 marker CD163 (Chapter 2) 
and the novel MΦ1 marker YKL-40 (Chapter 3). The relative abundant presence of CD163+ 
macrophages in bronchoalveolar lavage (BAL) fluid in moderate to severe COPD patients 
suggests that the peripheral lung can be considered to be a more anti-inflammatory 
environment compared to the central airways (Chapter 2). Furthermore, we found that 
former smokers compared to current smokers have a higher percentage of anti-inflammatory 
macrophages in BAL, but not in sputum, indicating that removal of the pro-inflammatory 
stimulus of cigarette smoking in the peripheral airways changes the environment to a more 
anti-inflammatory character. Others confirmed this finding by showing that the chemokine 
ligand 18 (CCL18), a marker of alternatively activated macrophages is lower in BAL from 
current smokers compared to never smokers [21]. In addition, reduced efferocytosis has been 
found in alveolar macrophages from smoking patients with COPD compared to ex-smokers, 
suggesting that smoking cessation induces mostly a MΦ2 phenotype in the peripheral 
airways [22]. The observation that serum and sputum levels of YKL-40 are elevated in current 
smokers as well as in smoking and ex-smoking COPD patients compared to never smokers 
without COPD, is in line with this finding [23-25]. We confirmed that levels and expression 
of YKL-40 are higher in in vitro cultured monocyte-derived MΦ1 compared to MΦ2. YKL-
40 levels were higher in sputum compared to BAL from the GLUCOLD patients, but no 
differences were found between current and ex-smokers with COPD (data not shown), which 
is in line with findings from a recent study [25]. In contrast to the anticipated predominance 
of MΦ1 macrophages in COPD, some studies have even suggested the contrary. An 
analysis of alveolar macrophages from moderate to severe, mostly smoking COPD patients 
demonstrated a lower expression of CD86 and CD11a (markers for co-stimulation and 
adhesion, respectively, needed for antigen presentation) compared to asymptomatic 
smokers and nonsmokers, suggesting a decreased MΦ1 phenotype in COPD [26]. However, 
this study did not evaluate the effect of smoking cessation on macrophage phenotypes. The 
MΦ2 predominance in murine alveolar macrophages and peripheral blood mononuclear 
cells (PBMCs) after cigarette smoke exposure, shown by increased CD163 expression and 
anti-inflammatory cytokines, has been confirmed in in vivo and in vitro mouse studies [27]. 
Furthermore, it is interesting to study which component(s) in cigarette smoke is responsible 
for the skewing of macrophages. One study found that nicotine can skew MΦ1 cells, derived 
from PBMCs of healthy donors, partially into a MΦ2 phenotype [28].
Increased numbers of macrophages found in small airways in COPD, which are associated 
with airflow limitation [16]. In addition, some studies suggest that macrophage phenotypes 
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are related to the degree of airflow limitation. One study found a correlation between 
increased serum YKL-40 and decreased lung function in patients with COPD [23], indicating 
that in severe stages of COPD more MΦ1 cells are present. In contrast to this, a small study 
found that in alveolar macrophages from smoking patients with mild COPD compared 
to asymptomatic smokers and nonsmokers, expression of genes related to MΦ2 was 
upregulated, whereas MΦ1-related genes were downregulated [29]. This suggests that 
in addition to smoking, also the degree of airflow limitation could explain skewing of 
macrophage phenotypes. The presented data above remain hard to interpret. Mouse models 
with only exposure to cigarette smoke are not fully comparable with humans exposed to 
multifactorial environmental factors, including cigarette smoke. In addition, very little is 
known about diversity, phenotypes and function of macrophages, such as luminal versus 
tissue macrophages in the large and small airways [19]. To summarize, cigarette smoking 
causes a disturbance in macrophage phenotypes in COPD, which depends on the type of 
macrophage, disease severity and the location of the respiratory tract studied. 
Possible options for treatment of COPD include the restoration of this imbalance [30]. 
Several possibilities have been evaluated. One study evaluated the effect of procysteine, a 
glutathione precursor, which is essential for both MΦ1 and MΦ2 function. The authors 
found that in alveolar macrophages and lung tissue derived macrophages from a murine 
COPD model, efferocytosis significantly increased after treatment with oral procysteine [31]. 
This group also found that after long-term use of low-dose azithromycin by COPD patients, 
phagocytosis of bacteria by alveolar macrophages was improved in combination with a 
higher expression of the mannose receptor (marker of MΦ2) [32, 33]. This suggests that after 
treatment with procysteine and azithromycin the macrophage phenotype is skewed towards 
MΦ2. However, these medications are not often prescribed in patients with COPD.
More importantly, treatment with (inhaled) corticosteroids is frequently prescribed in COPD. 
Steroids have been shown to adapt the disturbed balance of macrophage phenotypes. 
In vitro cultured PBMCs, differentiated with IL-4 followed by stimulation with fluticasone 
propionate, showed reduced T-cell proliferation and RFD1 expression (marker for inductive 
or pro-inflammatory macrophages), whereas RFD7 expression (marker for suppressive 
or anti-inflammatory macrophages) was increased [34]. In addition, they found that the 
effect of fluticasone remained active for at least 24 hours after steroid removal. In line with 
this, dexamethasone treatment of in vitro differentiated macrophages results in a MΦ2 
morphology and increased percentage CD163+ cells [9]. These studies all suggest a skewing 
phenomenon to a MΦ2 phenotype after corticosteroid treatment. We found that YKL-40 
expression and secretion by in vitro cultured MΦ1 cells was dose-dependently inhibited 
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by dexamethasone (Chapter 3). However, we could not detect a significant difference 
in serum and sputum levels of the MΦ1 marker YKL-40 after 30-month ICS in our group 
of COPD patients (Chapter 3). This is in line with a recent paper that showed no difference 
in serum YKL-40 in COPD patients treated with oral or inhaled corticosteroids [25]. Thus, it 
seems that ICS do not influence macrophage phenotypes in vivo in COPD as evaluated by 
YKL-40 [35]. A possible explanation is that certain phenotypes of macrophages are steroid 
resistant, as was observed in healthy subjects after LPS-inhalation [36]. HLA-DR+ inducible 
pulmonary monocyte-like cells (suggestive for MΦ1 cells), obtained from BAL fluid of these 
subjects, produced pro-inflammatory cytokines that did not respond on in vitro stimulation 
with dexamethasone, whereas alveolar macrophages responded by lower levels of IL-6 and 
IL-8. Another recent study showed that a subset of pulmonary tissue macrophages from 
COPD patients are less responsive to budesonide compared to macrophages of non-smokers 
and healthy smokers, measured by CXCL8 and TNF-α release after LPS-stimulation [20]. A 
possible mechanism of steroid resistance involves reduced expression of histone deacetylase 
2 (HDAC2), which can deactivate inflammatory gene expression in COPD. Smoking and 
oxidative stress may reduce HDAC2 activity and expression [37]. In addition, HDAC3 activity 
is inhibited by cigarette smoke exposure in PBMCs differentiated MΦ1, which show an 
increased production of IL-8 and IL-1β, thereby promoting chronic inflammation [38].
Finally, in patients with chronic kidney allograft injury who are treated with 
immunosuppressive treatment, including steroids, kidney biopsies showed areas with 
high numbers of CD163+ MΦ2 cells which correlated with the amount of collagen I 
deposition [39]. This study group also showed that in in vitro cultured PBMCs, stimulated 
with dexamethasone, gene expression of CD163 and TGF-β were both induced, suggesting 
that macrophages are skewed to an anti-inflammatory (MΦ2) and possible pro-fibrotic 
phenotype [39]. MΦ2-like cells are also present in mouse models of bleomycin-induced 
lung fibrosis, in which IL-10 attenuates bleomycin-induced inflammation and fibrosis [12]. 
In contrast, overexpression of IL-10 in this model induces extracellular matrix deposition in 
the lung [40]. Furthermore, corticosteroids can induce MΦ2-like cells and thereby promote 
fibrosis [41]. This observation is in line with our findings that after long-term treatment with 
ICS more collagen III and versican in large airways of COPD patients was found (as described 
in Chapter 4 and discussed in paragraph below), which was associated with an improved 
lung function. These observations show that macrophage heterogeneity is a complex 
process, which can be markedly influenced by a local and multifactorial environment. 
Steroids might influence the composition of this heterogeneous cell population, but may 
also have effects on extracellular matrix deposition.
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Inhaled corticosteroids and extracellular matrix production 
in COPD
Smoking and chronic airway inflammation both contribute to structural changes and 
remodeling in the airway wall and lung parenchyma in COPD [42, 43]. Remodeling is a result 
of changes in the extracellular matrix (ECM), a three dimensional structure which acts as the 
backbone of the lung tissue. It provides a scaffold for the cells and contributes to regulation 
of their activity, and its composition is an important determinant of lung function. The major 
ECM components are collagens, proteoglycans and elastic fibers [44]. The ECM has a high 
turnover even in healthy subjects, thereby maintaining its stability and functions. However, 
remodeling is a complex process, which results from many small changes in tissue structure 
that lead to tissue degrading and/or accumulation of proteins. Several mechanisms play a 
role in remodeling, such as cell proliferation, increasing cell volume, modified synthesis and 
deposition of ECM proteins and a disturbed balance between matrix metalloproteinases 
(MMPs) and tissue inhibitor of metalloproteinases (TIMP) [45]. A relative excess of MMPs 
and shortage of TIMPs, as in COPD, can result in irreversible pathological changes [46]. An 
example of the imbalance between MMPs and TIMPs is during exacerbations of COPD, as 
elevated plasma and serum levels of protein fragments of collagen type III, IV and VI and 
elastic fibers and decreased levels of versican were found, compared to stable COPD [47]. 
In addition, elevated levels of MMP-9 and decreased levels of TIMP-1 in sputum of patients 
with COPD have been found during an exacerbation [48]. This suggests that during an 
exacerbation the ECM is actively degraded. 
The composition of the ECM is regulated by several cells types, such as macrophages, 
fibrocytes and fibroblasts. Macrophages produce several growth factors, such as 
transforming growth factor β1 (TGF-β1), which contribute in wound repair and tissue 
regeneration. Macrophages are in close contact with the ECM proteins and interaction 
with these proteins can improve their phagocytic capacity [49]. However, cigarette smoke 
modifies the ECM proteins, and as a result the phagocytic capacity of macrophages is 
critically diminished [49, 50]. Furthermore, MΦ2 cells, especially MΦ2c, are important in 
wound healing and fibrosis [14]. When the process of wound healing is almost completed, 
MΦ2 cells turn into a suppressive phenotype, by the expression of e.g. arginase-1, and IL-
10, enhance the resolution of wound healing and restore homeostasis, thereby suppressing 
fibrosis [51, 52]. Although the pathogenesis of fibrosis is currently not fully understood, these 
data suggest that a disturbed balance between macrophage phenotypes can induce or 
inhibit fibrosis.
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Bone-marrow derived fibrocytes produce collagens along with inflammatory cytokines. 
They are induced by pro-fibrotic mediators like TGF-β, and have been found in areas 
of wound healing, as well as in lung tissue from asthmatic patients [53]. Even in young 
children with asthma, chronic inflammation causes thickening of the reticular basement 
membrane in combination with subepithelial fibrosis [54, 55]. The ECM components that 
are mainly changed in patients with asthma are collagens and the proteoglycans laminin, 
tenascin and fibronectin [56-59]. The increased amount of collagens and fibronectin in the 
airways make them stiffer, which may prevent collapse and thereby protect the bronchi 
from airway hyperreactivity or airway narrowing as has been found in animal models [60, 
61]. This reduced airway hyperresponsiveness and the association with increased airway 
wall thickness and subepithelial collagen deposition has also been found in asthmatic 
patients [62, 63]. Also in mild COPD patients, higher numbers of fibrocytes have been found 
compared to healthy subjects and patients with more advanced stages of COPD [64]. In 
addition, circulating fibrocytes are increased during acute exacerbations of COPD and were 
associated with a lower lung function and a higher mortality [65]. 
ICS have been found to significantly decrease the number of fibrocytes in mild COPD 
patients compared to non-treated patients. In addition, ICS inhibited the release of MMPs 
and prevented collagen degradation in in vitro culture systems [64, 66]. Although less 
fibrocytes are found after treatment with ICS in COPD, these results may suggest that 
corticosteroids inhibit ECM breakdown. Furthermore, some studies suggest increased matrix 
deposition after treatment with corticosteroids, which has already been suggested some 
decades ago by Torry et al. [67], showing that the number of colony-forming human fibrotic 
lung fibroblasts increases after stimulation with dexamethasone. This implies that fibroblasts 
obtained from chronically inflamed, fibrotic lung tissue behave differently under growth 
conditions compared to fibroblasts obtained from healthy lung tissue. The increased collagen 
deposition under inflammatory conditions, such as in COPD, has been confirmed in in vitro 
cultured human lung fibroblasts [68]. These observations are in line with the GLUCOLD 
study in which COPD patients treated with 30-month ICS, had increased content of collagen 
III and versican in large airways (Chapter 4). However, some studies suggest that only some 
components of the ECM is steroid-sensitive. A previous study in a rat model sensitized to 
ovalbumin, fluticasone prevented remodeling of the airways when given simultaneously 
with this allergen, but the structural changes remained when fluticasone was given post-
allergen exposure [69]. Furthermore, asthmatics treated for 6 weeks with ICS showed no 
change in collagen deposition in the airway wall [70]. Collagen remodeling in human airway 
smooth muscle cells (ASM) in a gel area was steroid resistant [71]. Another study showed 
that collagen I and fibronectin expression in ASM cells from asthmatics were unchanged by 
corticosteroids, whereas corticosteroids induced the expression of collagen I and fibronectin 
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in ASM cells from non-asthmatics [72]. A possible explanation for the partially steroid 
resistance of the remodeling process, is that altered ECM components, such as collagen type 
I, are less responsive to dexamethasone [73]. This may to some extent explain why in our 
group of COPD patients, collagen I content was not affected by treatment with ICS. 
Another reason for altered ECM production is epithelial-mesenchymal transition (EMT), 
a process in which epithelial cells acquire properties of mesenchymal cells. It has been 
suggested that EMT is active in the airways of COPD, as the mesenchymal markers S100A4 
and vimentin have been found in the airway epithelium [74]. The GLUCOLD study group 
showed previously that after 30-month treatment with fluticasone, expression of genes 
involved in epithelial cell signaling, oxidative stress, remodeling and apoptosis was 
decreased in patients with moderate to severe COPD [75]. This study demonstrated a 
reduced expression of transmembrane serine protease (TMPRSS)-4, which is an important 
protein in EMT. Another study found that epithelial activation, basement membrane 
fragmentation and mesenchymal biomarkers were reduced in bronchial biopsies of mild to 
moderate COPD after treatment with 6 months of inhaled corticosteroids [74]. In contrast, 
other genes involved in focal adhesion, gap junction and extracellular matrix deposition 
were increased after treatment with ICS [75]. These results suggests that ICS alters the gene 
expression profile involved in EMT and in remodeling of COPD.
In summary, the above presented results suggest that whereas (inhaled) corticosteroids 
may have pro-fibrotic properties, their effect differs between the various extracellular matrix 
proteins. In our study we found an increased deposition of collagen type I after long-term 
treatment with ICS, which was associated with a better lung function, suggesting that ICS 
induced changes in ECM contributes to this. However, it remains the question whether 
airway remodeling is (partially) reversible, which mechanism is most susceptible and at 
which time point therapeutic intervention should be given to prevent the progressive course 
of the disease.
Withdrawal of ICS relapses lung function decline and airway 
inflammation
Inhaled corticosteroids are currently widely prescribed for prolonged periods in patients 
with all stages of COPD, although compliance to any (chronically) prescribed treatment is 
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approximately relatively low (30-50%) [3]. According to current guidelines, ICS should only be 
prescribed to patients who will benefit most, namely symptomatic patients with severe and 
very severe COPD with frequent exacerbations [76]. This implies that many patients who are 
currently using ICS should actually discontinue their ICS.
What happens when long-term used ICS are withdrawn? The most feared adverse event, 
namely adrenal insufficiency, develops only in approximately 7% of asthmatic patients [77]. 
Several studies have evaluated the effect of discontinuation of ICS. One of the most recent 
studies, the WISDOM trial, found a similar risk of exacerbations in severe and very severe 
COPD patients who continued or discontinued ICS. However, lung function decline was 
significantly greater after one year of ICS withdrawal compared to those who continued ICS 
[77, 78]. Another study in patients with symptomatic mild and moderate COPD with less 
than 2 exacerbations each year, showed no deterioration in symptoms and exacerbations 
and a stable lung function after 6 months of follow-up [79]. A disadvantage of these 
studies is that they did not have a prolonged randomized treatment period with ICS before 
withdrawal, which may differentially affect the outcome of withdrawal, nor a long-term 
follow-up. In addition, patient characteristics at baseline and during follow-up regarding 
clinical and inflammatory parameters, quality of life and airway hyperresponsiveness are 
only partially available in the studies. This difference in disease severity of COPD, duration 
of steroid treatment and follow-up time makes it difficult to compare the currently available 
withdrawal studies [80-82].
In the first part of the GLUCOLD study, ICS withdrawal after 6 months of treatment induced 
increased bronchial inflammatory cells, airway hyperresponsiveness and worsened quality of 
life, compared to 30-month continued treatment with ICS, without effect on lung function 
decline [2]. These effects on inflammation and clinical parameters have been confirmed 
by others [82-85]. In the GLUCOLD follow-up study (Chapter 5), we found that 5-year 
discontinuation of ICS after previous 30-month treatment with ICS induces a relapse in lung 
function decline, in combination with deterioration in airway hyperresponsiveness and 
quality of life. Furthermore, bronchial T-cells and mast cells and several sputum cell counts 
increased after ICS cessation, which was associated with accelerated lung function decline 
(Chapter 6). Therefore, the relapse in clinical and pathological parameters after long-term 
withdrawal of ICS as described in the present study, confirmed the results found during the 
first part of the GLUCOLD study. 
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Why is it important to study the long-term effect of withdrawal of ICS, when already by 
ICS withdrawal after 6-month treatment with ICS a relapse in bronchial inflammation and 
quality of life was found? By studying long-term ICS treatment, we speculated that disease 
modification could have been reached. Although no official definition exists, disease 
modification can be described as ‘an improvement in, or stabilization of, structural or 
functional parameters as a result of reduction in the rate of progression of these parameters 
which occurs whilst an intervention is applied and may persist even if the intervention is 
withdrawn [86]. Only functional parameters, such as FEV1, exacerbations and health-related 
quality of life, are easily measured to monitor disease modification. However, our longitudinal 
study shows that withdrawal of ICS even after previous long-term treatment with ICS, does 
not lead to a sustained disease modifying effect, as we found a relapse in lung function 
decline, quality of life, airway hyperresponsiveness and an increase in airway inflammation 
(Chapter 5 and 6). Thus, ICS does not influence the disease progression; instead, the positive 
effects of ICS fade out after withdrawal. It is interesting to speculate on the reason for the 
progressive course of COPD. Options could be the persistent smoking habits, a chronic 
inflammatory process that continues despite smoking cessation, or auto-immunity. As ICS 
seem beneficial in a subgroup of COPD patients [87], our results warrant studies in large 
cohorts of patients with substantial disease heterogeneity that are treated for a prolonged 
period with ICS compared to ICS withdrawal.
This increase in inflammatory parameters after discontinuation of ICS is not a specific feature 
of COPD, but has also been found in asthma. Mild to moderate asthmatics treated with 
mometasone for 8 weeks followed by 4 weeks of withdrawal, showed an increase in exhaled 
nitric oxide (FeNO) already in the first week after discontinuation of ICS [88]. Another study 
in adults with severe asthma showed that tapering of ICS resulted in an increase in airway 
hyperreponsiveness to methacholine and hypertonic saline and an increase in sputum 
eosinophils [89]. In asthmatic children, it has been found that withdrawal of ICS for 4 months 
increased FeNO, peripheral blood eosinophils and serum eosinophil cationic protein (ECP), 
compared to the group that continued with ICS [90]. Predictors of loss of asthma control 
were high blood eosinophils during ICS treatment, variability of peak expiratory flow (PEF) 
and increased sputum eosinophils during tapering of ICS [91, 92]. Small-sized particle ICS 
might be more effective in reducing systemic and pulmonary inflammatory parameters 
in asthma compared to normal sized particle ICS [93]. In COPD patients treated with lower 
doses of small-sized ICS equal exacerbation rates were found compared to the group treated 
with higher doses with conventionally sized ICS [94].
Should all COPD patients be treated for a prolonged time with ICS? When only considering 
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the results from the first part of the GLUCOLD study, showing an attenuation in lung function 
decline, improvement in quality of life and airway hyperresponsiveness and decreased 
bronchial inflammation [2], one might conclude that ICS have many beneficial effects in at 
least some subgroups. However, the prescribing physician should keep in mind that ICS use 
may have potential serious adverse effects, such as pneumonia and fractures, especially in 
long-term users, which is dose-related and depending on the type of ICS [95]. Patients with 
long-term use of fluticasone have been suggested to be more at risk compared to those who 
use budesonide [96]. Most importantly, no conclusions can be drawn from the presented 
data in Chapter 5 and 6 whether very long-term ICS use prevents decline in lung function and 
airway inflammation compared to patients who discontinued ICS, as the number of patients 
in the subgroup that continued ICS treatment was too small to draw firm conclusions. In 
addition, data from the GLUCOLD study showed that a subset of COPD patients with specific 
features, such as less severe emphysema, less hyperinflation, less inflammation and fewer 
packyears, will benefit most from treatment with ICS [87]. This emphasizes the importance 
of proper phenotyping of patients with COPD, to identify those who may benefit most from 
anti-inflammatory treatment, taking components such as physiological, radiological, genetic 
and environmental factors into account, as was already suggested by Orie and colleagues in 
1961 [97]. 
Limitations of the studies and methodological considerations
The GLUCOLD study started with 114 steroid-naive patients. After the first, randomized 
part of the trial 85 patients continued and at the end of the follow-up study only 61 
patients completed the study, which is approximately half of the patients that started. The 
main reason for patient withdrawal was disease progression, comorbidity of patients and 
health problems of their relatives. After 7.5 years, 29 patients underwent the last, fourth 
bronchoscopy. The relatively low number of patients per original treatment group was 
further split in subgroups who used ICS during the GLUCOLD follow-up study. Therefore, our 
group of patients and related outcomes are difficult to compare to other studies. Still, the 
sample size was sufficient to find associations between clinical and inflammatory outcomes 
(Chapter 6).
In the present cross-sectional studies (Chapter 2 and 4), current and ex-smokers with COPD 
were included for the analysis. This could have led to a selection bias, since ex-smokers 
could have experienced more smoking-related symptoms and therefore quitted smoking. 
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Whether patients had quitted smoking was only based on information provided by the 
patient, as was in line with other studies [17, 98], and not confirmed by e.g. a cotinine urine 
test. Hence, there is a possibility that ex-smokers were actually still smoking. Besides, ex-
smokers had similar packyears and lung function compared to current smokers. In addition, 
a post-hoc analysis showed that smoking was unlikely to be a major confounder for airway 
inflammation and effects of ICS [2]. 
Monocyte-derived macrophages from healthy subjects were cultured in vitro and 
differentiated towards classical MΦ1 and alternatively MΦ2. This is an oversimplification 
of the heterogeneity of macrophages, as at least other subtypes of especially MΦ2 can be 
found [12]. However, the exact role of these subsets in respiratory diseases, especially 
COPD remains to be established. In addition, well-defined MΦ1 markers are still under 
debate. Furthermore, in vitro cultured macrophages differentiate under the influence of 
specific stimuli that may differ from those that regulate differentiation in vivo in the local 
environment in the lung. Indeed, a heterogeneous lung-derived macrophage population 
is present in the lung that is not restricted to classically defined MΦ1 and MΦ2 subsets [19]. 
Therefore, macrophage phenotypes in vitro and in vivo are not fully comparable [30, 99]. It 
requires further studies towards specific (human) macrophage markers and determination of 
the functions of the heterogeneous macrophage populations.
COPD is a very heterogeneous disease, which is more complex than the conventional 
proposed entities of emphysema and chronic bronchitis. The central airways have a different 
composition of e.g. cellular inflammation, the epithelium and of extracellular matrix 
components compared to the small airways and lung parenchyma [43, 100]. In the first part 
of the GLUCOLD study, we collected bronchoalveolar lavage (BAL) samples, but this had to 
be stopped due to ethical considerations as some patients had complications (fever and 
pneumonia in one patient) of the procedure. During the bronchoscopies, we are (logically) 
only able to sample the large airways for bronchial biopsies. Furthermore, as we used one or 
two biopsies of the large airways, we cannot exclude the possibility that local heterogeneity 
of bronchial cells and extracellular matrix proteins caused a bias in our results. In addition, we 
can only speculate on the effect of inhaled corticosteroids in the small airways. 
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Directions for future research
• Which pro- and anti-inflammatory macrophage markers are suitable for both analysis 
in vitro and in vivo in COPD? Can these markers be used to monitor treatment effects?
• What is the effect of ICS on MΦ1 and MΦ2 macrophages in bronchial biopsies and 
peripheral airways in COPD?
• Can we use a personalized medicine approach, based on e.g. gene expression profiles, 
proteomics or metabolomics analysis, to improve the treatment of COPD patients?
• Are there particular stages of the disease that are most sensitive to the clinical and 
pathological benefits of corticosteroids?
• Is there a renewed place for systemic drugs in COPD?
• Which other potential anti-inflammatory treatments are beneficial for COPD? Does this 
require targeting highly selected pathways or does not this suffice given the biological 
complexity of the disease?
• Does continuation of dual (combination of anticholinergic and β2-agonists) 
bronchodilating agents after withdrawal of ICS prevent lung function decline?
• When is a deterioration of lung function decline detectable, following withdrawal of 
inhaled corticosteroids after previous long-term treatment?
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In dit proefschrift staan de effecten van sigarettenrook op ontstekingscellen (en in het 
bijzonder: macrofagen) en de behandeling met geïnhaleerde ontstekingsremmers 
(inhalatiecorticosteroïden) bij patiënten met chronische obstructieve longziekte (COPD) 
centraal. In het eerste deel van deze samenvatting wordt deze ziekte, de achtergrond en de 
behandeling besproken; in het tweede deel van deze samenvatting wordt ingegaan op de 
resultaten die in dit proefschrift zijn beschreven.
COPD
COPD is een acroniem voor de Engelse term ‘Chronic Obstructive Pulmonary Disease’ en is 
een langdurige en blijvende ziekte. Vooral vroeger werd COPD ook wel chronische bronchitis 
en emfyseem genoemd, hoewel vooral de term emfyseem nog regelmatig wordt gehanteerd. 
Patiënten met deze aandoening hebben in toenemende mate last van bijvoorbeeld 
kortademigheid in rust en bij inspanning, hoesten, opgeven van slijm (sputum) en reageren 
op bepaalde prikkels, zoals weersveranderingen of rook. De ene patiënt heeft meer of andere 
klachten dan de andere patiënt. Een fase waarin er een toename is van de klachten, wordt 
een longaanval of exacerbatie genoemd en wordt vaak uitgelokt door een luchtweginfectie. 
COPD wordt gekenmerkt door een versnelde achteruitgang van de longfunctie. Volgens het 
Rijksinstituut voor de Volksgezondheid en Milieu (RIVM) waren er in 2011 in ons land meer 
dan 350.000 mensen die lijden aan COPD en het is momenteel de derde doodsoorzaak 
wereldwijd. 
Risicofactoren voor COPD
De belangrijkste risicofactor voor het ontwikkelen van COPD is het roken van sigaretten. 
Langer roken en meer sigaretten per dag leidt tot een hogere kans op het ontwikkelen 
van COPD. Ongeveer 10-20% van alle rokers ontwikkelt COPD; omgekeerd heeft 90% van 
alle COPD patiënten gerookt. Een belangrijke vraag is waarom sommige rokers wel COPD 
ontwikkelen, en anderen niet. Dit heeft te maken met een complex geheel van erfelijke 
factoren, in combinatie met omgevingsfactoren waar het lichaam aan wordt blootgesteld. 
Daarnaast kan meeroken, luchtverontreiniging en beroepsmatige blootstelling aan bepaalde 





Hoewel COPD nu onder één noemer valt, zijn er veel verschillen tussen patiënten. Dat komt 
doordat COPD een heterogene ziekte is, wat inhoudt dat onder andere door de hoeveelheid 
roken, lichaamsgewicht, aantal exacerbaties, inspanningsbeperking en psychische status er 
verschillende subgroepen van patiënten zijn. Daarnaast zijn er ook inwendige verschillen, 
zoals afwijkingen in de luchtwegen, verhoogde vatbaarheid voor infecties en veranderde 
cellulaire afweer die er voor zorgen dat het beloop van COPD zich op verschillende manieren 
kan presenteren. Deze heterogeniteit impliceert dat subgroepen van COPD patiënten 
gerichter behandeld zouden moeten worden. 
De longen en luchtwegen bij COPD
Longfunctie 
Vanaf de leeftijd van ongeveer 20-25 jaar gaat bij iedereen jaarlijks de longfunctie 
achteruit met zo’n 25-30ml. Patiënten met COPD hebben met 60ml per jaar een versnelde 
achteruitgang van de longfunctie. Rokende COPD patiënten hebben een snellere 
achteruitgang van de longfunctie ten opzichte van ex-rokers met COPD; het ‘stoppen 
met roken’-advies is daarom voor elk stadium van COPD relevant. Longfunctiemetingen, 
waarbij de hoeveelheid uitgeademde lucht wordt gemeten, zijn cruciaal voor het stellen 
van de diagnose COPD. Door luchtwegvernauwing, ook wel (luchtweg)obstructie genoemd, 
ontstaat een vermindering in de geforceerde hoeveelheid uitgeademde lucht, gemeten met 
de één-seconde-waarde (de maximale hoeveelheid lucht die in één seconde kan worden 
uitgeblazen, FEV1). Als er luchtwegobstructie bestaat, is het uitademen van lucht bemoeilijkt 
door een verhoogde luchtwegweerstand, vergelijkbaar met het effect van het uitademen 
door een rietje. De hoogte van de FEV1 is een maat voor de ernst van de luchtwegobstructie 
en kan geclassificeerd worden in mild (GOLD klasse 1), matig (GOLD 2), ernstig (GOLD 3) of 
zeer ernstig (GOLD 4). Hierbij staat GOLD voor de internationale consensus op het gebied 
van COPD. Omdat alleen de uitademing moeilijker gaat, maar de inademing niet, kan bij 
ernstig COPD lucht in de longen achterblijven na volledige uitademing, vergelijkbaar met 
de lucht in een fietsband (lucht kan er wel in, maar via het ventiel niet eruit). Dit wordt 
hyperinflatie genoemd.
Door het roken ontstaat schade aan de longblaasjes, ook wel de alveoli genoemd, waar de 
gaswisseling van zuurstof (O2) en koolzuur (CO2) plaatsvindt. De ernst van deze schade kan 
gemeten worden met de diffusiecapaciteit. Patiënten met COPD kunnen meer last krijgen 
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van kortademigheid als zij in contact komen met bepaalde prikkels, zoals vochtig weer, 
bepaalde geuren of sigarettenrook. Dit wordt hyperreactiviteit van de luchtwegen genoemd. 
Een methacholine provocatietest kan gebruikt worden om te meten in welke mate de 
luchtwegen gevoelig zijn voor prikkels. 
Luchtwegontsteking
Door de blootstelling aan sigarettenrook ontstaat er een chronische ontstekingsreactie 
in de luchtwegen. Welk component of welke componenten van de sigarettenrook daar 
verantwoordelijk voor zijn is tot nu toe onbekend, aangezien er circa 5000 verschillende 
stoffen in sigarettenrook zitten. De rook komt in eerste instantie in contact met de 
luchtwegwand (epitheelcellen) en het aangeboren, niet-specifieke afweersysteem. De 
rook zorgt ervoor dat er een cascade van reacties op gang komt, waarbij verschillende 
ontstekingscellen betrokken zijn, zoals macrofagen, CD8+ T-cellen en neutrofiele 
granulocyten, onder invloed van bepaalde stoffen, zoals chemokines en cytokines, worden 
aangetrokken worden vanuit het bloed naar de longen met als doel om de schadelijke 
effecten tegen te gaan. De cellen raken ‘geactiveerd’ door contact met rook, waardoor de 
cytokines en chemokines vrijkomen, en kunnen bijdragen aan schade aan de luchtwegen 
en alveoli. Hoewel het stoppen met roken de achteruitgang van de longfunctie vermindert, 
blijkt uit onderzoek dat het stoppen met roken de luchtwegontsteking maar ten delen 
vermindert.
Macrofagen
Macrofagen zijn afweercellen van het aangeboren immuunsysteem die een belangrijke rol 
spelen bij chronische ontstekingsprocessen, zoals bij COPD. Hoewel er meer macrofagen 
aanwezig zijn in de longen van COPD patiënten ten opzichte van gezonde controle personen, 
werken deze cellen minder effectief in het opruimen van bacteriën (fagocytose). Macrofagen 
blijken uit meerdere subtypen (fenotypes) te bestaan, die zowel in in vitro (buiten het 
lichaam) als in vivo (in het lichaam) gemakkelijk in elkaar kunnen overgaan (plasticiteit). Een 
simpele variant van deze subtypen zijn MΦ1 en MΦ2 macrofagen (ook wel Mf1 en Mf2): MΦ1 
hebben eigenschappen die het ontstekingsproces bevorderen (pro-inflammatoir), zoals het 
afscheiden van cytokines die passen bij ontstekingen. MΦ2 cellen werken juist de ontsteking 
tegen (anti-inflammatoir), o.a. door het afscheiden van cytokines die ontsteking remmen. Er 




beschrijft de effecten van sigarettenrook op de macrofagen fenotypes bij patiënten met 
COPD. Tevens wordt een nieuwe marker voor MΦ1, namelijk YKL-40, onderzocht voor het 
gebruik bij in vitro gekweekte macrofagen en in serum en sputum van patiënten met COPD 
na behandeling met ontstekingsremmers.
Remodellering van de luchtwegen
De extracellulaire matrix (ECM) is een driedimensionale structuur die als het ware het 
skelet van de longen vormt. Deze matrix bestaat uit drie belangrijke componenten, 
namelijk elastine, proteoglycanen en collagenen. Door de langdurige blootstelling aan 
omgevingsfactoren, zoals sigarettenrook, gaan de luchtwegen zich aanpassen, een proces 
dat ‘remodellering’ wordt genoemd. Deze remodellering vindt op meerdere plekken in 
de longen plaats, zowel in de grote en kleine luchtwegen als in het longweefsel. De eerste 
plek waar de schade door de geïnhaleerde rook ontstaat, is bij de epitheelcellen, de 
binnenbekleding van de luchtwegen. Door de rook raken de trilhaartjes, die bovenop 
de epitheelcellen zitten beschadigd, waardoor ze het slijm dat in de luchtwegen zit niet 
meer goed richting de keel kunnen verplaatsen. Door langdurige blootstelling aan rook 
ontstaan er epitheelcellen met een andere vorm zonder trilharen (ook wel metaplasie 
genoemd). Daarbij ontstaan door sigarettenrook meer cellen die slijm produceren (goblet 
cel hyperplasie). Deze twee mechanismen geven onder andere de typische rokershoest 
bij patiënten met COPD. Het relatieve ‘stilstaan’ van het sputum zorgt voor een toename 
in vatbaarheid voor luchtweginfecties. Daarnaast zorgt de rook voor een verdikking 
van het basale membraan, die laag die onder de epitheelcellaag ligt. Ook worden 
er stoffen afgescheiden die de luchtwegen dikker maken, wat kan bijdragen aan de 
luchtwegvernauwing. Tenslotte lopen de alveoli ook schade op door de sigarettenrook en 
ontstaat er emfyseem. De door sigarettenrook opgewekte ontstekingsreactie is de drijvende 
kracht voor de remodellering. Dit proefschrift beschrijft de effecten van sigarettenrook en 
geïnhaleerde ontstekingsremmers op de componenten van de ECM in de grote luchtwegen 
van patiënten met COPD.
Behandeling van COPD
Tot nu is er geen behandeling die COPD kan genezen. De behandeling is er daarom 
op gericht om de klachten van kortademigheid en sputumvorming zo goed mogelijk 
te onderdrukken. Dit kan op twee manieren: een niet-medicamenteuze en een 
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medicamenteuze behandeling. Het belangrijkste niet-medicamenteuze advies aan rokende 
COPD patiënten is het stoppen met roken. Dit heeft positieve effecten op de klachten, de 
achteruitgang van de longfunctie en het aantal exacerbaties. Dit is voor veel patiënten een 
uitdaging en voor velen erg lastig, waarbij rokers die gestopt zijn vaak opnieuw gaan roken. 
Roken moet daarom ook worden gezien als chronische ziekte. 
De medicamenteuze ingeademde behandeling (inhalatiemedicatie) heeft twee belangrijke 
pijlers: de luchtwegverwijders en de inhalatiecorticosteroïden. De luchtwegverwijders geven 
op diverse manieren verslapping van de gladde spiercellen rondom de luchtwegen en zijn 
de eerste stap in de behandeling van COPD. Ze zijn in kort- en langwerkende varianten 
beschikbaar en geven verlichting van de benauwdheid. Inhalatiecorticosteroïden zijn 
ontstekingsremmers (ook wel ICS genoemd) en kunnen de ontsteking in de luchtwegen 
remmen door hun lokale werking. ICS hebben dezelfde werkzaamheid als Predniso(lo)
n, maar worden in een veel lagere dosering, lokaal en via inhalatie toegediend. ICS worden 
afgebroken in de maag, waardoor de concentratie steroïden in de bloedbaan erg laag 
is. Bijwerkingen van ICS zijn onder andere een schimmelinfectie in de mond en keel 
en heesheid. Eerder onderzoek heeft aangetoond dat ICS bij enkele patiënten ook een 
longontsteking kan veroorzaken. In de huidige richtlijnen worden ICS geadviseerd (in 
combinatie met of zonder luchtwegverwijders) bij patiënten met ernstig of zeer ernstig 
COPD (GOLD 3-4) met veel klachten en meer dan twee exacerbaties per jaar. Eerder 
onderzoek heeft laten zien dat ICS verbetering geeft van de klachten en van het aantal 
exacerbaties per jaar. Tot nu toe zijn er wisselende resultaten van ICS gezien op de 
achteruitgang van de longfunctie. Het GLUCOLD-onderzoek heeft dit ook onderzocht 
en vond juist dat 30 maanden behandeling met de ICS fluticason met of zonder 
luchtwegverwijder (salmeterol) een verminderde afname van de longfunctie geeft in 
combinatie met een vermindering van de ontstekingscellen in de luchtwegen, en betere 
kwaliteit van leven. 
Stoppen met ICS
In de dagelijkse praktijk worden ICS vaak voorgeschreven aan patiënten met COPD, ook 
als zij weinig klachten of minder dan twee exacerbaties per jaar hebben. Slechts een derde 
van de patiënten gebruikt hun medicatie dagelijks en regelmatig worden deze medicijnen 
slechts een paar maanden gebruikt. Tot nu toe is maar weinig onderzoek gedaan naar de 
effecten van het stoppen van ICS. Enkele onderzoeken vonden een toename in het aantal 




stoppen van ICS nog niet goed in kaart gebracht. Dit proefschrift heeft de effecten van het 
langdurig stoppen van ICS onderzocht op de longfunctie en de ontstekingscellen in de 
luchtwegen na eerdere langdurige behandeling. 
Proefschrift
In dit proefschrift zijn de resultaten beschreven van onderzoek naar de effecten van roken en 
ICS op luchtwegontsteking (met nadruk op macrofagen) en de mate van remodellering van 
de luchtwegen. Daarnaast is onderzoek gedaan naar de effecten van stoppen van ICS op de 
longfunctie en luchtwegontsteking bij patiënten met COPD. Voor het onderzoek is gebruik 
gemaakt van de gegevens van de eerder verrichtte GLUCOLD* studie, en is ook aanvullend 
onderzoek gedaan bij de patiënten die de GLUCOLD studie hadden afgerond: de GLUCOLD 
vervolgstudie (ook wel GLUCOLD2 studie). Deze studie werd uitgevoerd in het Leids 
Universitair Medisch Centrum te Leiden en het Universitair Medisch Centrum Groningen te 
Groningen.
* Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease
De onderzoeksdoelen van het huidige proefschrift zijn:
1. Is er een verschil in het fenotype van macrofagen in sputum en bronchoalveolaire 
lavage (BAL, longspoeling) tussen rokende en ex-rokende COPD patiënten?
2. Wat is het effect van ontstekingsremmers op de MΦ1 marker YKL-40 bij in vitro (in het 
laboratorium gekweekte) pro-inflammatoire macrofagen, en in bloed en sputum van 
COPD patiënten in vivo?
3. Ontstaat er verandering in de structuur van de luchtwegwand (remodellering) na roken 
en na langdurig gebruik van ICS bij COPD?
4. Wat is het effect van langdurig stoppen van ICS op de achteruitgang van de longfunctie 




Voor de GLUCOLD studie zijn 114 mensen met matig tot ernstig COPD (longfunctie tussen 
20 en 80% van voorspelde waarde) onderzocht, zowel rokende als niet-rokende mensen in 
de leeftijd tussen 45 en 75 jaar. Deze vrijwilligers mochten geen astma hebben (gehad). Bij 
aanvang van het eerste deel van de studie werden ze uitgebreid onderzocht op symptomen, 
longfunctie, hyperreactiviteit en luchtwegontsteking in sputum. Tevens werd een 
kijkonderzoek in de longen (bronchoscopie) verricht, waarbij een BAL en luchtwegweefsel 
(biopten) werden verkregen. Hierna werden patiënten door middel van loting in 4 
behandelgroepen verdeeld (Figuur 1), 6 of 30 maanden behandeling met geïnhaleerde 
onstekingsremmers met en zonder luchtwegverwijder of placebo (nepmedicijn), waarbij de 
behandeling voor zowel de onderzoekers als de deelnemers onbekend was. Elke 3 maanden 
werd de longfunctie en kwaliteit van leven gemeten, en na 6 en 30 maanden werd opnieuw 
de luchtwegontsteking onderzocht (sputum, BAL, biopten). Na 30 maanden behandeling 
hadden 85 mensen het eerste deel van de studie doorlopen. De uitkomsten van de GLUCOLD 
studie (GL1) zijn eerder gepubliceerd door Thérèse Lapperre en Jiska Snoeck-Stroband.
Tijdens het tweede gedeelte van de GLUCOLD studie (vervolgstudie, GL2) werd de 
longfunctie en kwaliteit van leven jaarlijks gemeten. Hyperreactiviteit en sputum werd 
onderzocht na 2 en 5 jaar; biopten werden na 5 jaar opnieuw verkregen. De totale studieduur 
komt hiermee op 7,5 jaar. Tijdens de laatste 5 jaar werden de patiënten behandeld door hun 
eigen longarts of huisarts volgens de laatste richtlijnen. In de praktijk betekende dit dat het 
merendeel van de deelnemers van de studie geen of weinig ontstekingsremmers gebruikten 
tijdens GL2. Uiteindelijk hebben 61 patiënten de totale studie afgerond. 
 
Figuur 1: Studie opzet tijdens eerste (GL1) en tweede (vervolg, GL2) deel van de GLUCOLD studie.
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Hoofdstuk 2: Anti-inflammatoire macrofagen in sputum en BAL van rokende en ex-
rokende COPD patiënten.
Macrofagen spelen als afweercellen een belangrijke rol bij de ontwikkeling van COPD. 
Macrofagen vormen een heterogene populatie met MΦ1 (pro-) en MΦ2 (anti-inflammatoire) 
cellen. Eenmaal gedifferentieerde macrofagen blijven de mogelijkheid behouden tot 
verandering van fenotype. Dit houdt in dat als macrofagen in aanraken komen met een 
inflammatoire prikkel, de MΦ2 cel kan veranderen in een MΦ1 cel, en andersom. Er wordt 
aangenomen dat in de grote luchtwegen, die als eerste in aanraking komen met onder 
andere bacteriën en omgevingsfactoren, meer MΦ1 cellen aanwezig zijn. In de kleinere 
luchtwegen en alveoli zijn juist meer MΦ2 cellen aanwezig om de gaswisseling goed te 
laten verlopen. In dit hoofdstuk is het effect van roken op de anti-inflammatoire macrofagen 
onderzocht. Hiervoor hebben we de MΦ2 marker CD163 gebruikt naast bepaalde pro-
inflammatoire (interleukine 6 en 8) en anti-inflammatoire eiwitten (elafine en Secretory 
Leukocyte Protease Inhibitor [SLPI]), die aanwezig zijn in BAL en opgewerkt sputum van 
rokende COPD patiënten en COPD patiënten die gestopt zijn met roken. De belangrijkste 
resultaten van dit onderzoek zijn:
• Ex-rokers met COPD hebben een hoger percentage van CD163-positieve macrofagen en 
een groter totaal aantal cellen, maar een kleiner aantal in BAL ten opzichte van rokende 
COPD patiënten.
• Het percentage CD163-positieve MΦ2 macrofagen is hoger in BAL dan in sputum.
• Er is geen verschil tussen rokers en ex-rokers met COPD in de concentratie pro- en anti-
inflammatoire eiwitten aanwezig in BAL en sputum.
Deze resultaten suggereren dat stoppen met roken het fenotype van macrofagen 
gedeeltelijk kan veranderen naar een anti-inflammatoire type in de longen van 
COPD patiënten. Dit gaat niet gepaard met een verandering in aantal neutrofielen, 
ontstekingsbevorderende of ontstekingsremmende eiwitten in het sputum of BAL. Tevens 




Hoofdstuk 3: Effect van ontstekingsremmers op YKL-40 op pro-inflammatoire 
macrofagen
MΦ1 en MΦ2 macrofagen worden met verschillende markers gekarakteriseerd. In Hoofdstuk 
2 werd CD163 beschreven als een marker voor MΦ2 cellen, in hoofdstuk 3 wordt de nieuwe, 
potentiële marker YKL-40 beschreven als marker voor MΦ1 cellen. YKL-40 is een chitinase-
achtig eiwit dat onder andere door macrofagen en andere celtypes wordt afgescheiden en 
is geassocieerd met verschillende ontstekingsziekten, waaronder astma en COPD. Eerder 
onderzoek heeft laten zien dat YKL-40 sterk wordt onderdrukt door dexamethason (een 
sterke ontstekingsremmer), waardoor de indruk bestaat dat YKL-40 voornamelijk op MΦ1 
cellen zit. In ons laboratorium hebben we dit verder onderzocht door monocyten (voorlopers 
van macrofagen) uit bloed te isoleren, in vitro te kweken in het laboratorium tot MΦ1 en MΦ2 
cellen en deze vervolgens te stimuleren met stoffen die ontsteking opwekken. Tenslotte 
werden de cellen behandeld met dexamethason. Verder is onderzocht welk fenotype van 
gekweekte macrofagen het meest boodschapper RNA (mRNA) tot uiting brengt en YKL-
40 eiwit uitscheidt. Ook is het effect van dexamethason op de fenotypen van macrofagen 
bestudeerd. Als laatste is het effect van ICS op YKL-40 in bloed en sputum van patiënten met 
COPD onderzocht. De bevindingen van dit onderzoek zijn als volgt:
• Gekweekte MΦ1 cellen maken meer YKL-40 mRNA en scheiden meer YKL-40 eiwit uit ten 
opzichte van MΦ2 cellen, onafhankelijk van de stimulatie van de cellen.
• Dexamethason remt dosis-afhankelijk YKL-40 mRNA expressie en eiwit uitscheiding in 
MΦ1 cellen.
• Hogere eiwitconcentraties YKL-40 wordt gevonden in bloed vergeleken met sputum van 
patiënten met COPD.
• Behandeling met ICS verandert de hoeveelheid YKL-40 eiwit in sputum en bloed van 
patiënten met COPD niet na 30 maanden behandeling met ICS.
Deze resultaten suggereren dat YKL-40 een geschikte marker is voor in vitro gekweekte 
MΦ1 cellen, maar niet gebruikt kan worden om het effect van ICS behandeling te meten in 
serum en sputum van patiënten met COPD. Een mogelijke verklaring hiervoor kan zijn dat 
MΦ1 cellen een specifieke stimulatie nodig hebben, die toegediend kan worden bij in vitro 





Ontstekingsremmers en luchtwegwand remodellering
Hoofdstuk 4: Effect van roken en ontstekingsremmers op de samenstelling van 
extracellulaire matrix (ECM) in de luchtwegwand van COPD patiënten.
Het weefsel rondom de luchtwegen is een driedimensionale structuur, die ook wel de 
extracellulaire matrix (ECM) wordt genoemd. Deze bestaat onder andere uit elastische vezels, 
proteoglycanen en collagenen. Eerder onderzoek heeft aangetoond dat langdurig roken 
onomkeerbare schade veroorzaakt aan de elastische vezels in de alveoli. Dit suggereert dat 
er door sigarettenrook ook veranderingen kunnen ontstaan in de structuur en componenten 
van de wand van de kleine en grote luchtwegen, een proces dat bijdraagt aan de 
luchtwegvernauwing. In dit hoofdstuk is onderzocht wat de effecten zijn van roken en ICS op 
verschillende componenten van de ECM in de grote luchtwegen, namelijk elastische vezels, 
proteoglycanen (versican en decorine) en collagenen (collageen I en III). De uitkomsten van 
dit onderzoek zijn:
• (Stoppen met) roken heeft geen effect op de diverse componenten van de ECM in de 
grote luchtwegen van COPD.
• Langdurig behandelen met ICS geeft een toename van versican en collageen III in de 
grote luchtwegen.
• Er is een relatie tussen de hoeveelheid collageen I en de longfunctie na langdurige 
behandeling met ICS.
Bovenstaande resultaten suggereren dat de samenstelling van de luchtwegwand verandert 
in patiënten met COPD na langdurige behandeling met ICS. Deze remodellering van de 
luchtwegen, kan er mogelijk voor zorgen dat ze stugger en stijver worden en voorkomen het 
samenvallen van de luchtwegen bij de ademhaling. 
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Effect van stoppen met ICS op longfunctie en luchtwegontsteking
Hoofdstuk 5: Langdurig stoppen met ICS na 2,5 jaar behandeling veroorzaakt 
versnelde achteruitgang in longfunctie bij patiënten met COPD.
Het GLUCOLD onderzoek heeft eerder laten zien dan 2,5 jaar behandeling met ICS een 
verminderde achteruitgang van de longfunctie geeft, verminderde luchtweghyperreactiviteit 
en betere kwaliteit van leven. In de dagelijkse praktijk gebruiken veel patiënten de 
onstekingsremmers echter kortdurend of onregelmatig. Tot nu toe zijn de effecten van 
stoppen met ICS onvoldoende onderzocht. Dit is belangrijk om te weten, omdat ICS mogelijk 
ook de onderliggende mechanismen van COPD zou kunnen veranderen (ziekte modificatie). 
In dit hoofdstuk hebben we onderzocht wat de effecten zijn van langdurig stoppen (vijf 
jaar) van de ICS na eerder 2,5 jaar behandeling. Hiervoor zijn de patiënten van het eerste 
deel van het onderzoek gevraagd om mee te doen aan het vervolgonderzoek. Patiënten zijn 
behandeld door hun eigen longarts of huisarts. Het merendeel van de patiënten gebruikte 
geen of onregelmatig ontstekingsremmers. Jaarlijks werd de longfunctie en kwaliteit van 
leven gemeten evenals de hyperreactiviteit van de luchtwegen. De belangrijkste resultaten 
van dit onderzoek zijn:
• Langdurig stoppen met ICS leidt tot een versnelde jaarlijkse achteruitgang van de 
longfunctie ten opzichte van de periode dat wel ICS worden gebruikt.
• Patiënten die langdurig gestopt zijn met ICS hebben een toename in 
luchtweghyperreactiviteit ten opzichte van de periode dat ze wel ICS gebruikten.
• Langdurig stoppen van ICS geeft enige achteruitgang van de kwaliteit van leven ten 
opzichte van de periode dat de patiënten werden behandeld met ICS.
Bovenstaande resultaten suggereren dat actief gebruik van ICS alleen een positief effect 
heeft op de longfunctie, kwaliteit van leven en mate van luchtweghyperreactiviteit tijdens 
actief gebruik van de ICS, maar dat bij langdurig staken ervan deze effecten weer verdwijnen. 
Er lijken dus door ICS behandeling geen langdurige en blijvende veranderingen in het 
ziekteproces (geen ziektemodificatie) op te treden die persisteren na het stoppen met ICS. 
Patiënten met matig tot ernstig COPD is een aparte groep van patiënten, die de snelste 
achteruitgang van de longfunctie hebben. Juist daardoor valt er in deze groep de meeste 
winst op de longfunctie te behalen met de behandeling met ICS. Toch dient de conclusie van 




zien dat COPD patiënten moeten doorgaan met de langdurige behandeling met ICS. Dit was 
ook niet het doel van het huidige onderzoek en zal verder onderzocht moeten worden in 
toekomstige onderzoeken.
Hoofdstuk 6: Langdurig stoppen met ICS na 2,5 jaar behandeling leidt tot toename 
van luchtweg ontsteking bij patiënten met COPD.
Het GLUCOLD onderzoek heeft eerder laten zien dat 2,5 jaar behandeling met ICS zorgt voor 
een afname van het aantal CD3-, CD4-, en CD8-positieve cellen en mestcellen. Tevens werd 
een afname gevonden in het aantal neutrofielen, macrofagen en lymfocyten in het sputum. 
Wederom is tot nu toe onbekend wat de effecten zijn van het langdurig stoppen van de 
behandeling met ICS op het aantal ontstekingscellen in de luchtwegen. De patiënten die in 
Hoofdstuk 5 werden genoemd, werd gevraagd of zij ook sputum wilden inleveren (na 2 en 5 
jaar vervolgonderzoek) en een kijkonderzoek weefselstukjes (biopten) uit de luchtwegwand 
wilden ondergaan (na 5 jaar vervolgonderzoek). De belangrijkste bevindingen van dit 
onderzoek zijn:
• Vijf jaar stoppen met ICS na eerdere 2,5 jaar behandeling geeft een toename van het 
aantal CD3, CD4, en CD8 positieve cellen en mestcellen in biopten.
• Langdurig stoppen met ICS geeft een toename van het totaal aantal cellen in sputum, 
en het aantal macrofagen, neutrofielen en lymfocyten in sputum. 
• Er is een relatie tussen een versnelde afname van longfunctie en toename van aantal 
sputum macrofagen en luchtweg neutrofielen.
Deze resultaten laten zien dat ICS de luchtwegontsteking onderdrukken zolang deze 
inhalatiemedicatie wordt gebruikt. Wederom is er geen aanhoudende ziekte aanpassing 




Perspectief voor toekomstig onderzoek
De onderzoeken zoals beschreven in dit proefschrift hebben bijgedragen aan de kennis over 
macrofagen fenotypes, luchtweg remodellering en lange termijn effecten van stoppen met 
de behandeling met ICS. Uiteraard zijn dit slechts puzzelstukjes van de grote puzzel over 
ontsteking in de longen van COPD patiënten en de behandeling daarvan. De hier beschreven 
onderzoeken roepen daarom ook nieuwe vragen op, die in toekomstig onderzoek nader 
uitgezocht dienen te worden.
• Wat is het effect van ICS op CD163 (of andere MΦ2 markers) en YKL-40 (of andere MΦ1 
markers) positieve macrofagen in grote en kleine luchtwegen van patiënten met COPD?
• Zijn andere pro- en anti-inflammatoire macrofagen markers wellicht geschikter om het 
effect van ontstekingsremmers te monitoren?
• Wat zijn de effecten van ICS op de remodellering van de kleine luchtwegen en alveoli bij 
COPD?
• Welke groepen van COPD patiënten hebben het meeste baat bij de behandeling met 
geïnhaleerde ontstekingsremmers? Kunnen bepaalde (epi)genetische profielen of 
gen expressie profielen herkend worden die reactie op ontstekingsremmers kunnen 
voorspellen?
• Blijven de positieve effecten op longfunctie, ontsteking en kwaliteit van leven 
aanhouden bij zeer langdurige (>2,5 jaar) behandeling met ICS?
• Zijn er andere potentiële ontstekingsremmende medicijnen beschikbaar om de 
progressie van COPD te verminderen? Zijn ICS met fijnere deeltjes meer geschikt om de 
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